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Abstract 
 
The design of a photoswitchable homeodomain artificial transcription factor (PATF), 
modelled on an engrailed homeodomain, for the purpose of controlling DNA binding 
affinity and controlling the transcription process in cells using light has been 
investigated. This study was conducted using a 3,3’-bis(sulfo)-
4,4’bis(chloroacetamino)azobenzene crosslinker, alkylated between two cysteine 
residues with different spacings (i, i+4, i, i+7 and i, i+11) and either a rigid or flexible 
linker domain. In previous studies, basic leucine zipper transcription activators have 
been photocontrolled in living cells by incorporating a photoswitchable azobenzene 
crosslinker. 
Circular dichroism spectroscopy showed the conformation of crosslinked PATF (XL-
PATF) peptides (i, i+11 spacing) containing rigid and flexible linkers could be 
controlled reversibly by light. Fluorescence anisotropy experiments using labelled DNA 
confirmed the in vitro DNA binding affinity of PATF was considerably higher with the 
crosslinker in the trans (ground state) configuration than in the cis (photoexcited state) 
configuration. Further studies of peptides with i, i+4 and i, i+7 spacings with a semi-
rigid and rigid linker domains showed increased binding affinity with the crosslinker in 
the cis configuration.  
Initiation of transcription was investigated by an in vitro transcription assay to measure 
the ability of PATF molecules to moderate the production of RNA by irradiation with 
UV light. PATF molecules with i, i+11 spacings showed increased transcriptional 
activation with the crosslinker in the ground state configuration and i, i+4 and i, i+7 
spacings resulted in increased transcription activation with the crosslinker in the excited 
state conformation. Control of 50% of transcriptional activity was achieved for i, i+11 
  
 
 
  
v 
spacings, and PATFs with a rigid linker domain were more effective switches than 
those with flexible linkers.  Using i, i+4 and i, i+7 spacings in PATFs resulted in a 
lower degree of control but, as anticipated, transcriptional activation was increased after 
irradiation. 
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Chapter 1  
Introduction
  
Preface 
 
Transcription and translation are the essential processes required for synthesis of 
specific proteins from DNA. As such they are fundamental to every living organism and 
impact on all biological processes, including growth, development and the ability of an 
organism to respond to environmental changes.  
Transcription is the process, during which a particular segment of DNA is copied to 
create a messenger RNA (mRNA), and is used as a key point for regulation of the 
expression of genetic information. Proteins known as transcription factors, which bind 
to DNA and initiate the transcription process, regulate transcription. The mRNA 
molecules produced are then used as templates for protein synthesis during translation 
and the protein products derived from them can alter behaviour in particular cell types 
or in response to a particular stimulus.  
The proliferation of light-controllable photonic compounds that can be incorporated into 
biomolecules provides an alternative strategy to rapidly and reversibly control 
transcription and subsequent protein signaling pathways. In conjunction with 
macromolecular function in biological systems, this technology may in the future be 
used to develop new artificial photoreceptors with medical and biosensor applications. 
 
  
 
 
  
3 
1.1 Transcription of Genes 
 
Gene transcription is a process in which mRNA is synthesised from a specific DNA 
template by enzymes known as RNA polymerases. The process begins with RNA 
polymerases binding to a target DNA sequence known as a promoter close to the 
beginning of the gene and is controlled by proteins known as transcription factors, 
which bind to specific DNA sequences located at the promoter sites of the target genes. 
Motor proteins termed helicases (belonging to the translocase family of proteins) move 
directionally along nucleic acid stands unwinding the DNA, allowing the RNA 
polymerases to move along the gene copying the antisense (3’ end) of the DNA 
resulting in the production of mRNA composed of complementary bases to those in the 
template DNA strand (Figure 1.1). 
 
 
Figure 1. 1. Basic transcription scheme with binding of transcription factor binding to target DNA and 
recruiting RNA polymerase enzyme.   	  
Transcription factors contain structural elements known as DNA-binding domains 
(DBD), which recognise double or single stranded DNA in either a DNA sequence-
!"#$%&'$(($Transcription 
Factor 
  
 
 
  
4 
specific or non-specific manner.1 Transcription factors also contain a separate activation 
domain (AD). The AD dictates whether to activate or repress transcription by recruiting 
components associated with the transcription machinery or the repression machinery 
respectively. Regulation of gene expression is an important biological process because 
it allows cells to produce proteins appropriate for a given situation. Organisms as 
diverse as bacteria, animals, and plants respond to elevated temperatures by a rapid and 
transient increase in the synthesis of conserved polypeptides collectively referred to as 
heat shock proteins (Hsp). 2 When eukaryotic cells are exposed to elevated 
temperatures, heat shock factor (HSF) is activated and binds to heat shock element 
(HSE) promoters to up-regulate production of Hsp70 to help fold newly synthesised 
proteins and stabilise existing ones to overcome heat stress. 1 This is essential for 
eukaryotes, prokaryotes and viruses as the ability to control transcription increases the 
adaptability of an organism.  
 
1.1.1 Prokaryotic Transcription 
 
The prokaryotic genome is considerably smaller than that of eukaryotes. In prokaryotes, 
virtually all RNA is synthesised by a single DNA-dependent RNA polymerase. The 
only exception is the synthesis of short RNA primers complementary to ssDNA 
template strands by an enzyme known as primase. In prokaryotes there is no nucleus to 
separate the processes of transcription and translation, so they happen simultaneously in 
the cellular cytoplasm; translation of an mRNA strand often occurs even while 
downstream mRNA is still being synthesised.  In bacteria, genes encoding enzymes of a 
particular metabolic pathway are usually grouped adjacent to one another in a cluster on 
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the chromosome, allowing all the genes in the group to be expressed in a coordinated 
fashion through transcription into a single polycistronic mRNA (a single RNA 
transcript that encodes more than one polypeptide). 3 This allows a single control point 
for an entire metabolic pathway. 
In E. coli, the RNA polymerase holoenzyme is a complex multimeric protein (~450 
kDa). It is made up of 4 main subunits, two α subunits, β, β’ and interchangeable σ 
subunits (α2ββ’σ). The largest subunit, β’ (~155 kDa), is used for DNA binding while β 
(151 kDa) binds nucleoside triphosphate substrates and interacts with the σ subunits. A 
number of related proteins, known as σ-factors, can serve as σ-subunits. The different σ-
factors allow the RNA polymerase holoenzyme to recognise different DNA promoter 
sequences that identify transcription start sites. 3 Both β and β’ contribute to the 
formation of the catalytic site for RNA synthesis, while the two α subunits are essential 
for assembly of the enzyme and activation by regulatory proteins.  
1.1.1.1 Transcription initiation 	  
Transcription process is made up of four stages: binding of RNA polymerase at 
promoter site, initiation of polymerisation, chain elongation and chain termination. The 
process begins with the σ-subunit of RNA polymerase recognising and binding to the 
promoter sequence. The RNA polymerase and the promoter form a closed promoter 
complex, where the dsDNA has not yet been unwound so that the RNA polymerase can 
read the base sequence of the DNA template strand and transcribe it into a 
complementary RNA sequence. RNA polymerase binds an ‘envelope’, a nucleotide 
sequence spanning the region from -70 to +20, where the +1 position is defined as the 
transcription start site (the base in DNA that specifies the first base in the RNA 
transcript).  
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Prokaryotic promoters vary in sizes from 20 to 200 base pairs, but typically consist of a 
40 base pair region located to the 5’-side of the transcription start site. The promoter has 
two consensus sequence elements. The Pribnow box containing a conserved hexameric 
sequence (5’-TATAAT-3’) is usually located 10 nucleotides upstream from the 
transcription start site, and another hexameric sequence (5’-TTGACA-3’) located 35 
nucleotides upstream from the transcription start site. 4, 5 The σ-subunits of RNA 
polymerase bind to these consensus elements as well as other sequences that provide 
specificity.  
Next, the DNA duplex must be ‘opened’ so that RNA polymerase can gain access to the 
single stranded template in order for transcription to begin. The efficiency of 
transcription initiation is inversely proportional to the melting temperature (Tm) in the 
Pribnow box, which suggests that the A:T-rich nature of this region is suited for easy 
unwinding of the DNA duplex and creation of the open promoter complex. 3 The σ-
subunit of RNA polymerase is directly involved in unwinding the dsDNA, and its 
interaction with the non-template strand holds the complex formed between RNA 
polymerase and promoter DNA open, with the σ-subunit acting as a sequence-specific 
single-stranded DNA-binding protein.  The RNA polymerase has two binding sites for 
nucleoside triphosphates (NTPs) during initiation step; the initiation site and the 
elongation site. The first nucleotide binds at the initiation site, base-pairing with the 
exposed base at the +1 position within the opened promoter complex. The second 
incoming nucleotide binds at the elongation site, base-paring with the +2 base. The 
polymerase then catalyses nucleophilic attack by the 3’-OH of the growing RNA chain 
on the α phosphorus atom of a complementary ribonucleoside triphosphate. 
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1.1.1.2 Chain Elongation and Termination 	  
The σ-subunit dissociates once a short oligonucleotide chain has been synthesised and 
subsequent elongation of the RNA transcript is governed solely by the core polymerase 
(α2ββ’). As the RNA transcript gets longer, tangling of the RNA transcript to the non-
template DNA strand can occur and topoisomerases are employed to unknot tangled 
DNA segments during the transcription process. 3 Once the desired mRNA strand has 
been completely transcribed, prokaryotic cells use two methods to terminate elongation; 
intrinsic termination governed by the presence of a specific sequence that terminates 
transcription 2 or a protein called ρ termination factor. ρ Termination factor binds to 
mRNA as a homohexamer and posess RNA-dependent ATPase and helicase activities. 2 
It actively terminates transcription, using the energy from ATP hydrolysis to mediate 
the dissociation of the nascent transcript. 6 In E. coli, ρ termination factors are used at 
the end of genes and operons and at regulatory sites (attenuators) preceding genes. 6 
Intrinsic termination, (also known as ρ-independent termination) on the other hand can 
terminate transcription by the mRNA forming hairpin structures. A protein bound to 
RNA polymerase known as nusA then binds to the hairpin structure tightly enough to 
halt the polymerase, ultimately terminating transcription. 7, 8 
 
1.1.1.3 Regulation of Prokaryotic Transcription 	  
Although transcription in prokaryotes is highly efficient, it needs to be regulated to 
enable adaptation to environment changes and stress. In bacteria, genes encoding 
enzymes are often grouped adjacent to one another resulting in a polycistronic mRNA 
encoding many of the enzymes of the metabolic pathway. The rate of transcription is 
only limited by the accessibility of the promoter sequence to RNA polymerase, 
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therefore regulation of transcription is carried out by transcription factors acting as 
repressors (or negative regulators), which bind tightly to specific sites located next to 
the promoter (operator sites). Interaction of a regulatory protein with the operator 
controls transcription of the gene cluster by controlling access of RNA polymerase to 
the promoter. These combinations of operator and promoter sequences are known as 
operons. 3 An example of such a repressor is bacteriophage λ repressor. Bacteriophage λ 
is a virus that infects E. coli and has two modes of infection; the lytic pathway which 
destroys its host, or the lysogenic pathway where it becomes part of its host. In the lytic 
pathway, viral functions are fully expressed; viral DNA and proteins are rapidly 
produced and packaged together, leading to eventual lysis of the host cell and the 
release of approximately 100 progeny virions. In the lysogenic pathway, the phage 
DNA becomes integrated into the host-cell genome and can be replicated together with 
host-cell DNA for many generations (Figure 1.1.1.3.1). 1 Environmental changes can 
trigger the expression of this dormant viral DNA, which leads to the formation of 
progeny virus and lysis of the host. For example, studies have shown that when 
lysogenic E. coli are irradiated with UV light almost the entire population will undergo 
lysis. 5  
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Figure 1.1.1.3. 1. Diagram of the lytic and lysogenic pathways of bacterial λ phage. 1 
 
In a lysogenic bateria, a single λ phage gene is actively transcribed and translated to a 
single protein – the λ repressor. This repressor works as both a positive and negative 
regulator. It binds to operators (OR1, OR2 and OR3) on the host-integrated λ DNA, 
turning its own gene ‘on’ and repressing all other phage genes. UV light inactivates the 
λ repressor, resulting in the synthesis of a second phage regulatory protein known as 
Cro. 5 Cro, a protein essential to lytic growth, binds to the same sequence as the λ 
repressor, but has the opposite effect. The promoter sequences for repressor and Cro are 
adjacent to each other and overlap the operator sites (Figure 1.1.1.3.2). 
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Figure 1.1.1.3. 2 . Transcription of λ repressor. OR1, OR2 and OR3 are the binding sites for λ repressor 
(R) and Cro. Cro, a repressor, works in opposition to the phage’s repressor to control the genetic switch 
that determines whether a lytic or lysogenic cycle will follow infection. Cro and repressor compete for 
control of an operator region containing three operators (OR1, OR2 and OR3) that determines the state of 
the lytic/lysogenic genetic switch. If this competition is won by the repressor, R, transcription of the Cro 
gene is blocked and repressor synthesis is maintained, resulting in lysogeny. If the competition is won by 
Cro, the late gene of λ phage will be expressed, resulting in lysis. In this case, Cro blocks transcription 
that occurs from PRM, the promoter that is responsible for the maintenance of repressor transcription. 5 
 
These two regulatory proteins in combination with RNA polymerase and their promoter 
and operator sites on the DNA constitute a regulatory ‘switch’ and exemplify negative 
transcription control in prokaryotes.    
 
1.1.2 Eukaryotic Transcription 	  
Transcription in eukaryotes is a much more complex process than in prokaryotes. In 
prokaryotes transcription and translation are closely coupled, in eukaryotes transcription 
occurs inside the nucleus and translation happens in the rough endoplasmic reticulum. 
This spatial and temporal separation of transcription and translation enables eukaryotes 
to regulate gene expression in much more intricate ways, contributing to the richness of 
eukaryotes. 1 
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In bacteria, polypeptide chains are encoded by triplet codons in DNA, which is also the 
case for higher organism such as eukaryotes. It was discovered that newly synthesised 
RNA chains isolated from the nuclei of eukaryotic cells are much larger than the mRNA 
molecules that result from them. This is due to the presence of sequences known as 
intervening sequences, most commonly known as introns, that are removed from the 
primary transcript by a process known as RNA splicing, leaving only sequences that are 
found in mature RNA known as exons (for expressed region, Figure 1.1.2.1). The 
splicing of introns is carried out by a complex of small nuclear RNA (snRNA) and 
protein subunits collectively known as the spliceosome, which recognises trigger 
sequences in nascent RNA that specify splice sites. 1 Introns nearly always begin with 
GU and end with an AG that is proceeded by a pyrimidine-rich tract (Figure 1.1.2.2). 
Individual exons encode discrete structural and functional units of proteins, for example 
the central exon of myoglobin and haemoglobin genes encodes a heme-binding region 
that can reversibly bind O2. 1 Other exons specify α-helical segments that anchor 
proteins in cell membrane. An entire domain of protein may be encoded by a single 
exon.  
 
Figure 1.1.2. 1. Diagram of exons and introns in pre-mRNA and mRNA after splicing by spliceosomes. 
The UTRs are non-coding parts of exons at the end of the mRNA. 
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Figure 1.1.2. 2. Consensus sequence for the splicing of mRNA precursors. 
 
While prokaryotes use a single type of polymerase for the synthesis of almost all RNA, 
the nucleus of eukaryotes contains three types of RNA polymerases differing in 
template specificity, localisation and susceptibility to inhibitors. The three types of 
RNA polymerases are: RNA polymerase I is found in the nucleoli and specifically 
transcribes the genes for 18S, 5.8S and 28S ribosomal RNA. RNA polymerase II, 
located in the nucleoplasm, is used to synthesise messenger RNA (mRNA); and RNA 
polymerase III, also located in the nucleoplasm, is used to synthesise all transfer RNA 
(tRNA) and other ribosomal RNA molecules. 1 Similarly to prokaryotes, eukaryotic 
RNA polymerases do not require a double stranded primer and synthesis proceeds in the 
5’ -> 3’ direction according to instructions given by an antiparallel DNA template 
strand (the coding strand). 
Type II eukaryotic RNA polymerases contain between 8 and 12 subunits, just over 
double that of their prokaryotic counterpart. Two large subunits known as RPB1 (~220 
kDa) and RPB2 (~220 kDa) correspond to the catalytic β and β’ subunits in the core of 
the prokaryotic enzyme. To initiate transcription RNA polymerase II promoter 
sequences are required. These are located about 25 bases upstream of the transcription 
start site and are known as the TATA box. The TATA box is present is nearly all 
eukaryotic organisms that give rise to mRNA. Studies on the TATA box sequences 
have demonstrated that mutation of a single base pair strongly impairs promoter 
Exon 1 Exon 2 Pyrimidine tract AG 5’ 3’ 
Intron 
5’ Splice site 3’ Splice site 
GU 
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activity, highlighting the importance of these RNA polymerase II specific recognition 
sequences. 9 Most TATA boxes are flanked by GC-rich sequences.  
Many promoters contain a CAAT box, and some contain a GC box and sequences 
containing a TATA box and the loci of these motifs, where present, in the upstream 
region collectively define the promoter. The presence of a CAAT box, usually located 
around -80 relative to the transcription start site, signifies a strong promoter. 3 One or 
more copies of the sequence GGGCGG or its complement (also known as the GC box) 
have been found upstream from the transcription start sites of ‘housekeeping genes’. 
Housekeeping genes encode proteins commonly present in all cells and essential to 
normal function. 3 Constitutively expressed genes, which are continuously expressed 
rather than regulated, tend to include GC boxes located around the 35 bases upstream of 
the transcription start site.  
Transcription Factor II (TFII) complexes guide RNA polymerase II to the transcription 
start sites. Transcription is initiated by the TFIID complex binding to the TATA box, 
where TFIIA is recruited, followed by TFIIB (Figure 1.1.2.3). RNA polymerase II and 
then TFIIE join the other factors to form a complex called the basal transcription 
apparatus. 1 This complex can transcribe DNA, albeit slowly, but additional 
transcription factors are required for selectivity and to achieve higher levels of mRNA 
synthesis. The key initial event is the recognition of the TATA box by the TATA box 
binding protein (TBP, section 1.2.7.1, Figure 1.2.7.1), an approximately 30 kDa 
component of the 700 kDa TFIID. TBP is known to bind 105 fold more tightly to the 
TATA box than to non-cognate sequences and the dissociation constant of the specific 
complex is approximately 1 nM. TBP consists of two similar domains each containing 
two α helices and a five-stranded antiparallel β sheet. The bases of the TATA box bind 
to the concave surface of TBP and the saddle-shaped protein induces large 
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conformational changes in the DNA strand. A sharp kink is produced at each end of the 
seven base pair TATA box, causing a partial unwinding of the double helix and a 
widening of its minor groove, enabling extensive contacts with the anti-parallel β-sheets 
on the concave side of TBP. The resulting complex features many hydrophobic 
interactions at this interface, with four phenylalanines intercalated between base pairs of 
the TATA box. The flexibility of AT-rich sequences is exploited to bend the DNA 
locally whilst the B-DNA structure is conserved outside the TATA box. This complex 
is asymmetric, creating a unique start site and assuring that transcription proceeds 
unidirectionally. 
The complex machinery described above is only sufficient for basal transcription; many 
more transcription factors are involved in the initiation and regulation of the specific 
additional genes required in each particular cell type and/or in response to other signals. 
To understand these greater levels of complexity it is important to examine the methods 
used by the proteins involved to recognise and bind to specific DNA sequences, as well 
as how these proteins interact with one another, and how such interactions influence 
which genes are transcribed and the level of transcription. 
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Figure 1.1.2.3. Diagrams of the pathways in the assembly of the basal transcriptional complex. 
Transcription factors TFIIA, B, D, and E are essential in initiating transcription by RNA polymerase II. 
The stepwise assembly of these general transcription factors begins with the binding of TFIID to the 
TATA box. This is in turn recruits TFIIA, B and D, followed by RNA polymerase II. 
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1.2 Eukaryotic Transcription Factors 	  
The structures of many transcription factors and their complexes with DNA have been 
obtained using X-ray crystallography and NMR spectroscopy and have revealed 
conserved structural elements that make direct contact with DNA (DNA-binding 
domains [DBD]). 10 Transcription factors can be classified into families based on the 
overall structure of their DBDs which include: homeodomains, zinc finger proteins, 
steroid receptors, MADS-box proteins, basic zippers (bZIP), basic helix-loop-helix 
(bHLH) proteins and β-sheet motifs. 
 
1.2.1 Homeodomains 	  
Many eukaryotic transcription factors make use of the highly conserved homeodomain 
structure to recognise specific DNA sequences. Homeodomains are approximately 60 
amino acid residues long and are encoded by a 180-bp DNA sequence known as 
homeobox, or homeotic genes. Homeoboxes were first identified in many of the genes 
that help control embryogenesis in the fruit fly Drosophila melanogaster. 11 Mutation of 
these genes can result in altered distribution of Drosophila body parts; for example, by 
introducing mutations to Antennapedia homeotic gene, it was possible to grow an extra 
leg in the region which contains the antenna in a normal fly. 12, 13 Other genes such as 
Ultrabithorax are responsible for repression of the formation of wings in the third 
thoracic segment of the fly. 14, 15 The engrailed homeodomain is responsible for segment 
polarity in Drosophila during embryogenesis, where it defines the anterior and posterior 
compartments both in segmentation and in limb specification. Engrailed is known to 
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bind preferentially to DNA sequences in the promoter of the engrailed gene for positive 
feedback. 16 Correct function of these genes are key to development in Drosophila.   
Homeodomains are characterised by a helix-turn-helix (HTH) motif that makes contact 
with the major and minor grooves of its DNA target recognition site. 17 X-ray 
crystallography shows homeodomains to be globular and contain three α-helices, with 
helix I and II almost exactly antiparallel to each other, whereas helix III crosses over the 
remaining two helices at an angle of approximately 120 oC (Figure 1.2.1.1). 16 
 
 
Figure 1.2.1.1. Crystal structure of engrailed homeodomain-DNA complex (3HDD.pdb). 18 Helix-III can 
be clearly seen lying inside the major groove of the DNA. In turn this helix-III is stabilised by 
perpendicular helices I and II, which are anti parallel to each other forming a hydrophobic core. 
 
One face of helix-III is hydrophobic and packs against helices I and II to form the 
hydrophobic core of the protein domain. The opposite face side of helix-III is 
hydrophilic, with multiple positive charges; it fits into the major groove of DNA 
making contacts with the bases and sugar backbone phosphates and forms the DNA 
binding domain of homeodomain. 16 Seven amino acids from helix-III make contacts 
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with the phosphate groups in the DNA backbone and align the recognition helix in the 
major groove so that base-specific contacts can be made by other residues. For example, 
hydrogen bonds are made with DNA bases by Asn51 and Gln50, whilst Ile47 makes 
hydrophobic contacts with a thymine (Chapter 3). 16 The N-terminal flexible arm 
makes additional specific contacts to bases in the minor groove, allowing residues 3, 5 
and 7 to make base-specific contacts; whilst residue 6 interacts with the sugar-
phosphate backbone. The loop between helices I and II interacts with the DNA 
backbone on the other side of the major groove. 19 Attempts to reduce the size of the 
wild type engrained homeodomain by removing parts of the N-terminal resulted in a 10-
fold reduction of binding affinity to the target DNA, emphasising the importance of the 
N-terminal region to the stability of the protein. 20   
Crystal structures of λ Cro protein and the DNA binding domain of λ repressor revealed 
a conserved recognition motif consisting of an α-helix, a turn, and a second α-helix. 21 
However, these prokaryotic DBDs tend to be small parts of much larger proteins and 
the HTH cannot fold or function on their own. In constrast, homeodomains can fold 
properly and bind to target DNA even in the absence of the remainder of the protein. 21 
Homeodomains are known to interact with other proteins for gene regulation. For 
example, the MAT α2 homeodomain protein found in yeast interacts with two different 
DNA-binding proteins MCM1 (a protein from the MADS-box family of transcription 
factors) and MAT α1 (another homeodomain protein) in order to successfully bind to 
operator sequences and regulate the transcription of cell type-specific genes. 19, 22 
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1.2.2 Basic Zippers 	  
The basic-region-leucine-zipper (bZip) domain is one of the simplest protein structures 
used for DNA recognition and binding. They consist of a region rich in amino acid 
residues with basic sidechains that bind to DNA and a leucine-rich region known as 
leucine zipper, that causes dimerization of bZip proteins. 17 This type of domain is found 
in many eukaryotic transcription factors including the yeast transcription activator 
GCN4 23 and the transforming oncoproteins Fos and Jun that together make up the AP-1 
family of factors. 24 	  
A typical leucine zipper region is approximately 30-40 residues long with a leucine at 
every third and seventh residue, forming a heptad repeat. Studies have demonstrated 
that these leucines drive dimerization by forming a parallel coiled-coil structure. 25 
Figure 1.2.2.1 illustrates the end view of a leucine zipper coiled-coil and the seven 
unique amino acid postions (a, b, c, d, e, f and g) found in each heptad. 26, 27 Residues 
‘a’ and ‘d’ are typically hydrophobic along the dimerization interface to create a 
hydrophobic core that contributes most of the energy needed to stabilise the zipper. 27, 28 
Leucine is the favoured hydrophobic residue for the ‘d’ position and isoleucine is the 
favoured residue for the ‘a’ position. 29, 30 The ‘g’ and ‘e’ position of the leucine zipper 
frequently contain charged amino acids. 31 Studies on the atomic structure of leucine 
zipper dimers have shown that oppositely charged amino acids in the ‘g’ positions and 
the following ‘E’ position lie across the hydrophobic interface and interact inter-
helically, leading to the stabilisation of the structure this helping to regulate the 
specificity of bZip protein dimerisation. 26, 32-35, 36 
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Figure 1.2.2.1. End-view diagram of coiled-coil structure. Looking down the helix axis from N-terminus 
to C-terminus, with the amino acids in the seven unique positions (a, b, c, d, e, f and g ) of the heptad 
presented as circles, oriented as the amino acid side chains would exit the α-helix. Amino acids on the 
second helix of the dimer are denoted A, B, C, D, E, F and G. The potential electrostatic interactions 
between the g of one helix and the following E postion of the opposite position (g <-> E) are indicated by 
the black dashed-arrow. The opposite side of a leucine zipper coiled-coil is identical in a homodimer but 
different in a heterodimer. 27   
 
NMR and X-ray crystallographic studies on Fos-Jun heterodimer and GCN4 
homodimer complexes demonstrate how a pair of zippers wrap around each other 
resulting in a parallel, two-stranded α-helical coiled-coil with a continuous hydrophobic 
interface. 16, 25 36 Dimerization of leucine zippers is essential for DNA binding with 
mutations that prevent dimerization also preventing DNA binding. 37 Dimerization 
facilitates DNA binding by organising two DBD α-helical structures to bind to a 
palindromic DNA recognition site; clamping around the major groove of the DNA like 
a pair of scissors (Figure 1.2.2.1). 5, 36  
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Figure 1.2.2.2. Crystal structure of GCN4 (orange) leucine zipper (upper part) bound to DNA 
(1ysa.pdb). 26 
 
1.2.3 Zinc Fingers 	  
Zinc finger proteins were first described in transcription factor TFIIIA of Xenopus, a 
protein which plays a critical role in regulating the transcription of the 5S ribosomal 
RNA genes by RNA polymerase III. 4 Upon purifying this transcription factor a 
repeated structure was found, with between seven and eleven atoms of zinc associated 
per molecule of purified protein. 38 Cloning the gene encoding TFIIIA revealed that this 
repeated structure contained two invariant cysteine and two invariant histidine residues, 
which were each thought to bind to a single zinc atom. 39, 40 NMR and X-ray studies 
showed that the two cysteine, two histidine finger is a compact globular domain made 
up of a 12-residue α-helix packed against an irregular β-sheet and the zinc sandwiched 
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between them. 40 The histidines are located on the inside face of the helix, whereas the 
cysteines flank a hairpin turn (Figure 1.2.3.1). 
 
Figure 1.2.3.1. Diagram of a zinc finger motif. The zinc ion is shown in purple, the α-helix is shown in 
orange, the β-strands are in green and the turns are in cream. The zinc atom can be seen coordinating 
with two histidines and two cysteines (1aay.pdb). 41   
 
Zinc co-ordination via cysteine and histidine residues serves as a scaffold for the helical 
region, which comes into direct contact with the DNA, 5 two anti-parallel β-sheets also 
pack against the α-helix to help stabilise it. 42 When bound to DNA, the α-helix lies in 
the major groove of the DNA and makes sequence specific interactions with the bases 
of DNA whilst the β-sheets lie further away from the helical axis of the DNA and 
contact the phosphate backbone (Figure 1.2.3.2). 40, 43  
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Figure 1.2.3.2. Crystal structure of zinc finger protein Zif268 bound to the target DNA (1aay.pdb). 41 
 
1.2.4 Basic Helix-Loop-Helix Proteins 	  
The Basic Helix-Loop-Helix domain (bHLH) is a structural motif common to a family 
of transcription factors. These include the E12 and E47 human transcription factors, 
which play a key role in the development of the nervous system, 44 MyoD which 
activates genes specific to skeletal muscle, 5 and MASH-1 which is a central factor for 
the regulation of the differentiation of committed neuronal precursor cells of the 
peripheral nervous system. 45 The motif consists of two amphipathic helices, containing 
all the charged amino acids on one side of the helix, separated by a non-helical loop of 
variable length 44 with one of the helices containing a basic region responsible for 
binding to a DNA target known as E-box. 46 The bHLH motif works in a similar fashion 
to the leucine zipper, causing dimerization of the transcription factor molecule and 
facilitating DNA binding by basic sidechains (Figure 1.2.4.1). 47 
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Figure 1.2.4.1. Crystal structure of bHLH protein MyoD bound to its target DNA (1mdy.pdb). 48 The α-
helices are shown in orange and the loops are in yellow. 
 
Accordingly, deletion or mutation of the MyoD basic domain protein does not prevent 
dimerization but does prevent binding of the protein to target DNA, 49 whereas 
mutations or deletions in the helix-loop-helix region, prevent both dimerization and 
DNA recognition. 5 When the DNA binding domain of MyoD was deleted, the resulting 
protein lost specific DNA binding ability. Selectivity was restored by substituting the 
basic domain of MyoD with the DBD domain of E12 protein. 50 However, the hybrid 
protein does not activate muscle-specific gene expression, suggesting that in addition to 
mediating DNA binding, the basic region of MyoD also contains additional elements 
involved in the activation of muscle-specific genes. 5, 50 Replacing three amino acids 
within the E12 basic region to their MyoD equivalents allowed the E12 basic region to 
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activate muscle-specific gene expression after DNA binding by the protein. 51 The 
crystal structure of MyoD bound to DNA (Figure 1.2.4.1) 48 suggests that these amino 
acids play a role in allowing the MyoD basic region to assume a particular conformation 
in which it interacts with other transcription factors. 5 Kanshal et al., have demonstrated 
that the substitution of these same amino acids in E12 for their MyoD equivalents 
allows the mutant E12 protein to bind to another muscle-specific transcription factor 
MEF2A, an interaction normally a unique property of MyoD, 52 suggesting that the 
basic domain functions both as a DNA binding domain and as a site for protein-protein 
interactions critical for transcriptional activation. 
 
1.2.5 Nuclear Receptors 	  
Nuclear receptors are the largest family of eukaryotic transcription factors and are 
responsible for sensing steroidal and non-steroidal hormones. The binding of these 
hormones to their cognate receptors activates the receptor and allows them to bind to a 
number of specific sites on DNA. 16 Related receptors include retinoic-acid receptors 
and a legion of orphan receptors (receptors that have not yet been paired with 
physiological ligands, such as the nerve growth factor-induced receptor NGFI), which 
play major roles in intracellular signaling and carcinogenesis. 53 The activated forms of 
these receptors bind to target DNA and activate transcription of genes. 5 
In common with other most transcription factors, the nuclear receptors have structural 
features in common comprising a central, sequence specific, DNA binding domain and 
a ligand binding domain (LBD) contained in the C-terminal half of the receptor and 
recognises specific hormonal and non-hormonal ligands. 54 These receptors contain 
variable N-terminal and C-terminal domains, as well as a variable length hinge region 
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between the DBD and LBD. Nuclear receptors can exist as homo- or heterodimers with 
each partner binding to specific regulatory element sequences that exist as half-sites 
separated by variable length nucleotide spacers between direct or inverted half-site 
repeats. 54 These nuclear receptors can also be classified into two different groups: Class 
1 receptors (steroid hormone receptors), function as homodimers and bind to half-site 
regulatory element inverted repeats, and Class 2 receptors which exist as heterodimers 
with Retinoid X Receptor partners and function in a ligand dependent manner (Figure 
1.2.5.1) (Figure 1.2.5.2). 55 
 
Figure 1.2.5.1. Structure of Retinoid X Receptor bound to DNA (1by4). The α-helices are shown in 
orange, the turns are in grey, the β-strands are in green and the zinc atoms are in purple. 
 
  
The DBDs of nuclear receptors have structures reminiscent of zinc finger proteins 
where each DBD contains two tetrahedrally coordinated zinc ions, but with four 
cysteine residues rather than the two cysteine and two histidine residues acting as the 
  
 
 
  
27 
ligands; an arrangement seen in some sub-families of zinc finger proteins. 39 NMR and 
X-ray crystallography shows these domains contain two loop-helix motifs that are 
folded together to form a single structural unit, where each motif has a zinc ion liganded 
by two cysteines from the start of the loop and two cysteines from the N-terminus of the 
α-helix (Figure 1.2.5.2). 16, 56 The α-helices in the domain are highly amphipathic and 
the hydrophobic surfaces in each pack together to produce a stable and extensive 
hydrophobic core that stabilises the structure of the domain.  
 
 
Figure 1.2.5.2. Structure of the glucocorticoid receptor bound to target DNA (1r40.pdb). It binds to DNA 
as a dimer, the first helix of each subunit makes contacts with the bases on the DNA, while the second 
helix makes backbone contacts and acts a dimerisation interface. The α-helices are shown in orange, the 
turns are in grey, the β-strands are in green and the zinc atoms are in purple. 56  
 
1.2.6 MADS-box Proteins 	  
MADS-box proteins are DNA binding domains named after the first four transcription 
factors in which they were discovered: Mcm1 (minichromosome maintenance 1) in 
yeast, 57 AG (Agamous) and DEFA (Antirrhinium majus) in plants, 58 and SRF (Human 
serum response factor) in vertebrates. 59 These domains bind to DNA as a dimer and are 
organised in three layers (Figure 1.2.6.1). 59 The N-terminal region of the MADS-box is 
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predominantly hydrophilic with a high proportion of basic residues, whereas the C-
terminal region is predominantly hydrophobic. 60 The N-terminal region binds to DNA 
through an anti-parallel coiled-coil of two amphipathic α-helices, one from each 
monomer of the dimer. The coiled-coil is oriented parallel to the minor groove and the 
DNA is bent around the protein with each α-helix binding in adjacent major grooves. 
The next layer of the domain is a four-stranded antiparallel β-sheet, packed against the 
coiled-coil, followed by an irregular coiled region and a short α-helix. 17 Myocyte 
Enhancer Factor 2 (MEF2) is a transcription factor belonging to this family of MADS-
box proteins involved in the regulation of a number of muscle-specific genes and is 
postulated to potentiate the transcriptional activity of myogenic bHLH proteins such as 
MyoD, E12 and E47 proteins by recognising the basic region of these factors. 61, 62, 63, 64  
 
 
Figure 1.2.6.1. Structure of SRF-DNA complex (1srs.pdb). 59 α-helices are in orange and β-sheets in 
green. The binding of the protein causes bending of the DNA by 72 o. 
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1.2.7 β-Sheet Motifs 
1.2.7.1 TATA Binding Proteins 
 
TATA-box binding protein (TBP) is required by all three eukaryotic RNA polymerases 
for correct initiation of transcription of ribosomal, messenger, small nuclear and transfer 
RNAs. 65 The TBP binds DNA as a monomer consisting of a curved antiparallel β-sheet 
buttressed by helices. The concave surface of the β-sheet binds to the minor groove of 
the TATA box, and the DNA is kinked in two places resulting in DNA bending by 
approximately 100 o (Figure 1.2.7.1). 17, 65 Two pairs of phenylalanine residues make 
contact with the DNA, inserted between adjacent base-pairs resulting in the kinks in the 
DNA structure; other, polar side-chains make contacts with the base pairs in the minor 
groove and there are further hydrophobic interactions between TBP and the minor 
groove of the DNA. 66, 67  
 
Figure 1.2.7.1. Structure of TBP bound to target DNA (1cdw.pdb). 65 The α-helices are shown in orange, 
the β-sheets in green and coils in grey. 
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1.2.7.2 Rel Family 	  
The Rel family plays a major role in the immune response in higher organisms. The 
members of this family all contain the Rel homology region (RHR) that is responsible 
for protein dimerisation and DNA recognition. The structure consists of two β-sandwich 
domains of which the N-terminal domain binds to the DNA bases using well-defined 
loops between the β-strands (Figure 1.2.7.2). The C-terminal is the dimerization 
domain and is involved in binding to the phosphate backbone. 68, 69  
 
Figure 1.2.7.2. Structure of the homodimeric NF-κB p50 transcription factor in complex with a κB site 
(1nfk.pdb). 68 The α-helices are in orange, the β-sheets are in green and coils are in grey. 
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1.3 DNA Binding Specificity of Proteins 	  
Many DNA-binding proteins make use of α-helices to make contact with major grooves 
of DNA. 65, 70 However, an isolated α-helix from these known motifs cannot bind DNA 
in a site-specific fashion or perform regulatory functions without the surrounding 
regions of the protein. 21 The orientation of α-helices to the major groove (or minor 
groove) also plays an important part on how these proteins bind onto their target DNA 
and when the particular pattern of amino acids on the surface of the protein matches the 
pattern of groups on the surface of the DNA double helix, binding takes place through 
the formation of hydrogen bonds and van der Waals contacts. 71 High specificity 
requires recognition of a number of bases in a DNA, although DNA binding domains of 
proteins often only require three to four bp of nucleotide sequence for recognition. Such 
short sequences occur too frequently to be unique and uniquely recognisable. In order to 
achieve higher specificity, several classes of DNA-binding proteins, such as bZIP 
proteins require, as previously discussed, dimerization of their monomer, in order to 
increase the total number of nucleotides recognised as well as the possibility of a 
variation in spacing between the two half-sites. Both of these measures increase the 
rarity of occurrence of the particular sequence and spacing of bases, increasing 
specificity. Protein-protein interactions are therefore vital for specific DNA binding and 
activation of gene transcription.   
Direct contact with DNA bases is vital for site-specific binding but the methods used to 
contact bases differ greatly between DNA-binding protein families. Structural studies 
have shown direct hydrogen bonds between the protein side chains and the bases, 
occasional hydrogen bonds between the polypeptide backbone and the bases, hydrogen 
bonds mediated by water molecules and hydrophobic contacts are all used to achieve 
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specificity. 21 An example of water-mediated specific contact can seen in the bHLH 
domain of MyoD, where a nitrogen atom from Arg 111 side chain makes contact with 
oxygen of a guanine in the binding site through a water molecule (Figure 1.3.1). 72 
 
Figure 1.3.1. Diagram of MyoD-DNA complex with the water molecule (red sphere) mediating the 
contact between the protein and DNA via Arginine 111 (green and blue) (1mdy.pdb). 72  
 
Contacts made by proteins with the DNA backbone can also play an integral role in 
site-specific recognition. In the most well characterised complex, such as helix-turn-
helix motif and zinc finger proteins, approximately half of all the hydrogen bonds are 
involved in making contacts with the DNA backbone; almost all of these contacts 
involve the phosphodiester oxygens. 21 There is no obvious pattern to which residues 
make contact with the backbone, with many different side chains’ functionalities, 
including the –NH of the polypeptide backbone, known to hydrogen bond to the 
phosphodiester oxygens.  
In addition, the DNA structure can also influence specificity. There are many examples 
where the binding of protein causes bending of DNA, these include TATA binding 
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proteins where the concave surface of the β-sheet causes bending of the DNA of 
approximately 100 ° upon binding to the minor groove, and the MADS-box serum 
response factor (SRF) protein that also causes DNA to bend by 72 °. 65, 59 
The double-stranded DNA structure can be described as a polymer with uniform 
structure, containing negatively charged sugar phosphate backbone and a core of 
stacked base pairs whose edges are exposed in the major and minor grooves. Each base 
pair has a set of characteristic functional groups, by which each DNA sequence can be 
described as having a chemical ‘signature’ characterized by the pattern of these groups 
exposed in the DNA grooves. 73 DNA binding proteins, such as transcription factors, 
recognise this chemical surface combined with its sequence-dependent variations in 
structure and flexibility by having a surface that is chemically complementary to that of 
the DNA, forming a series of favourable electro static and van der Waals interactions 
between the protein and the base pairs.    
The vast majority of proteins recognise functional groups in the major groove of the 
DNA, as it is here that each base pair can be uniquely distinguished. The pattern of 
hydrogen bond donors and acceptors is less varied in the minor groove, with A-T 
similar to T-A and G-C similar to C-G. 73 It has also been suggested that sequence 
specificity may arise from hydrogen bonding interactions between the protein and 
DNA, due to the requirement for near collinear apposition of donor and acceptor 
groups.  73 Bidentate interactions, by which a single side chain forms two or more 
hydrogen bonds with the DNA allow an even greater degree of specificity than a single 
hydrogen bonds to a side chain. In order to achieve this interaction, amino acids must 
contain more than one hydrogen-bonding atom. 74 Arginine for example can recognise a 
guanine base through bidentate interactions. There are two possible arginine-guanine 
interaction conformations, the end-on approach interacts with one or both of the distal 
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nitrogen atoms (Figure 1.3.2.A-C) and the side-on approach uses the Nε and Nη1 atoms 
(Figure 1.3.2.D). 73, 74 It has been suggested that the first interaction conformation is 
preferred over the second due the easier access of arginine side chain as probes 
compared to extending along the groove floor. 74 Van der Waals interactions also play 
an important part in specificity, where they impose steric constrains on the types of 
bases that can be accommodated at particular positions, therefore also playing a role in 
sequence selectivity. 74 
 
Figure 1.3.2. Diagrams of bidentate interactions. The arrows are drawn between interacting atoms, 
pointing from the donor to the acceptor. 74  
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The specificity of a DNA binding protein to its cognate site can be determined by the 
difference in ΔG obtained for binding to a specific (S) and a non-specific (NS) site 
(Equation 1.3.1), or the ratio of the apparent dissociation constants (KD) for those sites 
(Equation 1.3.2). 
ΔΔG = ΔGNS – ΔGS                                                                                      Equation 1.3.1 
Specificity = KDNS / KDS                                                   Equation 1.3.2 
Specificity of several prokaryotic and eukaryotic transcription factors has been 
determined using the above methodology (Table 1.3). 
Protein Specificity 
λ Cro (OR1) 1.8 × 105 
lac repressor 
MASH-1 
GCN4 
engrailed homeodomain 
2.9 × 107 
3.2 
31 
26 
 
Table 1.3. Specificity values of λ Cro, 75 lac repressor, 76 MASH-1, 77 GCN4 78 and engrailed 
homeodomain 79 transcription factors.  
 
1.4 Stabilisation of DNA-binding proteins and α-helices in vitro 	  
Small peptides corresponding to the isolated helical or other motifs are usually 
disordered in solution, since the folding process is thermodynamically disfavoured. 
Naturally occurring proteins overcome this barrier using complex folds to display a 
small number of functionally important amino acids. This pre-organisation of the 
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conformation of small numbers of functional amino acids into the recognition motif is 
important for potent recognition of the binding domain of the protein. 
The α-helix is stabilised by hydrogen bonding between the amide NH and the 
carboxylic (C=O) groups of the peptide backbone. The C=O group of one amino acid (i) 
makes a H-bond to the NH group situated four residues ahead in the sequence (i+4) 
(Figure 1.4.1.A).  
 
Figure 1.4.1. Diagrams of an α-helix. A) Cartoon representation of a helix back bone to the helix axis. 
Hydrogen bonds are represented in black dotted lines. Other atoms are in standard colours. B) Diagram 
of dipoles on the helix. 80  
 
The C=O group is almost parallel to the axis of the helix pointing towards the NH group 
and hydrogen bonded to it, while the side chains point away from the axis. One turn of 
the helix incorporates 3.6 amino acid residues, involving 13 atoms from the O to the H 
of the H bond.  Each amino acid residue extends the helical axis by 1.5	   Å. With 3.6 
residues per turn, this is equal to 5.4	  Å of the travel along the helix axis per turn which 
is also referred to as the translation distance or the ‘pitch’ of the α-helix. Since the first 
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and last four residues differ from the interior ones as they cannot make the intrahelical 
hydrogen bonds between the backbone C=O groups of one turn and the NH group of 
residues in the next, they therefore require hydrogen bonds to be made with either 
solvent or other residues in the protein. The first and last residues of a helix are 
frequently residues whose sidechains can provide such hydrogen bonds. 80 Helices are 
often amphipathic, where one side has hydrophobic residues that bind to hydrophobic 
areas in the protein, and the other has hydrophilic residues that interact with water. The 
alignment of dipoles of the amide bond backbone nearly parallel to the axis of an α-
helix causes a net dipole moment with its positive pole at the N-terminus and negative 
pole at the C-terminus (Figure 1.4.1.B). 80  
In order for an α-helix to form from a disordered coil, four amino acids must adopt an 
α-helical conformation, making the i + 4 hydrogen bond. This nucleates the formation 
of further hydrogen bonds, propagating the α-helix at a rate and extent dependent on the 
intrinsic helical propensity of each amino acid residue. 81 However, disordered 
polypeptide chains in solution have considerable conformational freedom and high 
entropy. If side chains contain hydrogen-bonding groups, then these groups make bonds 
with the polypeptide backbone, if favourable, or with solvent molecules. Formation of a 
helix results in substantial loss in conformational freedom of the peptide due to the 
rigidity enforced by intra-helical hydrogen bonding, but this is compensated for by the 
release of water previously hydrogen bonded to the amides. 80 
The helical propensities of amino acids were initially investigated by examining the 
frequency that each amino acid occurs in α-helical, β-sheet, and random coil 
conformations. Latterly, the helical propensity was refined by studying the helical 
content of designed peptides comprised mainly of alanine. Alanine has the smallest side 
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chain of the L-amino acids and does not make electrostatic interactions with solvent 
molecules and therefore serves as a good model for calculating relative energies. 80 
Using alanine-based peptides, Charkrabartty et al. measured the α-helical propensity of 
all amino acids, and developed a theory to describe the α-helix-random coil transition of 
polypeptides (Table 1.4.1). 82, 83 It was concluded from the values obtained that most 
amino acids oppose folding, where arginine and leucine residues are helix-indifferent 
and only alanine strongly favours helix formation. 83 
 
Residue 
 
Helix Propensity 
  
Residue 
 
Helix 
Propensity 
 
Ala 
Arg+* 
Leu 
Lys+ 
Glu 
Met 
Gln 
Glu- 
Ile 
Tyr 
His 
Ser 
 
1.54 
1.04 
0.92 
0.78 
0.63 
0.60 
0.53 
0.43 
0.42 
0.37 
0.36 
0.36 
  
Cys 
Asn 
Asp 
Asp- 
Trp 
Phe 
Val 
Thr 
His+ 
Gly 
Pro 
 
0.33 
0.29 
0.29 
0.29 
0.29 
0.28 
0.22 
0.13 
0.06 
0.05 
~ 0.001 
 
Table 1.4.1. Helical propensity values of amino acids measured at 273 K; a higher value is indicative of 
the likelihood of this amino acid accruing in an α-helix. 83 (*) arginine is protonated and positively 
charged. 
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The large helical propensity of alanine compared to glycine (which lies on the other end 
of the spectrum) is due to several reasons. Firstly, glycine is inherently more helix 
destabilising than alanine because glycine has greater conformational freedom in the 
unfolded state; assuming a helical fold is therefore more entropically unfavourable. 
Secondly, on folding from an extended conformation alanine buries more solvent-
accessible hydrophobic surface area than glycine. Thirdly, the side chain of alanine can 
hinder the solvation of NH and C=O groups in the unfolded state, reducing the number 
of hydrogen bonds made with solvent, which is important for the C- and N-termini of 
helices. 80 Therefore, alanine generally imparts more stability in the middle positions of 
an α-helix because it buries more solvent-accessible area, while glycine is preferred at 
the termini as it allows less hindered solvation of the amine and carboxylate groups. 
This effect is most noticeable at the N-terminus because the side chain points backwards 
along the helix. 80 Amino acids such as glutamic acid, aspartic acid, threonine and 
serine are also preferred at the N-terminus (N-cap) because they act as hydrogen bond 
acceptors for a free NH2 group, stabilising the helix. Similarly, residues that can act as 
hydrogen bond donors, such as arginine or lysine, are improve helix stability when 
placed at the C-terminus. 80, 84, 85  
Synthetic strategies aimed towards stabilising the helical structure include acylation or 
succinylation of the N-terminus, 84, 86 lactam bridging, 87 disulfide formation, 88, 89 
multiple salt bridges, 90 hydrazone linkages and use of unnatural amino acids (Figure 
1.4.3). 91, 92, 93  
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Figure 1.4.3. Diagrams of the α-helical hydrogen bonding network and two different strategies of 
stabilising this structure. A) unmodified α-helix (H-bond interaction highlighted in blue), B) hydrazone 
bond (blue) and C) α-helix with a thioxo amino acid. Note that the H-bond formed by the thiol group 
(red) is weaker and longer, and the amine H-bond (blue) is stronger than the H-bonds usually formed in 
helices.  
 
Miwa et al. demonstrated that a thioxo amino acid can be used to stabilise the yeast 
transcription factor GCN4. 93 The thioxo amino acid was incorporated into a helix where 
the sulfur formed a longer and weaker hydrogen bond with the amine of the i + 4 
residue while the amine of the thioxo amino acid formed a stronger hydrogen bond than 
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the natural occurring hydrogen bonds in α-helices (Figure 1.4.3). However, it was 
demonstrated that these linkages do not otherwise affect the formation of the helix, or 
the oligomerisation of the protein, but did endow peptides with higher thermal stability. 
93  
Another method of using unnatural amino acid to stabilise the helical structure was 
demonstrated by Schafmeister et al.94 A pair of α-methyl amino acids bearing olefinic 
side chains of varying length amino acids with R or S stereochemistry (Figure 1.4.4) 
were incorporated into peptides based on the C-peptide, the 13 N-terminal residues of 
RNAse A, at the i and either i + 4 or i + 7 positions and cyclised via olefin metathesis to 
cross-link one or two turns, respectively, of the helix. 94, 95, 96 Hydrocarbon stapling 
increased the helicity and resistance to proteases of the synthetic peptides.  
 
Figure 1.4.4. Chemical structures of modified A) S- and B) R-amino acids with olefinic side chains of 
variable length. 94 
 
Many investigations have sought to stabilise small helical peptides by pre-organising 
the helix to reduce the entropic cost of folding. 81, 97, 98, 99 One strategy to achieve helical 
stability in smaller peptides is to introduce the key functional residues (for example for 
DNA recognition and binding) into natural scaffolds with a well-defined and stable 
helical structure. Zondlo et al. presented an example of this use of natural scaffolds to 
create miniature proteins with novel activities using avian pancreatic polypeptide (aPP).  
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A small, well-folded protein consisting of a single α-helix stabilised by hydrophobic 
interaction with a type II polyproline helix, aPP was modified to contain residues used 
by the yeast transcription factor GCN4 to recognise specific DNA target site by the 
process known as protein grafting to contruct a 42 amino acid peptide that exhibited 
high DNA affinity and specificity at 4 °C (Figure 1.4.5). 100, 101 However, the activity 
was lost at room temperature, observed via electrophoretic mobility shift assay. 100 In 
order to overcome this temperature dependency, a phage library containing peptides 
with random mutations on the poly-proline helix was employed to select peptides active 
at room temperature. 101 The resulting p007 peptide demonstrated high affinity for the 
GCN4 cognate sequence at 25 °C. Further investigation of the 29 amino acids of p007 
to the DNA affinity, specificity and secondary structure by alanine-scanning 
mutagenesis, it was concluded that all residues on the α-helix and most of the residues 
on the poly-proline helix were important for DNA-affinity and specificity. 102 The same 
system was also employed to synthesize a miniature homeodomain with 100 times 
increased affinity for its cognate DNA relative to the orginal recognition helix alone. 103    
Weston et al. designed an 18-residue miniature decarboxylate enzyme, Apoxaldie-1, 
based on a neurotoxic peptide apamin found in bee venom, in which a helical region is 
stabilised by two disulfide linkages. The helix displays three lysine residues on the 
solvent exposed side of an α-helix that are catalytically active (Figure 1.4.6). 104 
Apoxaldie-1 demonstrated high stability to thermal denaturation and to high 
concentrations of the denaturant guanidinium chloride due to the presence of two 
disulfide linkages found in apamin. 105 The decarboxylation rate of this miniature 
enzyme was found to be approximately four orders of magnitude faster than n-
butylamine. 104 
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Figure 1.4.5. X-ray diffraction structure of aPP (2bf9). The α-helix is shown in orange and the proline 
residues in combination with other residues adopt a proline-type II structure that is shown in blue 
(proline residues are shown as sticks).  
 
 
Figure 1.4.6. Diagram of Apoxaldie-1. 104 The disulfide bonds are represented in yellow, the catalytic 
lysine side chains are in red and the α-helix is shown in blue. 
 
Talanian et al. have demonstrated that removal of the leucine zipper region from the 
bZIP protein GCN4 could be compensated for by using a covalent disulfide bond to 
effect dimerisation of the remaining basic domain. The resulting peptides proved 
capable of binding to DNA, with a dissociation constant of approximately 10 nM (via 
EMSA), which is of similar affinity and specificity to those of parent protein (Figure 
1.4.7). 106  
  
 
 
  
44 
 
Figure 1.4.7. Diagram of a substitution of the leucine zipper dimerisation motif by a disulfide bridge. 106 
 
Helices may also be stabilised by inducing conformational contraints through the use of 
cross-linkers. For example, para-disubstituted benzene rings were used to link the side 
chains of residues in a peptide with an i, i+7 relationship. 107 Acetylenic crosslinkers of 
different lengths with varying degrees of flexibility (Figure 1.4.8) were used to modify 
lysine residues in either i, i+4 or i, i+7 spacings in order to stabilise α-helical structures 
in short peptides. Improved stabilization was confirmed by comparison to the same 
peptide cross-linked only with alkyl or oxyethylene skeletons. 108  
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Figure 1.4.8. Chemical structures of acetylenic crosslinking agents used to stabilise α-helices, where n 
corresponds to 1 or 2. 108  
 
 
1.5 Photocontrol of Peptide Conformation 	  
Rather than simply enforce secondary structures by the use of a covalently bound 
crosslinker, photocontrollable crosslinkers can facilitate reversible, light-dependent 
regulation of peptide or protein conformation. One such photocontrollable crosslinker is 
a spiropyran compound, which was introduced onto cysteine residues mutated into the 
sequence of the MscL channel protein found in E. coli. 109 Irradiation of the crosslinker 
with UV light (366 nm) led to photochemical ring opening process, with the formation 
of a charged zwitterionic merocyanine state (Figure 1.5.1).  
This isomerisation occurring inside the narrow protein pore causes hydration of the dye 
and weakening of the hydrophobic interactions used to maintain the closed channel 
conformation, so that the pore opens. When the crosslinker was exposed to visible light, 
the compound returned to its closed ring, uncharged state, allowing reversible control of 
the channel conductivity upon an optical signal. However, the amount of merocyanine 
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formed on irradiation consistently dropped after the first open-close illumination cycle 
and the isomerisation process was slow. 109  
 
Figure 1.5.1. Structures of the spiropyran and merocyanine states of the 3’,3’-dimethyl-1’-(2-
iodoacetyloxyethyl)-6-nitrospiro[2H-1-benzopyran-2,2’-indoline] photoswitch (R = iodine or MscL 
protein). 109 
 
Azobenzene is the most widely used photoswitchable crosslinker, it can adopt two 
conformations, cis (a non-planar conformation with C2 symmetry) and trans (a planar 
structure with C2h symmetry). 110, 111 The trans conformation of azobenzene is 10-12 
kcal mol-1 more stable than the cis isomer so that, at equilibrium in the dark, trans is the 
dominant isomer. 112, 113 The dark equilibrium state of azobenzene is >99% trans isomer 
(at 298K), whereas the amount of cis isomer that can be achieved upon irradiation is 
typically 70%-90% depending on the system. 114  
The azobenzene crosslinker undergoes a reversible photoisomerisation between both 
states, with trans to cis isomerisation occuring upon irradiation with UV light at 365 nm 
and a cis to trans isomerisation takes place at 420 nm or thermally (Figure 1.5.2). 110  
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Figure 1.5.2. (top) Isomerisation of the azobenzene and (bottom) electronic absorption spectra of the 
trans (blue) and cis (red) isomers of azobenzene. 
 
Four different pathways have been proposed as possible pathways for the 
photoisomerisation of the azobenzene crosslinker: rotation, inversion, concerted 
inversion, and inversion-assisted rotation (Figure 1.5.3). 111, 115, 110, 116 The rotational 
pathway involves loss of the N=N π-bond to allow free rotation about the N-N bond. 
Rotation changes the C-N-N-C dihedral angle while the N-N-C angle remains fixed at 
approximately 120°. 116 In the inversion mechanism, one N=N-C angle increases to 180° 
while the C-N=N-C dihedral angle remains fixed at 0°, resulting in a transition state 
with one sp hybridised azo-nitrogen atom.117 For isomerisation to occur by concerted 
inversion, both N=N-C bond angles need to increase to 180° in order to generate a 
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linear transition state. In inversion-assisted rotation, large changes in the C-N=N-C 
dihedral angle and smaller but significant changes in the N=N-C angles occur 
simultaneously. 111 The transition state formed in concerted inversion has no net dipole 
moment, whereas the other three pathways possess polar transition states. Relaxation 
from all four transition states can afford either the cis or trans isomer; therefore, all four 
mechanisms predict photostationary states consisting of both isomers. 111  
 
Figure 1.5.3. Schematic diagram to show the suggestive pathways for trans-cis isomerisation of the 
azobenzene: Rotation, inversion, concerted inversion and inversion-assisted rotation. 111 
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Azobenzene-based photoswitches require UV light for photoisomerization, which can 
limit their application in biological systems, where UV light can trigger unwanted 
responses such as apoptosis. 118, 119, 120, 121 However, the presence of substituents on the 
phenyl rings of the azobenzene crosslinker may strongly influence the positions and 
shapes of azobenzene absorption bands. Different amino groups at the ortho or para 
positions can drastically red-shift the spectrum. 112 The incorporation of a donating 
group at one para position and an acceptor group at the other para position (‘push-pull’ 
azobenzenes) can lead to further red-shifts. 112, 122 This can be explained by seeing the 
excited state as having more dipolar character than the ground state; 123 substituents that 
can donate electron density inductively or via resonance will stabilise the excited state 
more than the ground state, resulting in red-shifts. 124 Beharry et al. have developed an 
azobenzene crosslinker that is photoswitched by green light (530-560 nm) by 
substituting all four ortho positions of a 4,4’-diamidoazobenzene core (Figure 1.5.4. 
A)) with methoxy groups (Figure 1.5.4. B)). 125 However, this modification increased 
sensitivity towards reduction under biomimetic conditions with a half-life of only 1.5 
hours in a 1 mM reduced glutathione solution, limiting the potential for biological 
applications. 126 Substituents on the phenyl ring can also influence the thermal 
relaxation rate from cis-to-trans, which can be understood in terms of how the groups 
affect the degree of single bond character in the azo moiety. 127 Low pH can also 
increase the rate of thermal reversion to the trans isomer due to protonation at the azo 
moiety reducing the barrier to rotation. 128 The relaxation rates are also solvent 
dependent, with many substituents showing an increase in reversion rate with increasing 
polarity. 129, 130, 131, 132 
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Figure 1.5.4. A) Structure of parent 4,4’-diamidoazobenzene, B) structure of trans-2,2’,6,6’-
tetramethoxy-4,4’-diacetamidoazobenzene..The absorption of these compounds in the trans state are very 
similar to those of the parent azobenzene A. Irradiation of trans B with green light (530-560 nm) 
produced a mixture with approximately 80% fraction of the cis isomer, which is comparable to the 
fraction produced with the parent 4,4’-diamidoazobenzene. 125  
 
Azobenzenes are useful photoswitches because their isomerisation is rapid 
(nanoseconds) and can result in a strong change in geometry upon switching. The end-
to-end distance of each isomer is substantically different; the distance between the 
carbons at the para positions of the rings changes by approximately 3.5 Å.	   133 
Azobenzene possesses high photostability and repeated photoisomerisation does not 
degrade or destroy the compound. 134, 135 Whilst the structural changes induced by 
photoswitching depend on the magnitude of the end-to-end distance change of the azo 
compound, simply increasing the end-to-end distance of azobenzene may not 
necessarily increase the change upon isomerisation if the extension is too flexible. 127 
For example, azobenzenes para-substituted with urea or carbamate groups may have 
longer end-to-end distances compared to 3,3’-bis-(sulfo)-4,4’-
bis(chloroacetoamino)azobenzene crosslinker (discussed later), but their flexibilities 
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reduce the calculated net change in distance when alkylated onto peptide upon 
switching. 136 Isomers with overlapping end-to-end distance ranges will also reduce the 
degree of functional change observed, for example Beharry et al. have shown that 
minimal changes in helical content of a targeted peptide were observed for a 
dialkylamino-azobenzene unless the attachment points on the peptide were carefully 
optimised (Figure 1.5.5). 137 
	  
Figure 1.5.5. Structure of the dialkylamino azobenzene crosslinker. 137 
 
Azobenzene photoswitches can regulate the conformations of many different structural 
motifs. In proteins, β-hairpins are often identified as binding epitopes involved in 
protein-protein and protein-DNA interactions. However, β-hairpins are relatively 
unstable and difficult to characterise. Dong et al. incorporated an azobenzene 
crosslinker into a β-hairpin motif and were able to characterise the motif by NMR 
spectroscopy, demonstrating the successful folding of β-structures upon switching the 
azobenzene trans to cis. Trans-azo isomer exhibited a mostly disordered structure and 
cis-azo isomer led to the formation of the β-hairpin structure (Figure 1.5.6). 138  
 
N
N
Cl
O
N
N
N
N
Cl
O
  
 
 
  
52 
	   
Figure 1.5.6. Structure of the β-hairpin peptide with the azobenzene crosslinker. 138 
 
	  
Figure 1.5.7. Structure of synthetic cyclic peptide based on a β-finger peptide of neuronal nitric oxide 
synthase (nNOS) with amino acids glycine (G), leucine (L), Glutamic acid (E), threonine (T), phenyl 
alanine (F), aspartic acid (D), proline (P), isoleucine (I) and arginine (R) modified with an azobenzene 
crosslinker. The lysine side chain is for immobilisation on the sensor chip for binding studies using SPR 
techniques. 139  
 
Photocontrol of a β-hairpin peptide was also demonstrated by Hoppmann et al., who 
incorporated an azobenzene photoswitch into a synthetic cyclic peptide related to a β-
finger peptide of neuronal nitric oxide synthase (nNOS) which mediates the formation 
of a variety of multi protein complexes in the cell (Figure 1.5.7). 139, 140 nNOS interacts 
with syntrophin PDZ domain to mediate the production of nitric oxide to coordinate 
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muscle contraction.141 The binding of this crosslinked nNOS to target syntrophin PDZ 
was observed to change upon photoisomerisation. 139  
Woolley et al. have developed an extensive family of azobenzene crosslinkers, which 
can be attached via peptide side-chains rather than the backbone and which feature other 
substituents to modulate optical or physical properties. 142, 143, 144, 145 They all contain α-
haloacetamido groups, allowing selective reaction with cysteine residue side chains in 
the presence of other amino acids via an SN2 reaction. The switches are symmetrical so 
a single species is formed upon crosslinking. The most commonly used member of the 
family (Figure 1.5.8) features a minimum number of single bonds between the azo 
moiety and the peptide backbone to enhance coupling of the change in end-to-end 
distance of the switch to the peptide backbone and sulfonate groups to increase water 
solubility. 142, 146  
	   
Figure 1.5.8. The photoisomerisation of Woolley et al. designed 3,3’-bis-(sulfo)-4,4’-
bis(chloroacetoamino)azobenzene (BSBCA) crosslinker.  
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The ability to react with cysteine side chains allows this family of crosslinkers to be 
used to control α-helicity. 12416 Molecular modeling suggested that in order to stabilise 
the helical motif at trans conformation, an i, i +11 spacing of cysteine residues inserted 
into a sequence is the most appropriate to match the trans configuration crosslinker 
length of approximately 16.8 Å. To match the cis conformation length of approximately 
11.3 Å to a helix the cysteines need to be in the i, i +4 or i, i +7 spacings (Figure 
1.5.9).114, 147 
Time-resolved optical rotatory dispersion experiments on a crosslinked peptide 
demonstrated that the complex undergoes subnanosecond photoisomerisation to the cis 
form and re-isomerises on time scale of minutes. 148 Time-resolved IR spectroscopy 
experiments were used to examine the folding and unfolding of a photoswitchable 16-
residue alanine-based α-helical peptide and refined the isomerisation timescale to 
picoseconds with folding and unfolding occurring on a 100 ns to µs timescale. 149, 150, 151 
This is interpreted as the crosslinker tilting the energy landscape without altering the 
intrinsic conformational dynamics of the peptide, 127 an approach generally applicable to 
a variety of peptides and proteins. 152 Zhang et al. introduced an azobenzene crosslinker 
to the SH3 domain from Fyn-tyrosine kinase (FynSH3) and demonstrated that the 
energy difference between the trans and cis isomers of the crosslinker (approximately 
10-12 kcal mol-1) was greater than the folding free energy of uncrosslinked FynSH3, 
suggesting that photoisomerisation should be sufficient to drive the folding/unfolding of 
other globular proteins. 153 
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Figure 1.5.9. A) crosslinking reaction of azobenzene and peptide, B) isomerisation scheme of i, i+7 
spacings, C) isomerisation scheme of i, i+11 spacings.  
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By photocontrolling helix formation in small peptides, it is possible to control the 
conformation and binding of helical elements of transcription factors’ DBDs. Guerrero 
et al. reported that introducing an azobenzene crosslinker into an 18-residue polypeptide 
based on the recognition helix of the Q50K engrailed homeodomain in an i, i +11 
spacing caused the peptide to be more helical and have greater DNA binding affinity 
when the crosslinker is in the trans configuration. 154 Upon irradiating the crosslinked 
HDH-3 peptide, the cis conformation disfavoured the helical motif, reducing binding of 
the peptide to DNA. Guerrero et al. also demonstrated the ability to regulate the binding 
specificity of the muscle-specific transcription factor MyoD. 155 As previously 
discussed, MyoD belongs to a family of transcription factors that rely on a basic helix-
loop-helix domain for DNA binding. By substituting Met 116 and Ser 123 residues 
located on the water-exposed face of the recognition helix of MoyD with cysteines in an 
i, i +7 spacing, it was possible to introduce a BSBCA crosslinker, thus enabling the 
MyoD DNA recognition domain to be photoswitchable. 155 Ultimately, the binding 
control of this photoswitchable MyoD to target DNA was achieved upon isomerization. 
Woolley et al. demonstrated reversible control of a modified GCN4-bZIP protein using 
this crosslinker binding to its target DNA. 156 Alkylating the azobenzene on the 
cysteines spaced i, i+7 residues apart and away from the dimer interface resulted in the 
cis isomer enhancing the degree of helicity of the coiled-coil region. 156 This work was 
extended to manipulate the binding affinity of the AP-1 transcription factor Fos in vivo. 
157 The crosslinker was again attached to i, i+7 spaced cysteine residues introduced on 
the face of the helix away from the heterodimerisation interface. Upon photoactivation, 
the helicity of this crosslinked AFosW peptide is enhanced, leading to the formation of 
coiled-coil Fos-Jun heterodimers. This in turn reduces the population of Jun-Jun 
homodimers and reduces gene expression. 157 Crosslinked XAFosW reduced binding of 
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AP-1 to DNA up to 10-fold after UV irradiation in vitro. 157 The in vivo activity of the 
photoswitchable dominant negative XAFosW to AP-1 was carried out in 293T cells. 
Luciferase reporter (AP-1-Luc) under the control of an AP-1 promoter together with a 
β-galactosidase reporter under the control of a constitutive rous sarcoma virus (RSV) 
promoter (pRSV-Gal) was used in order to permit quantitative analysis. 157 Ratios of 
luciferase activity to β-galactosidase activity were used as an indication of specific 
inhibition of AP-1 activity. In order to minimise possible photodamage to cells, the 
isomerisation of trans XAFosW to cis XAFosW was done by irradiating the cells with a 
365 nm light-emitting diode in short bursts so that at the end of the incubation period, at 
least 50% of the linker moieties were expected to be present in the cis form in the 
irradiated cells. 157 When non-crosslinked AFosW was used, the activity of AP-1 was 
inhibited in a light-independent manner. However, when XAFosW was used, it was 
observed that the activity was light-dependent, which resulted in a decrease in AP-1 
activity upon photoisomerisation by as much as approximately 40%. 157 The 
effectiveness of XAFosW in the photocontrol of AP-1 activity in living cells was also 
confirmed by the use of AP-1 GFP reporter in combination with flow cytometry 
measurements confirming that cis XAFosW is a more potent AP-1 inhibitor than its 
trans isomer. 157 Mart et al. developed photoswitchable RNA binding peptides based on 
Rev-RRE complex, a regulator of virion protein (Rev), which interacts with the stem-
loop IIB of the Rev response element (RRE) of HIV type 1. 158 Rev binds to RRE 
containing mRNA, removing it from the nucleus, thus allowing expression of unspliced 
or singly spliced mRNA into different protein products. This is an important interaction 
as Rev-RRE interaction controls the infection cycle of HIV type 1, as the resulting 
products are needed for virus particle assembly. 158 Two Rev-based peptides (residues 
33-50 of Rev) Revi,i+7 and Revi, i+11 were designed by replacing two appropriately spaced 
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amino acids (i, i+7 and i, i+11 spacings) located on the solvent-exposed face of Rev α-
helix and opposite the residues involved with RNA bindings, with cysteine residues in 
order to accommodate the BSBCA photoswitchable crosslinker (Revi,i+7-XL-SO3H and 
Revi, i+11-XL-SO3H). 158 Upon photoisomerisation, slower relaxation rate of Revi,i+7-XL-
SO3H from cis to trans (UV-visible spectroscopy, 299 min) compared to Revi, i+11-XL-
SO3H (135 min) was observed. CD spectroscopy of the peptides at dark-adapted state 
(dad) also demonstrated that Revi, i+11-XL-SO3H adopted an α-helical conformation, 
whilst Revi,i+7-XL-SO3H adopted a less α-helical structure in dark-adapted state, but 
was mostly α-helical after photoisomerisation with 363 nm light. In order to perform 
binding studies, the peptides were labelled with fluoresceinamide (FAM) on their N-
termini, allowing FRET measurements of RNA binding affinities from the peptides to a 
RNA molecule labelled with cyanine dye CY3 acceptor fluorophore. 158 However 
binding studies of Revi, i+11-XL-SO3H and Revi,i+7-XL-SO3H  could not be performed 
due to the low solubility of the fluorescently labelled and alkylated peptides. Hence 
unlabelled Revi, i+11-XL-SO3H and Revi,i+7-XL-SO3H were instead used to displace 
FAM Revwt from a preformed complex with 5’-Cy3-labelled RRE. trans Revi, i+11-XL-
SO3H demonstrated lower binding affinity to RRE (247 nM) than the Revwt-RRE 
complex (5.8 nM), whereas no binding as observed for Revi,i+7-XL-SO3H in either trans 
or cis conformations. Molecular dynamics simulations revealed that the sulfonate 
groups disturbed the α-helical structure of Revi, i+11-XL-SO3H for all conformers of the 
crosslinker in a way that resulted in the bending of the peptide backbone. The presence 
of sulfonate groups on the crosslinker seems to cause steric hindrance with the 
phosphate backbone at the rim of the binding pocket. Therefore a non-sulfonated 
BSBCA was used, resulting in the production of Revi,i+7-XL-H and Revi, i+11-XL-H 
peptides. 158 trans Revi, i+11-XL-H demonstrated improved affinity for RRE (24 nM) 
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whereas cis Revi, i+11-XL-H demonstrated a decrease in affinity (66 nM). The 
dissociation constant (KD) trans Revi, i+7-XL-H-RRE complex was obtained (1 µM), 
whereas cis Revi, i+7-XL-H-RRE complex demonstrated higher binding affinity (607 
nM).          
Wysoczanski et al. reported a NMR structure of a photoswitchable pro-apoptotic Bak-
based peptide in complex with pro-surviving protein BclXL. 159 The photoswitchable 
peptide was based on the sequence of a 16 residues Bak wild type (Bakwt) with the I81F 
substitution known to increase the affinity for BclXL. 160 The BSBCA photoswitchable 
crosslinker was introduced to two cysteine residues in an i, i+11 spacing, on the face of 
the helix predicted to orient away from the binding region, generating BakI181Fi, i+11-XL. 
159 NMR studies have demonstrated that upon binding to the surface groove of BclXL, 
BakI181Fi, i+11-XL is coiled into a slightly distorted helix and the binding appeared to be 
driven almost exclusively by hydrophobic interactions. Despite the fact that the 
presence of the crosslinker on BakI181Fi, i+11-XL had caused distortion on the complex, 
forcing the hydrophobic side chains out of the position adaopted by Bakwt, the binding 
site of BclXL demonstrated a large degree of flexibility by remodelling itself to make 
favourable interactions with the crosslinker peptide.    
To date, most applications of azobenzene photoswitches to controlling biomolecular 
functions have been carried in vitro. The ultimate aim would be taking this a step 
further in achieving photocontrol of biological function in vivo. There are two possible 
ways of achieving this: firstly by introducing a biomolecule modified with a 
photoswitch to the living system by for example, microinjection or using cell-
penetrating peptide sequences, 157, 161 secondly where the target biomolecule is 
selectively modified in vivo.  
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In order to function in vivo, the azobenzene photoswitch must be chemically stable in 
reducing intracellular environments. 122 The intracellular redox potentials is maintained 
by the tripeptide glutathione present in its reduced form at approximately 1-10 mM 
concentration. 162 There have been indications that other azobenzene switches will be 
stable to intracellular reducing conditions. 119, 143 Sadovski et al. and Beharry et al. have 
demonstrated that diaminoazobenzene and BSBCA do not seem to reduce when 
incubated overnight with high concentrations of glutathione under in vitro physiological 
conditions. 119, 137, 163 Zhang et al. also reported a modified photoswitchable versions of 
cyclosporine A (an immunosuppressive drug) containing diamidoazobenzene-based 
switches that demonstrated resistance to glutathione reduction, which could also 
photoisomerise in human whole blood lysates. 164 
Bose et al. have also demonstrated that it was possible to incorporate a photoswitchable 
amino acid into proteins in E. coli. 165 Nonsense codon (amber TAG codon) suppression 
was used to introduce phenylalanine-4’-azobenzene (AzoPhe) into the E. coli catabolite 
activator protein (CAP) which appeared stable in vivo during the expression period 
(Figure 1.5.10). 165 UV-visible spectrum of the mutant CAP protein showed a distinct 
absorbance peak at 334 nm, corresponding to trans isomer of the AzoPhe. Irradiation of 
the mutant CAP with 334 nm light led to a reduction in the 334 nm peak and an 
increased absorbance at 420 nm. 165 The mutant CAP was finally irradiated with 420 
nm, resulting in complete conversion back to the 334 nm band, suggesting the 
successful incorporation of AzoPhe into the CAP protein. Since the binding of cyclic 
adenosine monophosphate (cAMP) to CAP results in conformational changes in the 
protein that increase its binding affinity to its promoter, resulting in enhanced 
transcription from CAP-dependent promoters, binding studies of mutant CAP were 
performed. It was postulated that trans and cis isomers of AzoPhe would differentially 
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affect the binding affinity of cAMP to CAP and, as a consequence, the affinity of CAP 
for its lac promoter. In the trans configuration, the mutant CAP demonstrated lower 
binding affinity to its promoter by approximately 4 fold compared to wild type CAP in 
the presence of cAMP (EMSA). Upon photoswitching, the cis mutant CAP 
demonstrated even lower binding affinity by approximately 4 fold compared to the 
trans mutant CAP, suggesting that upon isomerisation, mutant CAP/cAMP interaction 
is reduced, resulting in lower binding affinity to target promoter. 165    
	   
Figure 1.5.10. Structure of phenylalanine-4’-azobenzene.  
 
Beharry et al. created a fluorescent peptide capable of reporting the state of an attached 
azobenzene crosslinker though fluoresence quenching (Figure 1.5.11). 163 The peptide 
was synthesised with all D-amino acids to make it resistant to proteolytic degradation 
and was microinjected into zebra fish embryos. Photoswitching could be detected 
throughout the organism for at least 2 days. It was found that the switching rates and 
quantum yields were similar to those found in vitro, although the magnitude of the 
change in fluorescence was diminished (from 40% to 20%) and the relaxation rate to the 
trans form was accelerated. Nevertheless, these findings offer evidence to suggest that 
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appropriately chosen azobenzene derivatives will be practical tools for spatio-
temporally probing processes in vivo. 127 
  
	  	  
 
Figure 1.5.11. A) Structure of azobenzene photoswitch and the fluorescent peptide reporter. B) trans-to-
cis isomerisation of the fluorescent peptide reporter. 163 Irradiation of the crosslinked peptide at 365 nm 
causes trans-to-cis isomerisation of the photoswitch as well as fluorescein excitation. Irradiation with 
blue light (440-490 nm) causes cis-to-trans isomerisation as well as fluorescein excitation. Since the cis 
isomer of the crosslinked peptide has a lower quantum yield for fluorescence than the trans isomer, 
irradiation of a dark-adapted solution of reporter peptide with UV light produces a time-dependent 
decrease in fluorescence. Irradiation of cis peptide with blue light causes a time-dependent increase in 
fluorescence. The rates at which the switching processes is dependent on the intensity and the wavelength 
of irradiation. 163 
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1.6 Project Aims 
The aim of the project was to develop novel miniature photoswitchable artificial 
transcription factors (PATFs) for the modulation of protein-DNA interactions, and to 
demonstrate the ability to control the transcription process using these PATFs in an in 
vitro environment. The DNA recognition helix of a homeodomain transcription factor 
and an amphipathic α-helix activating domain (AH) were selected as a model system 
due to the high level of photocontrol in previous studies and the potency at initiating the 
transcription process of the activating domain. 151,  166 
The DNA recognition helix was modified at different residue spacings with azobenzene 
cross-linkers and linkers regions of different lengths and flexibilities were use to 
connect the DNA recognition helix and the activating domains modules. The effects of 
these changes on the resulting variants structure and function were investigated.    
	  	  
  
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods
  
 
 
  
65 
2.1 Materials 	  
All chemicals and oligonucleotides were purchased from Fisher, Sigma-Aldrich, New 
England Biolabs, Eurofins, Promega or Perkin Elmer. 
2.1.1 Culture Media 
2.1.1.1  Luria Bertani (LB) medium 	  
Bacto tryptone (10 g l-1), yeast extract (5 g l-1) and NaCl (10 g l-1) were dissolved in 
deionised water (1 l) and the medium was autoclaved for 1 hour and 30 minutes at 15 
lb/in2. 
2.1.1.2 Terrific Broth (TB) medium 	  
Bacto typtone (12 g), yeast extract (24 g) and glycerol (4 ml) were dissolved in 
deionised water (1 l) and the medium was autoclaved for 1 hour and 30 minutes at 15 
lb/in2 on a liquid cycle. Prior to use, 100 ml of a sterile filtered solution of 0.17 M 
KH2PO4 and 0.72 M K2HPO4 were added. 
2.1.2 Agar Plates 	  
Agar plates were prepared with autoclaved LB media containing agar (15 g  l-1) and the 
appropriate concentration of antibiotic (eg. ampicillin 100 mg l-1) when required. The 
solution was poured into 90 mm Petri dishes using aseptic techniques. Once set, the 
agar plates were stored inverted at 4 °C. When needed, the solution of bacterial culture 
was spread over the plate with a sterile glass rod or loop and incubated at 37 °C 
overnight. 
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2.1.3 E. coli Strains 	  
The E. coli expression strains used in this work were: BL21(DE3), BL21(DE3)RIL, 
BL21(DE3)RP, BL21(DE3)* and XL1-Blue. 
Strain Genotype 
BL21(DE3) F– ompT hsdSB (rB- mB-) gal dcm (DE3) 
BL21-CodonPlus-(DE3)RIL F– ompT hsd SB (rB- mB-) dcm+ Tetr E.coli 
gal λ (DE3) endA Hte [argU ileY leuW 
Camr]  
BL21-CodonPlus-(DE3)RP F– ompT hsd SB (rB- mB-) dcm+ Tetr gal λ 
(DE3) endA Hte [argU  proL Camr] 
BL21(DE3)* F– ompT hsdSB (rB– mB–) gal dcm rne131 
(DE3) 
XL1-Blue endA1 recA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ proAB laclqZΔM15 
Tn10 (Tetr)] 
 
Table 2.1.3. Genotype of the E.coli strains used in this work. 
 
The BL21 strains are designed for protein expression. The DE3 designation denotes that 
the strain contains the λDE3 lysogen carrying the gene for T7 RNA polymerase under 
control of the lacUV5 promoter allowing induction of the expression of recombinant 
proteins with isopropyl-1-thio-β-D-galactopyranoside (IPTG). The BL21-CodonPlus-
RIL strains contain extra copies of the argU, ileY, and leuW tRNA genes to allow 
higher expression level of heterologous proteins with high amount of AGA, AGG, AUA 
and CUA codons in the gene sequence. The BL21-CodonPlus-RP strains contain extra 
copies of the argU and proL tRNA genes to allow higher expression level of 
heterologous proteins with high amount of AGA, AGG and CCC codons in the gene 
sequence. The BL21* strains contain a mutation in the gene encoding RNase E, an 
  
 
 
  
67 
enzyme that degrades mRNA, so a higher level of mRNA is available for protein 
translation. The XL1-Blue strain is a host for optimal propagation of plasmids. This 
strain is used for cloning where high transformation efficiencies are required. 
2.1.4 Oligonucleotide sequences for PATF peptides 	  
Oligonucleotide sequences used in the cloning of PATF peptides are as follow: 
PATF-1 for1: 5’-	  
GAAGCGCAGTGTAAAATCGCGGCTAAGAACGCACGTGCGAAATGCAAGAAAGCTGGATCCG
GTGGCACTGGTGGCGGTTCTCCGGAATTCCCGGGTAT-3’     
PATF-1 for2: 5’-TGAGCTGCAAGAACTGCAAGAGCTGCAGGCCCTCCTGCAGCAAATG-3’    	  
PATF-1 rev1: 5’-	  
TTGCTGCAGGAGGGCCTGCAGCTCTTGCAGTTCTTGCAGCTCAATACCCGGGAATTCCGGAG
AACCGCCACCAGTGCCACCGGATCCAGCTTTCT-3’  
PATF-1 rev2: 5’-TGCATTTCGCACGTGCGTTCTTAGCCGCGATTTTACACTGCGCTTCCAT-3’ 
PATF-2 for1: 5’-
GAAGCGCAGTGTAAAATCGCGGCTAAGAACGCACGTGCGAAATGCAAGAAAGCTCCGCCGC
CACCGCCTCCGCCACCGCCTCCGCCACCGCCGGAATTCCCGGGTAT-3’  
PATF-2 for2: 5’-TGAGCTGCAAGAACTGCAAGAGCTGCAGGCCCTCCTGCAGCAAATG-3’ 
PATF-2 rev1: 5’-
TTGCTGCAGGAGGGCCTGCAGCTCTTGCAGTTCTTGCAGCTCAATACCCGGGAATTCCGGCG
GTGGCGGAGGCGGTGGCGGAGGCGGTGGCGGCGGAGCTTTCT-3’  
PATF-2 rev2: 5’-TGCATTTCGCACGTGCGTTCTTAGCCGCGATTTTACACTGCGCTTCCAT-3’ 
PATF-3 for1: 5’-	  
GAAGCGCAGTGTAAAATCGCGGCTAAGAACTGCCGTGCGAAAATTAAGAAAGCTCCGCCGC
CACCGCCTCCGCCACCGCCTCCGCCACCGCCGGAATTCCCGGGTAT-3’ 
PATF-3 for2: 5’-TGAGCTGCAAGAACTGCAAGAGCTGCAGGCCCTCCTGCAGCAAATG-3’ 
PATF-3 rev1: 5’-
TTGCTGCAGGAGGGCCTGCAGCTCTTGCAGTTCTTGCAGCTCAATACCCGGGAATTCCGGCG
GTGGCGGAGGCGGTGGCGGAGGCGGTGGCGGCGGAGCTTTCT-3’  
PATF-3 rev2: 5’-TAATTTTCGCACGGCAGTTCTTAGCCGCGATTTTACACTGCGCTTCCAT-3’ 
PATF-4 for1: 5’-	  
GAAGCGCAGATCAAAATCTGTGCTAAGAACTGCCGTGCGAAAATTAAGAAAGCTCCGCCGC
CACCGCCTCCGCCACCGCCTCCGCCACCGCCGGAATTCCCGGGTAT-3’ 
PATF-4 for2: 5’-	  TGAGCTGCAAGAACTGCAAGAGCTGCAGGCCCTCCTGCAGCAAATG-3’ 
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PATF-4 rev1: 5’-
TTGCTGCAGGAGGGCCTGCAGCTCTTGCAGTTCTTGCAGCTCAATACCCGGGAATTCCGGCG
GTGGCGGAGGCGGTGGCGGAGGCGGTGGCGGCGGAGCTTTCT-3’ 
PATF-4 rev2: 5’-TAATTTTCGCACGGCAGTTCTTAGCACAGATTTTGATCTGCGCTTCCAT-3’ 
 
2.1.5 Preparation of antibiotic solutions 	  
Stock solutions were prepared by dissolving each antibiotic in deionised water and filter 
sterilising using a 0.2 µm syringe filter before aliquoting for storage at -20 °C. 
Ampicillin stocks were prepared to a final concentration of 50 mg ml-1 in deionised 
water and used at a concentration of 100 µg ml-1.   
2.1.6 50× TAE (Tris-acetate/EDTA) electrophoresis buffer 	  
Per litre: 
242 g Tris base (pH 8.0) 
27.1 ml glacial acetic acid 
100 ml 0.5 M ethylene diamine tetraacetic acid (EDTA) 
2.1.7 10× SDS running buffer 	  
Per litre: 
30.3 g Tris base (pH 8.3) 
144 g glycine 
10 g sodium dodecyl sulfate (SDS) 
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2.1.8 SDS gel-loading buffer 	  
Per 10 ml: 
1.25 ml 0.5 M Tris-HCl (pH 6.8) 
2 ml 10% SDS 
0.2 ml bromophenol blue 
2.5 ml glycerol 
0.5 ml β-mercaptoethanol  
2.1.9 Staining buffer for SDS-PAGE 	  
0.25 % (w/v) Coomassie brilliant blue 
45% (v/v) methanol 
10% (v/v) glacial acetic acid 
All above in deionised water. 
2.1.10 Destaining buffer for SDS-PAGE 	  
10% (v/v) glacial acetic acid 
12% (v/v) isopropanol 
All above in deionised water. 
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2.1.11 Gel-loading buffer for agarose gel electrophoresis 	  
0.25% (w/v) bromophenol blue 
15% glycerol 
All above in deionised water.	  
2.1.12 IPTG 	  
100 mg/litre IPTG was dissolved in deionised water and sterilised by filtration through 
a 0.2 µm syringe filter.  
2.1.13 Lysis buffer 	  
50 mM potassium phosphate (pH 7) 
100 mM sodium chloride 
0.5 % Tween 20 
All above dissolved in deionised water. 
2.1.14 Guanidinium hydrochloride solution (Buffer A) 	  
6 M Guanidinium hydrochloride dissolved in deionised water. 
2.1.15 Ni2+-NTA binding buffer (Buffer B) 	  
50 mM Tris-HCl (pH 8.3) 
300 mM sodium chloride 
All above dissolved in 6 M guanidinium hydrochloride solution. 
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2.1.16 Ni NTA eluting buffer (Buffer C) 	  
50 mM Tris-HCl (pH 8.3) 
500 mM sodium chloride 
500 mM imidazole 
All above dissolved in 6 M guanidinium hydrochloride solution. 
2.1.17 Peptide re-suspension solution prior to HPLC 	  
40 % acetonitrile 
0.1 % trifluoroacetic acid (TFA) 
All above dissolved in deionised water. 
2.1.18 HPLC buffers 	  
Buffer A: HPLC grade acetonitrile 
0.1 % TFA 
Buffer B: Degassed deionised water 
0.1 % TFA 
2.1.19 Azobenzene alkylation buffer  154 
50 mM Tris base (pH 8.3) 
200 mM triscarboxyethylphosphine (TCEP) 
All above dissolved in deionised water. 
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2.1.20 Fluorescence Anisotropy assay buffer 154 
5 mM Tris-HCl (pH 7.9) 
150 mM sodium chloride 
6 mM magnesium chloride hexahydrate 
15 % glycerol   
All above dissolved in deionised water. 
2.1.21 Circular Dichroism and UV spectroscopy buffer 	  
5 mM potassium phosphate, pH 7.5. 
2.1.22 PATF in vitro binding assay 167   
50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.0 
100 mM potassium acetate  
5 mM calcium chloride 
6.5 % glycerol 
1 mM dithiothreitol (DTT) 
All above dissolved in deionised water. 
2.1.23 Hela in vitro transcription buffers and reagents  	  
The Promega HeLaScribe was used to carry out nuclear extract in vitro transcription. 
The procedure was followed according to the manufacturer’s instructions.  
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2.1.23.1 rNTP stocks 	  
25 × rNTP stock:  
                            10 mM rATP 
                            10 mM rCTP 
                            10 mM rGTP 
                            0.4 mM rUTP 
Final 1 × rNTP stock: 
                            0.4 mM rATP 
                            0.4 mM rCTP 
                            0.4 mM rGTP 
                             16 µM rUTP 
2.1.23.2 HeLa nuclear extract 1× transcription buffer 
  
20 mM HEPES (pH 7.9 at 25 °C) 
100 mM potassium chloride 
0.2 mM 	  ethylenediaminetetraacetic acid 
0.5 mM dithiothreitol 
20 % glycerol  
All above dissolved in deionised water. 
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2.1.23.3 Hela extract stop solution 	  
0.3 M Tris-HCl (pH 7.4 at 25 °C) 
0.3 M sodium acetate 
0.5 % sodium dodecyl sulfate 
2 mM ethylenediaminetetraacetic acid 
3 µg/ml tRNA   
All above dissolved in deionised water. 
2.1.23.4 Gel loading dye 	  
98 % formamide 
10 mM ethylenediaminetetraacetic acid 
0.1 % xylene cyanol 
0.2 % bromophenol blue 
All above dissolved in deionised water. 
2.1.23.5 TBE 10× buffer 	  
0.9 M Tris-base 
0.9 M boric acid 
0.5 M ethylenediaminetetraacetic acid 
All above dissolved in deionised water. 
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2.1.23.6 TE buffer 	  
10 mM Tris-HCl (pH 8.0 at 25 °C) 
1 mM ethylenediaminetetraacetic acid 
All above dissolved in deionised water. 
2.1.23.7 TE saturated phenol 	  
Equal amounts of TE buffer and phenol were mixed and the phases were allowed to 
separate. This was repeated until the aqueous phase reached a pH of ~8.0. 
2.1.23.8 TE saturated phenol:chloroform:isoamyl  alcohol (25:24:1) 	  
Equal amounts of TE buffer and phenol were mixed and the phases were allowed to 
separate. The lower part phenol phase (1 part) was mixed with (1 part) 
chloroform:isoamyl alcohol (24:1).  
2.1.23.9 Transcription assay mixture 	  
(11 – x) µl Hela nuclear extract 1 × transcription buffer, where x is the volume of 
nuclear extract used: 
1.5 µl (50 mM) magnesium chloride 
1 µl 25 × rNTP mix 
4 µl DNA template + PATF peptide mix 
1 µl [α-32P]rUTP (3000 Ci/mmol, 10 mCi/ml) 
Nuclease-free water was added to a give a final volume after addition of the nuclear 
extract of 25 µl. 
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2.2 Molecular biology methods 
2.2.1 Preparation of super competent cells 	  
The desired E. coli XL1-blue strain was inoculated overnight in 10 ml LB media 
without antibiotics at 37 °C overnight. A volume (1 ml) of the overnight culture was 
grown in 100 ml LB medium (in a 250 ml conical flask) at 37 °C with shaking at 180 
rpm, until an OD600 ~0.5 was reached (approximately 3 hours). The culture was then 
transferred into sterile 50 ml conical centrifuge tubes and was spun for 10 minutes at 
2000 g at room temperature. The supernatant was discarded. The pellet was 
resuspended in 20 ml of cold buffer A (30 mM potassium acetate, 100 mM rubidium 
chloride, 10 mM calcium chloride, 50 mM manganese chloride, glycerol 15%, pH 5.8) 
and left on ice for 15 minutes. The solution was centrifuged as before and the pellet 
resuspended again, this time in 5-10 ml of cold buffer B (10 mM 3-(N-
morpholino)propanesulfonic acid (MOPS), 75 mM calcium chloride, 10 mM rubidium 
chloride and 15% glycerol, pH 6.5), and left on ice for 1 hour. Aliquots (300 µl) were 
taken and stored at -80 °C. Buffers A and B were prepared in advance and sterilised by 
passing through a 0.22 µm filter.   
2.2.2 Transformation 	  
A sample of plasmid DNA (1 µl- 3 µl) and 100 µl of competent cells were mixed in an 
Eppendorf tube and incubated on ice for 30 minutes. The cells were subjected to a heat 
shock (40 °C) for 35-45 seconds and then placed again on ice for another 2 minutes. LB 
medium (1 ml) was added to the cells and the suspension was incubated at 37 °C for 1 
hour with shaking at 180 rpm. The solution was then centrifuged for 1 minute (13,000 
g) in a bench top microcentrifuge and the supernatant was discarded. The cells were re-
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suspended in fresh LB medium (~200 µl) and the solution was plated on an agar plate 
containing the appropriate antibiotic. The plate was incubated at 37 °C overnight. 
2.2.3 DNA isolation and purification 
2.2.3.1 QIAprep spin miniprep kit 	  
The QIAprep Spin Miniprep Kit was used for purification of 300 µg of high-copy 
plasmid DNA from 15 ml overnight cultures of E. coli in LB medium. The procedure 
was carried out according to the manufacturer’s instructions. 
2.2.3.2 Agarose gel electrophoresis 	  
Agarose gels were used for analysis and isolation of DNA fragments. 1% Agarose gels 
were made up from 1× TAE buffer using a microwave oven to dissolve the agarose and 
the mixture was poured into the minigel kit and left to set. Samples were mixed with the 
gel-loading buffer and loaded into the gel. Gels were run in 1× TAE buffer at 100 V for 
60 minutes after which the DNA was stained with ethidium bromide and visualised with 
a UV lamp at 254 nm. The DNA fragment of interest was extracted from an agarose gel 
with a clean, sharp scalpel. The QIAquick Gel Extraction Kit was used according to the 
manufacturer’s instructions (QIAGEN). 
2.2.4 Quantification of DNA and oligonucleotides in solution 	  
The concentration of nucleic acids was determined spectrophotometrically using a 
Thermo Scientific NanoDrop 1000 fluorospectrometer, by measuring the optical density 
(OD) of a solution of DNA or oligonucleotide at 260 nm.  
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2.2.5 Storage of plasmids 
2.2.5.1 Ethanol precipitation of Nucleic Acids 	  
To precipitate the purified DNA, 50 µl ammonium acetate (7.5 M) and 2.5 volumes of 
absolute ethanol were mixed with the DNA solution and the mixture was left for 10 
minutes at RT. The solution was then centrifuged for 15 minutes at maximum speed 
(~16,000 g) in a bench top microfuge. The supernatant was discarded and the pellet was 
washed with 250 µl of 80% ethanol. The solution was centrifuged for 10 minutes as 
before and the supernatant discarded. The pellet was dried at 37 °C in an oven and 
stored at -20 °C. 
2.2.5.2 Glycerol stock 	  
To prepare glycerol stocks a sample (0.8 ml) of cells from an overnight culture was 
aseptically mixed with 0.2 ml of sterile glycerol. Glycerol stocks were stored at -80 °C. 
2.2.6 Digestion with restriction enzymes 	  
Digestion reactions were performed with the desired volume of DNA (usually 10 µl) 
and the restriction endonucleases in their recommended buffers (New England Biolabs). 
The total volume for the reactions was 12 µl. Reactions were incubated for 2 hours at 37 
°C. For double digestions the buffer used was the recommended one that gave the 
highest digestion efficiency for both enzymes. The DNA product for the digestion was 
analysed by agarose gel electrophoresis. 
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2.2.7 Dephosphorylation of DNA fragments 	  
Following digestion with a single restriction enzyme, the vector should be 
dephosphorylated at the 5’-end with antarctic phosphatase to avoid self-ligation. DNA 
(0.5 µg 10 µl-1) was suspended in 1× NEBuffer (by New England Biolabs) and 5 units 
of antarctic phosphatase were added to the mixture. The solution was incubated for 15 
minutes at 37 °C. The enzyme was heat inactivated (at 65 °C) for 5 minutes, followed 
by purification of the DNA using QIAquick PCR purification protocol.   
2.2.8 Phosphorylation of DNA fragments (Kinase reaction) 	  
Forward oligonucleotides stock solutions (for1 and for2, 100 pmol) were diluted to 50 
pmol with deionized water. Equal volume quantities of 50 pmol for1 and for2 were then 
combined prior to phosphorylation. The same procedures were also applied to reverse 
oligonucleotides. Combined oligonucleotides were phosphorylated at the 5’-end with 
0.5 µl T4 polynucleotide kinase (20,000 U ml-1, New England Biolabs) in T4 ligase 
buffer (50 mM Tris-Cl (pH 7.5 at 25 °C), 10 mM magnesium chloride, 10 mM 
dithiothreitol, 1 mM ATP, 25 µg ml-1 BSA) and 2 mM magnesium chloride. The 
solutions were incubated at 37 °C for 2 hours, and subsequently purified using the 
QIAquick PCR purification protocol and stored at -20 °C for future use. The 
phosphorylation of for1:for2 and rev1:rev2 mixtures were done in separate tubes. 
2.2.9 Annealing Oligonucleotides 	  
Equimolar quantities of oligonucleotides were mixed in an Eppendorf tube that was 
placed in a thermal cycler at 95 °C. Gradually the temperature was reduced until the 
final temperature was at 15 °C over a period of 15 hours. The annealed oligonucleotides 
were stored at -20 °C. 
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2.2.10 Ligation Reaction 	  
Ligation was carried out to insert the desired gene into an expression vector. The 
digested plasmid and the annealed oligonucleotides were mixed together with 1 µl T4 
DNA ligase (10 U µl-1) and 1 µl 10× T4 DNA ligase buffer (400 mM Tris-Cl (pH 7.8 at 
25 °C), 100 mM magnesium chloride, 100 mM dithiothreitol, 5 mM ATP). The solution 
was then incubated at RT overnight or at 16 °C for 4 hours. Products were stored at -20 
°C. 
2.2.11 DNA sequencing 
    
All sequencing reactions were carried out by Cardiff University sequencing services 
using T7 promoter and T7 terminator primers. 
2.3 General methods for protein preparation and purification 	  
The expression of peptides was done using Novagen pET31b expression system. The 
procedure was conducted according to the manufacturer’s instructions.  
2.3.1 Growth of bacterial cultures 	  
Overnight cultures were grown in sterile conditions by inoculating a single colony from 
an agar plate into 5 ml LB medium containing the appropriate antibiotic. The cultures 
were incubated overnight at 37 °C with constant shaking at 180 rpm. 
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2.3.2 Protein expression using the T7 system 	  
The desired competent cells were transformed with plasmid DNA. For large scale 
expression, the colonies were grown overnight in 10 ml LB medium containing the 
appropriate antibiotic. The entire contents of each of the overnight cultures were 
transferred to separate 550 ml of fresh LB medium containing antibiotic in 2 litre 
conical flasks, and incubated until they reached an OD600 ~ 0.6-0.8. The cells were then 
induced with IPTG to a final concentration of 0.8 mM, and left to grow for 4 to 6 hours. 
Samples (1 mL) were taken from each flask (including a sample prior to induction) and 
a SDS-PAGE was run to analyse the extent of the expression of the target protein. The 
cells were then centrifuged at 6,000 g for 30 minutes at 4 °C and pellets were stored at -
20 °C. 
2.3.3 Purification of PATF proteins 
2.3.3.1 Lysis of cells 	  
Frozen pellets from a large-scale expression were thawed on ice and resuspended by 
vortexing in the appropriate lysis buffer. The suspension was sonicated for 10 minutes 
(5 s on, 5 s off) on ice using a Sonicator W-37 (Heat Systems Ultrasonics Inc.). The 
resulting lysate was centrifuged (40,000 g, 30 minutes) and the supernatant removed 
and kept for reference. A further 30 ml of lysis buffer was added to resuspend the pellet 
and the cells were then centrifuged at 17,500 g for 20 minutes. This step was repeated 
(obtaining the supernatant 2 and 3 from each step that were kept for reference). To the 
pellet, 20 ml Buffer A was added and resuspended for 60 minutes at 4 °C. The 
suspension was then centrifuged at 25,000 g for 30 minutes. The final pellet was also 
kept for reference, and solubilised protein was kept for further purification.  
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2.3.3.2 Purification of peptides by Ni NTA 
   
Solubilised protein was diluted with Ni NTA binding buffer B to 1× concentration. The 
mixture was loaded onto Ni-NTA agarose (QIAGEN) packed column pre-washed in Ni-
NTA binding buffer B. After passing the solubilised protein through the column, this 
was washed several times with buffer B to wash any unbound proteins. After washing 
several times the bound protein was then eluted from the column with eluting buffer C.  
2.3.3.3 Dialysis of the fusion protein 	  
In order to remove salt and urea, the protein was dialysed using Medicell International 
Ltd. dialysis membrane (12,000-14,000 MWCO) in deionised H2O overnight. Dialysis 
was carried out at 4 °C until the fusion protein precipitated out of the solution. The 
precipitated fusion protein was centrifuged at 5,000 g, the supernatant was kept for 
reference and the pelleted fusion protein was stored at -20 °C.  
2.3.3.4 Cyanogen bromide cleavage of fusion protein 	  
The pellet was dissolved in 80% formic acid (10 ml) and cyanogen bromide (0.3 g) was 
added to the mixture. This cleaved the desired peptide from the His-tag and KSI protein 
by reacting with methionine sidechains to truncate the polyamide chain with 
concomitant conversion of methionine into homoserine (Chapter 3). The flask 
containing this mixture was wrapped in aluminium foil and stirred under nitrogen for 
18-20 hours. The solvent was evaporated and the product resuspended in 
acetonitrile/water (1:1).  
The mixture was stirred for 1 hour and centrifuged (20 min, 4 °C, 25,000 g). The 
supernatant solution was purified by semi-preparative reverse phase HPLC (C18 
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column) eluting with a 10-100% gradient of aqueous acetonitrile containing 0.1% TFA 
over 1 hr. The sample was freeze-dried and analysed by MALDI-TOF. 
2.3.4 Mass spectrometry 	  
Matrix Assisted Laser Desorption Ionisation-Time of Flight (MALDI-TOF) mass 
spectrometry were performed to identify the purified proteins. α-cyano-4-
hydroxycinnamic acid (Figure 2.3.4) containing 1:1 MeCN/H2O was the matrix used 
for MALDI-TOF experiments. 
 
Figure 2.3.4. α-Cyano-4-hydroxycinnamic acid. 
2.3.5 Measurement and calculation of protein concentration 
2.3.5.1 Determination of the concentration of unalkylated PATF 	  
The concentrations of PATFs were determined spectrophotometrically. Absorbance 
measurements were taken at 210 nm, 215 nm and 220 nm using a Jasco V-650 UV-Vis 
spectrophotometer. A clean quartz cuvette was used to hold the samples. The 
measurements were repeated three times, taking the mean value to calculate the 
concentration, and were carried out in the following order: 
1 ml deionised water + 5 µl reference buffer (5 mM potassium phosphate) 
Cuvette was carefully washed with deionised water 
1 ml deionised water + 5 µl peptide solution 
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Peptide concentration was calculated using the equation: 
 C (mg ml–1) = [(Peptide–H2O) – (Buffer–H2O) × 201] / Xλ       Equation 1 
Where X210 = 20, X215 = 15 and X220 = 11. 
2.3.5.2 Determination of the concentration of Sulfo-azobenzene alkylated peptides 	  
The extinction coefficient of the sulfonate-azobenzene cross-linker is 24,000 M-1 cm-1 at 
363 nm 1 and was used to determine the concentration of cross-linked PATF peptides 
using Thermo Scientific NanoDrop 1000 spectrophotometer.  
2.3.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 	  
A volume (10 ml) of 15 % resolving gel (2.4 ml deionised water, 5 ml 30 % degassed 
acrylamide/bisacrylamide, 2.5 ml 1.5 M Tris-Cl (pH 8.8), 0.1 ml 10% w/v sodium 
dodecylsulfate) was mixed with polymerising agents ammonium persulfate (100 µl, 10 
% w/v in water) and TEMED (10 µl). The solution was immediately poured between 
the assembled glass plates and left to polymerise at RT. An aliquot (3 ml) of 5 % 
stacking gel (5.7 ml deionised water, 1.7 ml 30 % degassed acrylamide/Bis acrylamide, 
2.5 ml 0.5 M Tris-Cl (pH 6.8), 0.1 ml 10 % w/v SDS) containing was mixed with 10 % 
ammonium persulfate (100 µl) and TEMED (10 µl) and pipetted on top of the resolving 
gel. A comb was immediately inserted between the plates and the stacking gel was left 
to polymerise at RT.  The comb was then removed and the wells rinsed with 1× SDS 
running buffer. Samples, mixed with 1× SDS gel-loading buffer, were loaded into the 
gel (15 µl in the 10-well gels and 8 µl in the 15-well gels) and subjected to 180 V 
potential for 60 minutes. After electrophoresis, the gel was stained and destained using 
the corresponding buffers, followed by visualisation of the protein bands on a light box 
equipped with a UV lamp. 
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2.3.6 Crosslinking the PATF peptides with 3,3’-bis(sulfo)-4,4’-
bis(chloroacetamido) azobenzene crosslinker 	  
The appropriate PATF (1 mg) was dissolved in Tris-HCl buffer (3 ml, 50 mM, pH 8.3) 
and tris(2-carboxyethyl)phosphine (TCEP) stock solution (30 µl, 200 mM) was added. 
Crosslinker (4 eq, approx 1.5 mg) was dissolved in Tris-HCl buffer (1.2 ml, 50 mM, pH 
8.3), and was added in 3 aliquots to the protein solution at 20 minutes interval and 
stirred overnight at 5 oC. The cross-linked protein was purified by semi-preparative 
reverse phase HPLC (C18 column) eluting with 10-100% aqueous acetonitrile 
containing 0.1% TFA over 1 hour. The mass of the crosslinked PATF was confirmed by 
MALDI-TOF mas spectrometry. 
2.4 Photoisomerisation 	  
Photoisomerisation of dark-adapted (dad) XL-PATFs was achieved by irradiating a 
solution of the peptide with a 250 W metal halide UV Light Point Source (UV-P 280) 
coupled to a 360 nm band pass filter (10 nm bandwidth). Photoisomerisation was 
complete in less than 6 minutes as judged by the absence of further changes in the 
UV/Vis spectra. The percentage of isomerisation was calculated by using the respective 
extinction coefficients for the pure cis from (ε363 = 1100 M-1 cm-1) 2 and the trans form 
to determine the ratio from the obtained absorbance values before and after irradiation 
(Adad and Alid). 
Alid = Acis + Atrans 
Alid = x εcis d [BPN] + (1 – x) εtrans d [BPN]                   (x = fraction of cis isomer) 
x = Alid !!trans d[BPN ](!cis !!trans )d[BPN ]
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x = Alid ! Adad(!cis !!trans )d[BPN ]
                     Equation 2 
2.5 UV/Visible absorption experiments 	  
UV-Visible absorption experiments were carried out using a JASCO V-660 UV/Vis 
Spectrophotometer with a 1 cm path length cuvette. Samples were dissolved in 5 mM 
potassium phosphate (pH 8.0) to a final concentration of 2 µM and experiments were 
run at 25 °C. Assuming first order kinetics for the thermal cis-to-trans relaxation of the 
crosslinker, the half-life (t½) of the cis-isomer could be calculated with the equation: 
t½ = ln 2 / k 
Where k is the 1st order rate constant for the thermal relaxation process, which was 
calculated by plotting the natural logarithm of the percentage of cis isomer (calculated 
from the absorbance at 363 nm) versus time: 
ln (%Acis363) = -k t + c 
The activation energy for the isomerisation reaction was determined using the 
Arrhenius equation: 
RT
Ea
Aek
−
= 	  
Where Ea is the activation energy and A is the pre-exponential factor. 
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2.6 Circular dichroism (CD) spectroscopy 	  
CD spectra were recorded on a ChiraScan spectrometer. The temperature-dependent 
scans were performed at 25 °C using a 1 mm path length cuvette. The mean residue 
ellipticities [Θ]r of different states of PATFs were calculated according to the equation: 
[Θ]r = Θ / (10 n c l) 
Where n is the number of backbone amide bonds (46 in this case), c is the concentration 
and l is the pathlength (0.1 cm). The [Θ]r at 222 nm of dark adapted and irradiated XL-
PATF were found to be -12872 and -11735 deg cm2 dmol-1 respectively. 
The α-helical content of both dark adapted and irradiated XL-PATF were calculated by 
the following equation: 168 
% helicity =  (-100 × n × [Θ]r, 222) /  [40000 (n-4)] 
2.7 DNA Binding specificity measured by Fluorescence Anisotropy 	  
Fluorescence anisotropy measurements were performed at 15 °C on a Perkin Elmer 
Luminescence Spectrometer LS55 arranged in L format (494 nm excitation; 525 nm 
emission) using a 1 ml fluorescence quartz cuvette with samples dissolved in 5 mM 
Tris-HCl (pH 7.9), 150 mM sodium chloride, 6 mM magnesium chloride, 15% glycerol, 
containing 2.5 mM TCEP for measurements carried out with the unalkylated PATFs. 
Titrations of PATFs and XL-PATFs at concentrations 0-5,000 nM were successively 
added to 0.1-5 nM of fluorescein (5-FAM) labelled DNA in a total volume of 1 ml. The 
total volume varied less than 6% for each titration therefore the concentration of 
oligonucleotide can be assumed to have remained constant. For each anisotropy value 
ten measurements were taken using an integration time of 5 s.  
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The G factor (ratio of sensitivities of the monochromator for horizontally and vertically 
polarised light) can be calculated using the equation: 169 
G = I⊥ / I⎜⎜ 
where I⎜⎜ and I⊥ are the intensities of the fluorescent emissions in parallel and 
perpendicular planes, respectively, to the excitation plane. The G factor value was 
always close to 1.14 for both PATFs and XL-PATFs. Values for fluorescence 
anisotropy (A) were then determined from the equation: 170 
A = (I⎜⎜ – G I⊥) / (I⎜⎜ + 2GI⊥) 
Fluorescence anisotropy data were expressed as: 
F  = (A – AD) / (APD – AD) 
where A denotes the fluorescence anisotropy in the presence of the indicated 
concentration of protein, AD denotes the fluorescence anisotropy in the absence of 
protein, and APD denotes the fluorescence anisotropy at saturation. 170 
The data were fit to the Langmuir isotherm: 
FFit = 1 / (1+ KDn / [P]n) 
where KD is the apparent dissociation constant, [P] is the concentration of protein and n 
is the number of binding sites. 
2.8 Hela in vitro transcription assay 	  
The Promega HelaScribe kit was used to carry out nuclear extract in vitro transcription. 
The procedure was carried out according to the manufacturer’s instructions. 
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2.8.1 Incubation of PATFs with pUCML53 (and doubly digested pUCML53) 
plasmid template 	  
XL-PATF peptides (5 µL, 500 nM) were incubated with pUCML53 plasmid template (5 
µL 100 ng) at room temperature for 75 minutes to a total volume of 10 µL. For photo-
switched (irrad) XL-PATFs, the peptides were irradiated with UV source for 6 minutes 
prior to addition to the plasmid template. Upon addition of the irrad XL-PATFs, the 
mixture was irradiated with UV light for the remaining 75 minutes at room temperature. 
2.8.2 In vitro transcription reaction 	  
Incubated XL PATF and pUCML53 mixture was added to the transcription assay 
solution. 8 µl nuclear extract was then added to the mixture in order to start 
transcription to a total volume of 25 µl. The reaction mixture was incubated for 60 
minutes at 30 °C. For irrad XL-PATFs, the reaction mixture was irradiated for 3 
minutes every 15 minutes in the course of 1 hour reaction. After 1 hour, RNase T1 (10 
units, Thermo Scientific) was added to the reaction mixture and incubated for further 15 
minutes at 30 °C in order to cleave RNA transcripts other than the G-less cassette. 203 
The reaction was terminated by the addition of the stop solution (175 µl). In order to 
improve reproducibility, the Hela extract stop solution was warmed at 25 °C for one 
hour and vortexed well to mix prior to addition.   
2.8.3 Isolation of RNA transcript 	  
TE-saturated phenol (200 µl) was added to the reaction, and the resulting mixture was 
then vortexed for 60 seconds and centrifuged at 14,000 g for 5 minutes. The upper 
aqueous phase (150 µl) was transferred to a clean tube. The phenol phase was extracted 
again by addition of the stop solution (200 µl) and the mixture was vortexed as 
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described above. The aqueous layers were combined and extracted with 
chloroform:isoamyl alcohol (24:1) (300 µl), vortexed and spun at 14,000 g for 5 
minutes. The aqueous layer was then transferred to a clean Eppendorf tube. 
Alternatively, the RNA was mixed with phenol:chloroform:isoamyl alcohol (25:24:1) 
(200 µl), vortexed for 60 seconds and centrifuged at 14,000 g for 5 minutes. The upper, 
aqueous phase was then transferred to a clean Eppendorf tube. In order to precipitate 
RNA, 100 % ethanol (700 µl) was added to the aqueous layer, the resulting solution was 
mixed by vortexing and placed in dry ice bucket for 15 minutes before putting the 
sample in -80 °C freezer overnight. After overnight incubation, the tube was spun at 
14,000 g for 10 minutes at 4 °C by positioning the tube in the microcentrifuge so that 
the pellet will form in known orientation. The supernatant was carefully removed by 
pipetting, making sure not to disturb the pellet. Sometimes the pellet was not clearly 
visible. The pellet was then dried in a vacuum desiccator containing silica gel (260 mm 
diameter). 
2.8.4 Urea gel preparation 	  
For a single 7.5 % urea gel, a solution composed of 9.38 ml 40% 
acrylamide/bisacrylamide (ratio 23:1) solution, 2.5 ml 10 × TBE buffer, 7 M urea 
(21.02 g), and deionised H2O (38.12 ml) was made and carefully mixed so as not to 
introduce air bubbles. Polymerising agents, TEMED (300 µl) and ammonium persulfate 
(500 µl) were added. The mixture was immediately poured between the assembled glass 
plates (front plate: 16 × 19.7 cm; back plate: 19 × 19.7 cm; spacers: 1 mm) and fixed 
together using bulldog clips. A comb (20 teeth) was inserted and the plates were left to 
polymerise horizontally at room temperature, then stored at 4 °C. Gels were freshly 
prepared on the day of each experiment. Prior to use, the gels were pre-run in a vertical 
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gel electrophoresis apparatus (V1517, BRL Life technologies, Inc.) by subjecting them 
to a 250 V potential for 30 minutes at 4 °C eluting with 0.5 × TAE running buffer. 
2.8.5 Gel analysis of RNA transcripts and visualization 
    
After the RNA sample was dried of ethanol, the pellet carefully resuspended in 10 µl of 
nuclease-free water. An equal volume of loading dye was added to the resuspended 
pellet and the sample was heated at 90 °C for 10 minutes prior to loading onto a gel. 
The gel well was flushed with 0.5 × TBE buffer prior to loading of the samples. The gel 
was then run at a potential of 250 volts for 3 hours or until the bromophenol blue dye 
had dye just run off the gel. The gel was carefully removed from the plate and soaked in 
deionised water for at least 20 minutes in order to remove urea present in the gel which 
adversely affects the resolution of the subsequent imaging. The gel was then exposed to 
phosphorimaging screen for at least 3 hours before visualising on phosphorimaging 
scanner (Typhoon 9400, GE Healthcare Life Sciences). Quantification of the RNA 
transcript was done by densitometry using ImageJ software. Each transcription 
experiment had a positive control (CMV promega or pMLΔ53) and the quantification of 
each band was compared to the positive control. 
2.9 Synthesis of 3,3’-bis(sulfo)-4,4’-bis(chloroacetamido)azobenzene 
crosslinker 146 
2.9.1 Synthesis of 2-acetylamino-5-aminobenzenesulfonic acid 	  
2,5-Diaminobenzenesulfonic acid (15 g, 79.7 mmol, 1 equiv.) was added to glacial 
acetic acid (150 ml), the mixture was heated to 94 °C with stirring. Acetic anhydride 
(9.24 ml, 98 mmol 1.2 equiv.) was added dropwise to the reaction mixture over a period 
of 5 minutes. The mixture was left to stir at 94 °C for 2 hours. After 2 hours, the 
reaction flask was left to cool to room temperature, the precipitate filtered under 
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vacuum and rinsed with acetic anhydride (3 × 10 ml). A purple solid was obtained 
(4.91g, 26%). 1H NMR (400 MHz, DMSO) δ 10.36 (s, 1H, NH), 8.34 (d, J = 8.7 Hz, 
1H), 7.70 (d, J = 2.7 Hz, 1H), 7.35 (dd, J = 2.7 Hz, 8.8 Hz, 1H), 2.08 (s, 3H, CH3). 13C 
NMR (100 MHz, DMSO) δ 26.1, 121.8, 122.9, 125.4, 126.5, 136.0, 137.2, 169.0, 
HRMS EI+ve calculated 230.0361 for C8H10N2O4S, observed 230.0365. 
2.9.2 Synthesis of sodium 3,3’-bis(sulfonato)-4,4’bis(acetamido)azobenzene 	  
2-Acetylamino-5-aminobenzenesulfonic acid (4.91g, 21.31 mmol, 1 equiv.) was 
dissolved in H2O (51 ml), the pH of the solution was adjusted to pH 8.5 via addition of 
sodium carbonate (0.1 M) dropwise. This turned the solution from light pink to brown. 
The mixture was then cooled in an ice bath and sodium hypochlorite (available chlorine 
≥ 4%, 54 ml, 0.65 mol) was added dropwise over 5 minutes. The reaction flask was left 
to stir at -5 °C in an ice-cooled H2O/NaCl bath for 2 hours. Finally the mixture was 
wrapped in aluminium foil and left to incubate at 4 °C for 3 days. The precipitate was 
filtered and washed with hot ethanol to yield 3,3’-bis(sulfonato)-4,4’-
bis(amino)azobenzene (1.26g, 12%). 1H NMR (400 MHz, D2O) δ 8.18 (d, J = 2.3 Hz, 
1H), 7.98 (d, J = 8.7 Hz, 1H), 7.85 (dd, J = 2.4 Hz, 8.7 Hz, 1H), 2.12 (s, 3H, CH3). 13C 
NMR (100 Mhz, DMSO) δ 2.2, 121.9, 124.2, 125.9, 133.8, 136.3, 147.8, 172.4, HRMS  
calculated 455.0336 for C16H15N4O8S2-, observed 455.0318. 
2.9.3 Synthesis of sodium 3,3’-bis(sulfonato)-4,4’-bis(amino)azobenzene 	  
Sodium 3,3’-bis(sulfonato)-4,4’-bis(acetamido)azobenzene (0.050 g, 0.11 mmol, 1 
equiv.) was mixed with H2O (2 ml). Concentrated hydrochloric acid (0.56 ml) was 
added to the mixture and the reaction flask was heated with stirring at 110 °C for 2.5 
hours. The mixture was then left to cool to room temperature, and the solvent rotary 
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evaporated. The solids were re-dissolved in H2O (8 ml) and pH adjusted via addition of 
NaOH (0.1 M). The mixture was then freeze dried overnight resulting in solid sodium 
3,3’-bis(sulfonato)-4,4’-bis(amino)azobenzene (0.028 g, 69%). 1H NMR (400 MHz, 
DMSO) δ 7.90 (d, J = 2.3 Hz, 1H), 7.50 (dd, J = 2.3 Hz, 8.7 Hz, 1H), 6.71 (d, J = 8.7 
Hz, 1H) , 6.20 (s, 2H, NH2). 13C NMR (100 MHz, DMSO) δ 115.1, 121.4, 124.6, 
129.6, 141.6, 147.0, HRMS ESI –ve calculated 371.0125 for C12H11N4O6S2- observed 
371.0129.  
2.9.4 Synthesis of 3,3’-bis(sulfo)-4,4’-bis(chloroacetamido)azobenzene 
crosslinker 	  
Sodium 3,3’-bis(sulfonato)-4,4’-bis(amino)azobenzene (0.028 g, 0.075 mmol, 1 equiv.) 
was mixed with chloroacetic acid (0.191 g, 2.02 mmol, 25 equiv.) and chloroacetic 
anhydride (0.346 g, 2.03 mmol 25 equiv.). The mixture was heated at 87 °C with 
stirring overnight, left to cool to room temperature and continue to cool on ice for 
another 30 minutes to precipitate 3,3’-bis(sulfo)-4,4’-bis(chloroacetamido)azobenzene 
crosslinker. The precipitate was washed with excess dichloromethane in order to 
remove any residual chloroacetic acid and chloroacetic anhydride. The crosslinker was 
finally filtered under vacuum and the precipitate collected (0.023 g, 59%). 1H NMR 
(400 MHz, DMSO) δ 11.20 (s, 1H, NH), 8.52 (d, J = 8.8 Hz, 1H), 8.22 (d, J = 2.4 Hz, 
1H), 7.98 (dd, J = 2.4 Hz, 6.4 Hz, 1H), 4.23 (s, 2H, CH2). 13C NMR (100 MHz, 
DMSO) δ 44.2, 120.2, 121.1, 126.8, 137.4, 137.6, 147.7, 165.7, HRMS ESI -ve 
calculated 522.9557 for C16H13N4O8S2Cl2-, observed 522.9578.   
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3.1 Introduction 	  
This chapter describes the extension of the use of an azobenzene crosslinker to stabilise 
the recognition helix of a homeodomain transcription factor by adding a linker and 
activating domain to investigate whether the resulting molecule can act as a 
photoswitchable artificial transcription factor (PATF). The basis for the DBD element 
of these molecules will be a homeodomain. 171 DNA binding by full-length 
homeodomains relies on interactions between helix-3 of the helix-turn-helix motif and 
the major groove of DNA. Helix-3 in turn is stabilised by two anti-parallel helices, 
helix-1 and helix-2, which in turn are perpendicular to helix-3, forming a hydrophobic 
core between the helices (Figure 3.1.1).  
 
	  
Figure 3.1.1. Model of engrailed homeodomain with the helices-1 and -2 anti-parallel to each other and 
perpendicular to helix-3 binding to the major groove of DNA (3HDD.pdb). 
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This packing stabilises the recognition helix. The N-terminal arm of the complex 
(Figure 3.1.2), which is unstructured in the absence of DNA, wraps over the phosphate 
backbone to make DNA contacts in the minor groove. 172 Initial attempts to reduce the 
wild-type homeodomain to just the helix-turn-helix motif by removing the N-terminal 
arm resulted in a reduction in binding affinity to specific target DNA by up to 10 fold, 
most likely due to the loss of the N-terminal contacts with minor-groove edges of the 
first two bases of the core sequence TAAT that are common to the DNA binding sites 
of homeodomain proteins (Figure 3.1.2). 20 	  	  	  	  	  	  
 
	  
Figure 3.1.2. Binding of residues from the engrailed homeodomain that contact the DNA (1HDD). 173 
 
Residue 50 of homeodomains appears to be a key determinant of DNA-binding 
specificity, helping to distinguish between binding sites of the form TAATNN. 174 
Glutamine (Q) is the most commonly occurring residue at position 50, but other amino 
acids are found in various subfamilies. It was found that the tightest and most specific 
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binding to its cognate DNA sequence occurs when lysine (K) is present at position 50. 
Engrailed Q50K variants bind more tightly to TAATCC (QRE sequence) than wild-type 
engrailed binds to TAATTA (ERE sequence). 174 The Lys50 side chain projects directly 
into the major groove of the DNA making a series of hydrogen bonds with the guanine 
at the base pairs 5 and 6 of the optimal TAATCC binding site (Figure 3.1.3). 174, 175 
	  
	  
Figure 3.1.3. Schematic showing contacts between engrailed homeodomain and its cognate DNA. 
Phosphates that are contacted by the homeodomain are shown in blue and hydrogen-bond intermediate 
water molecules are shown in red. 18	  
 
Montclare et al. studied the isolated recognition helix (helix-3) of Q50K engrailed 
homeodomain and found that, without stabilisation, its binding to target DNA sequence 
TAATCC was reduced by approximately 800 fold (1.7 µM) compared to the wild type 
protein (2.1 nM). 103, 79 Subsequent work detailed how a miniature engrailed 
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homeodomain peptide can be stabilised by alkylating thiols of appropriately spaced 
cysteine residues within the section of a DNA binding protein (Figure 3.1.4) with the 
azobenzene-derived photoisomerisable cross-linker 3, 3’-bis(sulfo)-4,4’-
bis(chloroacetamido)azobenzene (BSBCA). 154, 176  
	  
Figure 3.1.4. A) Structure of crosslinker 3,3’-bis(sulfo)-4,4’-bis(chloroacetamido)azobenzene (BSBCA). 
B) Photoisomerisation of BSBCA linked to a protein structure with via the sidechains of two cysteine 
residues in an i, i+11 spacing. 154 C) Model of engrailed homeodomain with the helices-1 and -2 anti-
parallel (green) to each other and perpendicular to helix-3 (red) binding to the major groove of DNA 
(3HDD.pdb). D) Cartoon of modified helix-3 with an azobenzene crosslinker (right). 
 
In order to accommodate the azobenzene cross-linker the miniature engrailed 
homeodomain (HDH-3) was reduced to an 18-residue peptide, Ile45 and Ile56 were 
substituted with cysteines residues and the bulky Trp48, Phe49 and Lys52 of Q50K 
engrailed were replaced with helix-stabilising alanine residues in order to avoid steric 
conflict with the cross-linker. The C-terminal Ser59 was also substituted with the helix-
stabilising Ala (Figure 3.1.5.). 154,177      
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Figure 3.1.5. Schematic of HDH-3. A) Sequences of wild type engrailed homeodomain compared to 
HDH-3 peptide with the modified amino acids. B) Diagram of the helical wheel of cross-linked HDH-3. 
Residues that are in contact with DNA are marked with asterisk, blue and red circles represent charged 
residues. Residues that have been substituted in order to avoid steric clash with the cross-linker are 
marked in filled green circles. 154, 175 
 
An i, i+11 spacing of cysteine residues on helix-3 was used, corresponding to three 
turns of an α-helix and matching the trans configuration the azobenzene with length of 
approximately 16.8 Å between the para-acetoamido groups (Figure 3.1.4). This 
arrangement stabilised the helical structure of helix-3 in the dark state. Upon irradiation, 
the cis-conformation of the crosslinker is too short (approximately 11.3 Å) to readily 
accommodate an α-helical conformation, 142, 146 resulting in distortion of the helix and a 
reduction in DNA binding affinity. Dark adapted (dad) HDH-3 bound to its natural 
DNA target sequence QRE with a dissociation constant (KD) of 7.5 +/- 1.3 nM, making 
                                                           45             50             55         
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the complex 200 times more stable than that formed between the isolated helix-3 of 
engrailed and QRE DNA, 154, 103 although it still binds approximately 1000 fold less 
tightly that the full-length protein.15 Upon irradiation, the dissociation constant 
increased by nearly 20 fold  to 140 +/- 25 nM. 154 
3.2 Results and Discussion 
3.2.1. Design of i, i+ 11 Homeodomain Artificial Transcription Factors 
(PATFs) 	  
Giniger et al. designed a 15-residue sequence containing a core repeat of glutamic acid, 
glutamine and leucine, which was designed to form a four-turn, negatively-charged, 
amphipathic α-helix named AH (Table 3.2.1.1). This AH and a control sequence that 
should not form an amphipathic α-helix were attached to the yeast regulatory protein 
GAL4. 166 As predicted, AH functioned as an activating domain in a yeast extract 
cellular system and was as effective an activator as the natural yeast activator Gal4, 
whereas the variant with the non-amphipathic control sequence did not initiate the 
transcription process, suggesting that the amphipathic nature of activators is necessary 
for transcription activity. It is not known exactly how amphipathic α-helices function as 
transcriptional activating regions in eukaryotes, but they are believed to interact with 
RNA polymerase in a similar fashion to the negatively charged amphipathic α-helices 
found in transcription activators in bacteriophage λ and its close relative bacteriophage 
434. 178 Other activating domains use similar residues; for example, the Sp1 (Specificity 
Protein 1) transcription factor belongs to a family of glutamine-rich activating domains. 
The activating domain of Sp1 contains very few negatively charged residues but 
approximately 25% glutamine residues that are essential for function, deletion abolishes 
the ability of SP1 to initiate transcription. 179 Indeed, Gerber et al. demonstrated that a 
continuous run of glutamine residues with no other amino acids fused to the DNA 
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binding domain of GAL4 factor can activate transcription. 180 Inspired by CTF/NF1 
factor (or the CAAT box-binding transcription factor/nuclear factor-1) 181 which contain 
proline-rich (25%) activating domains, 182 Gerber et al. also demonstrated that a 
continuous run of proline residues fused to the DNA binding domain of GAL4 was also 
able to initiate transcriptional activation. 180 Other proline-rich transcription factors 
include the oncogene product Jun, AP2 (Activating Protein 2), and the C-terminal 
activation domain of the Oct2 homeodomain. 183  
Activation Domain	   Sequence 
AH ELQELQELQALLQQQ 
  
Table 3.2.1.1. Sequence of peptide designed to form an amphipathic helix (AH) and function as an 
artificial activation domain. In most E. coli-encoded activating peptides the hydrophobic face of the 
amphipathic helix is extended one helical turn beyond the final acidic residue of the negatively-charged 
face, and bears two hydrophobic residues in the final amphipathic turn. The ALL residues were added to 
mimic this and the final three Q residues were added to stabilise the carboxy-terminal end of the helix. 166  
 
Previous work in this field has demonstrated that artificial transcriptional activators can 
perform as well as their natural counterparts as long as key DBD and AD components 
are present. Dervan et al. synthesised a synthetic hairpin polyamide composed of N-
methylpyrrole and N-methylimidazole amino acids known to bind to the minor groove 
of DNA and fused it to the amphipathic helix (AH) activating domain described above. 
This molecule was able to stimulate promoter specific transcription by this miniature 
artificial transcription activator in vitro to 40 fold above the basal level. 167 The DBD 
and AH domains were initially linked by a dimerisation domain from yeast GCN4 
protein (residues 251-281) known to form coiled-coil structure, but the distance 
between the DBD and AH was also varied by the use of a flexible polyether linker. The 
length of the linker domains were discovered to affect the degree of activation; longer 
linkers resulted in low levels of transcription in a yeast nuclear extract assay, likely 
  
 
 
  
102 
because of the flexibility of the linker moiety projecting the AH too far away from 
DNA. Removing the linker domain entirely gave 25% of the activity of the DBD/GCN4 
dimerisation domain/AH construct, suggesting that either the dimerisation domain was 
important to the efficiency of activation or spatial separation of the activation module 
from DNA also plays a role in the efficiency of activation. 167 Dervan et al. later 
replaced the flexible linker with rigid oligo-prolines of varying incremental lengths (18-
45 Å) 184 and found the optimal length of the linker domain lay between 36-45 Å (12-15 
proline residues), where the linker length of 12 proline residues (36 Å) generated the 
largest degree of activation. 
Photocontrollable Homeodomain Artificial Transcription Factors (PATFs) were 
designed to consist of helix-3 of engrailed homeodomain with cysteine residues in order 
to attach an azo-benzene crosslinker at i, i + 11 spacing linked to an AH helix sequence 
by two different types of linker, a flexible MM8 linker or a rigid oligo-proline linker 
(PP) (Table 3.2.1.2) to assess the effect of the linker on the degree of activation (Figure 
3.2.1.2 and 3.2.1.3). 185, 45       
Name Sequences 
PATF-1 i, i+11 EAQCKIAAKNARAKCKKA-GSGGTGGGS-PEFPGIELQELQELQALLQQ 
PATF-2 i, i+11	   EAQCKIAAKNARAKCKKA-PPPPPPPPPPPP-PEFPGIELQELQELQALLQQ 
 
Table 3.2.1.2. Amino acid sequences of PATF peptides with flexible linker (PATF-1) and rigid linker 
(PATF-2). 
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Figure 3.2.1.2. Cartoon representation of PATF (top) with all the wild type components engrailed 
homeodomain HDH3 (red) as DNA binding domain, an activating domain AH (blue), and a linker 
connecting the two domains together (green).  
 
	  
Figure 3.2.1.3. Schematic of PATFs. A) Diagram of the helical wheel of cross-linked PATF-1 with i, i+11 
spacing and MM8 flexible linker, B) Diagram of the helical wheel of cross-linked PATF-2 with i, i+11 
spacing and oligo-proline linker (PP). Residues that are in contact with DNA are marked with asterisk, 
blue and red circles represent charged residues based on parent HDH-3 DNA binding domain. Residues 
that have been substituted in order to avoid steric clash with the cross-liner are marked in filled green 
circles. 154, 175   
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3.2.2 Construction of of PATF-1 and PATF-2 	  
The oligonucleotides encoding PATF were purchased from Eurofins (pre-
phosphorylation of oligonucleotide procedures are discussed in Chapter 2, Section 2.1.4 
and Section 2.2.8). The oligonucleotides (2 µl, 25 pmol, for1:for2 & rev1:rev2 in 
separate tubes) were phosphorylated at the 5’ end using T4 polynucleotide kinase (2.5 
µl, 10,000 U ml-1) in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 25 °C). The 
solutions were incubated at 37 °C for 60 min. The oligos were then annealed by mixing 
equimolar quantities of forward and reverse oligos in a heat block at 95 °C. After 5 min 
at 95 °C, the heat block was turned off and solution was left to cool to room 
temperature.  
The phosphorylated oligonucleotides (6 µl, 0.078 pmol) were ligated into a pET31b(+) 
vector (1:3 vector to insert ratio) via ligation of the desired gene with AlwNI digested 
dephosphorylated pET31b(+) (2 µl, 0.026 pmol) by mixing them together with T4 DNA 
ligase (0.5 µl) and 1 × ligase buffer (200 mM Tris-HCl, pH 7.6, 50 mM MgCl2, 100 
mM DTT, 10 mM ATP). The mixture was then incubated at 16 °C overnight and the 
resulting construct was used to transform E. coli XL1 Blue cells. The clones were 
checked by either re-digestion of plasmids with AlwNI to detect the removal of AlwNI 
restriction site upon successful insertion, or by PCR analysis (using T7 prom and term 
as primers) and then by DNA sequencing (Figure 3.2.2).  
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Figure 3.2.2. A) Map of the pET31b(+) expression vector and cloning charts of PATF-1 and PATF-2 
peptides. B) Agarose gels stained with ethidium bromide. Lane 1: 1 kb DNA ladder (fragment size is 
indicated in kbp), lane 2: circular pET31b(+), lane 3: empty AlwNI digested pET31b(+), lane 4: circular 
plasmid containing PATF-1 gene, lane 5: plasmid containing PATF-1 gene after AlwNI treatment 
(undigested), lane 6: circular plasmid containing PATF-2 gene, lane 7: plasmid containing PATF-2 gene 
after AlwNI treatment (undigested).  
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Sequencing results of chosen clones have confirmed the desired sequence for PATF-1 
(Table 3.2.2), however this was not the case for PATF-2 (Table 3.2.2) where one 
proline residue within the rigid oligo-proline linker was missing, making this an eleven-
proline linker rather than the initial twelve. This type of error can arise when there are 
high numbers of the same amino acids in a row. This could be due to the high amount 
of codon usage for a particular amino acid, where by having large quantity of residue of 
the same sequence, this can result in errors or some sequences not being translated. 186 
The other alternative explanation could be due to the repetitive nature of the proline 
sequences used in combination with polymerase slippage leading to some proline 
residues not being translated. Despite this error, the rigid linker of PATF-2 is still within 
the optimal length for the high degree of transcription activation as described 
previously. 184 The PATF-2 plasmid containing the missing proline residue was 
therefore used for protein expression (Table 3.2.2). 
Name Sequences 
PATF-1 i, i+11 gaagcgcagtgtaaaatcgcggctaagaacgcacgtgcgaaatgcaagaaagctggatccggtggcactggt 
  E   A   Q  C  K  I    A   A  K  N   A   R  A   K  C  K   K  A  G   S   G  G   T  G   
ggcggttctccggaattcccgggtattgagctgcaagaactgcaagagctgcaggccctcctgcagcaa 
  G   G  S  P   E  F  P    G   I  E   L   Q   E   L  Q  E    L  Q   A  L   L  Q  Q 
PATF-2 i, i+11	   gaagcgcagtgtaaaatcgcggctaagaacgcacgtgcgaaatgcaagaaagctccgccgccaccgcctccg 
 
  E   A   Q  C  K   I   A   A  K  N   A   R  A   K C   K   K  A  P    P   P   P   P  P    
 
ccaccgccgccaccgccggaattcccgggtattgagctgcaagaactgcaagagctgcaggccctcctgcag 
 
  P   P   P   P   P   P    E  F   P   G   I   E   L  Q   E   L  Q   E   L  Q   A   L  L  Q    
   
caa  
 
 Q 
 
Table 3.2.2. Sequencing results of PATF-1 and PATF-2 clones. The obtained sequences are in minuscule 
letters (top) and the translated sequences are in capital letters (bottom). 
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3.2.3 Expression and purification of PATFs 	  
To produce proteins, E. coli BLR(DE3) cells were transformed with a pET31b(+) 
plasmid harbouring a gene encoding the desired PATF product. The PATF gene is 
under the control of a promoter only recognised by T7 polymerase, which is itself under 
the control of a modified lac promoter (lacUV5). Isopropyl-β-D-1-
thiogalactopyranoside (IPTG) was added to growing cells in LB media, to allow 
expression of the T7 RNA polymerase gene, and, in turn, PATF. 1, 187 IPTG addition 
once cultures reached an OD600 of 0.6 rapidly induced synthesis of a fusion protein 
between bacterial ketosteroid isomerase (KSI) and PATF with a C-terminal His-tag. 
(Figure 3.2.2.1). 
                
                                                
Figure 3.2.3.1. SDS-PAGE analysis of the initial stages of PATF-1 purification. M: Protein marker 
(Fermentas), lane 1: Total cellular protein with no induction (negative control), lane 2: Total cellular 
protein 2 hour after induction, lane 3: Total cellular protein 5 hours after induction.  
 
Following 5 hours of expression, the cells were harvested by centrifugation, 
resuspended in lysis buffer and lysed by ultrasonication for 20 minutes (pulse on for 5 
seconds, pulse off for 5 seconds) at 40% intensity. The suspension was clarified by 
centrifugation (20 mins, 4 °C, 9,000 × g), then the supernatant was removed and the 
pellet resuspended in further lysis buffer with added sodium chloride (to 1 M). After 
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stirring for 2 hours the solution was centrifuged (20 min, 4 °C, 12,000 × g), and the 
supernatant discarded. The pellet was dissolved at room temperature in guanidine 
hydrochloride (6M), stirred overnight and centrifuged (30 min, 4 °C, 25,000 × g) to 
remove membrane debris. The supernatant was dialysed against H2O (3 L) using a 12-
14 kDa cut-off dialysis membrane at 4 oC overnight and centrifuged (20 min, 4 °C, 
12,000 × g).	  The pellet was then redissolved in 80% formic acid (10 ml) and cyanogen 
bromide (0.3 g) was added to cleave the His-tag and KSI protein by converting the 
methionine residues to homoserine with concurrent breakage of the following amide 
bond (Figure 3.2.3.2). The solution was stirred in a foil-wrapped flask under nitrogen 
for 18-20 hours.  
 
Figure 3.2.3.2. The mechanism of peptide cleavage by cyanogen bromide. 188 
The solvent was evaporated under reduced pressure and the product proteinaceous film 
was resuspended in acetonitrile/water (1:1). The mixture was stirred for 1 hour and 
centrifuged (20 min, 4 °C, 25,000 × g). The supernatant solution was purified by semi-
preparative reverse phase HPLC (Phenomenex Gemini C18 column) eluting with 10-
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100% acetonitrile/0.1% TFA, H2O/0.1% TFA gradient. The desired product peak was 
identified by MALDI-TOF, then corresponding fractions were pooled and freeze-dried. 
Reinjection of pure PATF peptides revealed that PATF-1 eluted at approximately 19 
minutes, whereas PATF-2 eluted at approximately 21 minutes using a 10-100% 
acetonitrile:water (containing 0.1 % TFA) linear gradient over the course of 60 minutes 
at a flow rate of 5 ml min-1 (Figure 3.2.3.3). PATF-1 differs in retention time compared 
to PATF-2 due to its more hydrophilic linker domain resulting in faster elution rate. The 
masses of PATF-1 and PATF-2 were measured by MALDI-TOF MS (Table 3.2.3.1). 
 
Figure 3.2.3.3. Chromatogram from the analytical HPLC analysis and MALDI-TOF mass spectrum of A) 
PATF-1 and B) PATF-2. 
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PATF Monoisotopic calculated 
mass 
Observed m/z 
PATF-1 4936.54 4870.68  
PATF-2 5386.88 5623.37  
  
Table 3.2.3.1. Monoisotopic calculated masses and observed masses of PATF-1 and PATF-2 peptides. 
The masses observed for PATF-1 and PATF-2 were deviated from the monoisotopic 
calculated masses by approximately 65.86 and 236.49 respectively. The reasons for this 
deviation stems from the fact that the MALDI-TOF mass spectrometer may have not 
been not calibrated properly before each measurement. It has also been suggested that 
the room temperature where the mass spectrometer is located can greatly affect the 
measurement. Fluctuation in the observed mass could be seen as the temperature of the 
room increases. Despite this deviation, we can assume that the correct peptides were 
obtained due to the confirmation from the sequencing results.   
After CNBr cleavage and purification via HPLC initial protein expression yielded only 
2 mg of PATF-1from 6 × 550 ml of media after 5 hours of expression at 37 oC. Three 
different DE3 cell lines were used to express the protein to attempt to improve the yield. 
PATF-1 proteins were expressed in BL21 (DE3) CodonPlus RIL, CodonPlus RP and 
Star lines (Figure 3.2.3.4). Expression of PATF-1 in RIL and RP from 6 × 550 ml 
culture resulted in 1-2 mg of PATF-1. Expression of PATF-1 in BL21 Star resulted in 
approximately 4 mg of PATF-1 from 3.3 litres of culture medium, after HPLC 
purification. Comparing Star cells to RIL and RP by SDS gel electrophoresis (Figure 
3.2.3.4), it seemed that more than 4 mg of proteins would have been present and that 
perhaps the problem was not from the level of expression but the method that was used 
to extract the protein. 
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After CNBr cleavage and solvent evaporation, the gelatinous substance was initially 
dissolved in acetonitrile/water (1:1). However, the peptide was poorly soluble in this 
mixture, acidified (0.1 % TFA) acetonitrile/water (2:3) was used, according to 
manufacturer’s recommendation. This, however, did very little to improve the final 
yield of the protein. Another possibility was that the insoluble gel of cleaved KSI 
protein physically entrapped some of the PATF-1 proteins, rendering it insoluble in 
acetonitrile/water solvent. It was decided to dissolve the gelatinous substance in 8 M 
urea and dialyze the substance in a 500 Da cut off membrane leaving, in theory, the 
PATF-1 in the membrane. Unfortunately, the HPLC trace (not shown) revealed no trace 
of PATF-1 from this method. It was therefore decided to continue expressing PATF-1 
using BL21(Star) cells. PATF-2 peptide was also expressed in BL21(Star) cells (Figure 
3.2.3.5).  
 
Figure 3.2.3.4. SDS-PAGE analysis of PATF-1 expression in A) RIL and RP cells and B) Star cells. M: 
Protein marker (fragment size is indicated in kDa, Fermentas), lane 1: No induction RIL, lane 2: 2 hours 
induction RIL, lane 3: 5 hours induction RIL, lane 4: Overnight induction RIL, lane 6: 2 hours induction 
RP, lane 7: 5 hours induction RP, lane 8: Overnight induction RP, lane 9: No induction Star, lane 10: 2 
hours induction Star, lane 11: 5 hours induction Star.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
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Figure 3.2.3.5. SDS-PAGE analysis of PATF-2 expression in Star cells. M: Protein marker (fragment 
size is indicated in kDa, Fermentas), lane 1: No induction PATF-2, lane 2: 1 hours induction of PATF-2, 
lane 3: 2 hours induction of PATF-2, lane 4: 3 hours induction of PATF-2, lane 5: 4 hours induction of 
PATF-2, lane 6: 5 hours induction of PATF-2. 
 
3.2.4 Synthesis of the 3,3’–bis-(sulfo)-4,4’-bis (chloroacetamino)azobenzene 
(BSBCA) crosslinker 
 
The 4 step synthesis of the 3,3’–bis-(sulfo)-4,4’-bis (chloroacetamino)azobenzene 
(BSBCA) crosslinker was carried out according to literature procedures. 146 2,5-
diaminobenzene sulfonic acid was acetylated with acetic anhydride in hot (94 °C) acetic 
acid. The monoacetylated product was then oxidised to an azobenzene using sodium 
hypochlorite solution (>4% chlorine availability). The de-acetylation of the azobenzene 
compound was performed using concentrated hydrochloric acid and water, where the 
mixture was heated under reflux for 2.5 hours, reduced to dryness followed by 
treatment with dilute sodium hydroxide. Finally, the azobenezene was chloroacetylated 
by chloroacetic acid and chloroacetic anhydride to produce the BSBCA crosslinker.   
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Figure 3.2.4. 3,3’-bis(sulfo)-4,4’-bis(chloroacetamido)azobenzene synthesis. 146 
Products were characterised by 1H and 13C NMR spectroscopy and mass spectrometry 
and the data obtained were concordant with literature values.  
 
3.2.5 Cross-linking of PATF-1 and PATF-2 with BSBCA crosslinker 
 
PATF cysteine sidechains were alkylated with BSBCA by a nucleophilic substitution 
reaction. At pH 8.3 the sulfhydryl groups are mostly deprotonated and the resulting 
thiolate groups act as nucleophiles towards the crosslinker methylene groups (Figure 
3.2.5.1). 
The HPLC method used for PATFs was reapplied for the crosslinked (XL-PATFs) 
peptides. The HPLC chromatographs show 360 nm absorption from the trans form of 
BSBCA coinciding with peptide peaks at 18 minutes for PATF-1 and around 19 
minutes for PATF-2 (Figure 3.2.5.2).	  The identity of the species were established by 
MALDI-TOF MS (Table 3.2.5.1). Similar deviation in masses by approximately 65.64 
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and 236.48 from the calculated monoisotopic masses of XL-PATF-1 and XL-PATF-2 
respectively were also observed. It was also assumed that this deviation stems from the 
fact that the MALDI-TOF mass spectrometer may have not been not calibrated properly 
before each measurement and the room temperature fluctuation may have also 
contributed to this deviation. Despite this deviation, we can also assume that the correct 
peptides were obtained due to the confirmation from the sequencing results.      
	  
Figure 3.2.5.1. Alkylation mechanism. 
 
XL-PATF Calculated monoisotopic 
mass 
Observed mass 
XL-PATF-1 5388.55 5322.91  
XL-PATF-2 5838.89 6075.37  
 
Table 3.2.5.1. Monoisotopic calculated masses and observed masses of XL PATF-1 and XL PATF-2 
peptides. 
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  Figure 3.2.5.2. Chromatogram from the analytical HPLC analysis and MALDI-TOF mass spectrum of 
A) XL PATF-1 and B) XL PATF-2. 
 
 
3.2.6 Spectroscopic characterisation of XL-PATF-1 and XL-PATF-2 
3.2.6.1 UV-Visible absorption 	  
The change in conformation of the crosslinker is readily observed by UV spectroscopy. 
Experiments at different temperatures were used to characterise the thermal 
isomerisation of irradiated BSBCA crosslinker, PATF-1 and PATF-2 from cis to trans. 
Both crosslinker and peptides were irradiated for 6 minutes under UV light (280 W 
lamp with 360 +/- 10 nm filter). The absorption spectrum of dark-adapted PATFs, 
where the azobenzene crosslinker is in the thermally stable trans-configuration were 
characterised by strong a maximum at 363 nm typical of the π- π* transition in amide-
substituted trans-azobenzenes. Irradiation with 360 nm light led to a significant 
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reduction of this maximum. The difference in absorption between the cis and trans 
conformations can be clearly seen (Figure 3.2.6.1.1). 
Irradiated crosslinker and XL PATF peptides revert to the dark-adapted state in a non-
photochemical process characterised by isosbestic points at 250, 317 and 434 nm, 
suggesting the presence of only two species in equilibrium. Assuming first order 
kinetics for the thermal relaxation cis-to-trans of the peptides, the rate constant k for the 
thermal relaxation process was calculated by plotting the natural logarithm of the 
percentage of cis-isomer (calculated from the absorbance at 363 nm) versus time 
(Figure 3.2.6.1.2). This allowed subsequent calculation of the half-life (t½) of the cis-
isomer (Chapter 2, section 2.5). The half-lives of XL PATF cis-to-trans thermal 
isomerisation were found to be 88 min and 55 min at 15 °C for XL PATF-1 and XL 
PATF-2 respectively (Table 3.2.6.1.1). The PATFs unexpectedly have significantly 
shorter half-lives than the HDH-3 DBD peptide upon which they are based (150 min at 
15 °C). The presence of the linker and AD must cause an increase in the relaxation rate. 
In particular, significant changes in relaxation rates for XL PATF-1 compared to XL 
PATF-2 at different temperatures suggest the different linkers exert a strong influence.  
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Figure 3.2.6.1.1. UV/Vis spectra of A) crosslinker, B) XL PATF-1 and C) XL PATF-2 at 25 °C. Spectra 
were acquired on the dark-adapted state (trans), the irradiated state (cis) and 2 minute intervals after 
irradiation. 
 
Previous studies on a modified pro-apoptotic peptide Bak72-87i,i+11 have shown that more 
helical peptides have significantly shorter half-lives compared to less helical peptide 
HDH-3. 189 It was also suggested that high α-helical content of the stabilised peptide 
form presumably leads to very high relaxation rates in the case of i, i+ 11 spacings and 
slower reversion rate in other spacings. 190 
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Figure 3.2.6.1.2. Relaxation of different PATF peptides as a function of time in the dark as monitored by 
UV (363 nm). A) BSBCA crosslinker, B) XL PATF-1 and C) XL PATF-2. Blue: 15 oC, Red: 25 oC Green: 
37 oC.  
 
Three different conditions were selected to determine the activation energy of reversion 
of XL PATF peptides, and the temperature dependence of the rates compared in an 
Arrhenius plot (ln k versus 1/T) (Chapter 2, section 2.5). Isomerisation was followed 
by UV spectroscopy (363 nm) at 2 minute intervals for a period of 40 minutes and the 
!"#
!$#
!%#
!&#
!'#
!(#
!)#
*#
*# %# )*# )%# (*# (%# '*# '%# &*# &%#
!"
#$%
&%
'(
#
)*+,#$+*"(#
!"#
!$%&#
!$#
!'%&#
!'#
(# &# )(# )&# '(# '&# $(# $&# "(# "&#
!"
#$%
&%
'(
#
)*+,#$+*"(#
B 
C 
!"#
!$#
!%#
&#
&# '# %&# %'# $&# $'# "&# "'# (&# ('#
!"
#$%
&%
'(
#
)*+,#$+*"(#
A 
!"#$%&#"'(%
)'
%&*
+*
,(
%
!"
"
#$"
"
#%"
"
#&"
" !""""""""""""'"""""""""""$!""""""""""$'""""""""""%!"""""""""%'""""""""""&!""""""""""&'"""""""""(!""""""""""('"
"
!"
"#$"
"#%"
"
#&"
"#("
"#'"
"
#)"
"#*"
"
#%"
"
#%+'"
"
#&+'"
"
#&"
"
#("
"
!""""""""""""'"""""""""""$!""""""""""$'""""""""""%!""""""""""%'""""""""""&!""""""""""&'"""""""""(!""""""""""('"
"
!""""""""""""'"""""""""""$!""""""""""$'"""""""""%!""""""""""%'""""""""""&!""""""""""&'"""""""""(!""""""""""('"
"
)'
%&*
+*
,(
%
!"#$%&#"'(%
)'
%&*
+*
,(
%
!"#$%&#"'(%
In (A-Ao) = -0.039 T – 0.8055 
In (A-Ao) = -0.020 T – 2.0414 
In (A-Ao) = -0.038 T – 0.8232 
In (A-Ao) = -0.088 T – 2.2145 
In (A-Ao) = -0.012 T – 2.1553 
In (A-Ao) = -0.026 T – 2.1540 
In (A-Ao) = -0.045 T – 2.0827 
  
 
 
  
119 
half-life (t½) was calculated. The thermal relaxation experiments were performed in 
triplicate for each of the peptide. These data were used to construct Arrhenius plots of 
the XL PATF peptides which showed similar activation energies for both peptides 
(Figure 3.2.6.1.3) (Table 3.2.6.1.2). The isomerisation of the peptides proved to be 
fully reversible and temperature dependant as expected. The half-life of isolated 
crosslinker was 35 min at 15 °C (Figure 3.2.6.1.1) (Figure 3.2.6.1.2), a value 
concordant with previously reported values. 175     
Peptide t½ at 15 °C (min) t½ at 25 °C (min) t½ at 37 °C (min) 
XL PATF-1 88 +/- 4.0 32 +/- 3.1 18 +/- 1.5  
XL PATF-2 55 +/- 3.6 26 +/- 3.1  15 +/- 2.5 
 
Table 3.2.6.1.1. Half-life of the cis-isomer for PATF-1 and PATF-2 peptides. 
 
	  
Figure 3.2.6.1.3. Arrhenius plot of the UV relaxation rates of XL PATF-1 (blue) and XL PATF-2 (red).  
 
Peptide Ea (kJ mol-1) A (s-1) 
XL PATF-1 49.7 +/- 0.5 1.99 × 107 +/- 1.19 × 104 
XL PATF-2 44.4 +/- 1.1 1.43 × 106 +/- 4.13 × 104 
  
Table 3.2.6.1.2. Arrhenius parameters for the relaxation of different XL PATF peptides. 	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3.2.6.2 Circular Dichroism (CD) spectroscopy of PATF peptides 
 
CD spectra were measured to analyse the secondary structure of XL PATF peptides and 
observe changes induced by photoswitching. A typical CD spectrum of an α-helical 
protein possess a maximum at 190 nm with minima of approximately equal intensity at 
208 and 222 nm. Dark-adapted XL PATF-1 gave a spectrum resembling that expected 
for a helical structure (Figure 3.2.6.2.1). 36 In contrast to the HDH-3 DBD peptide, the 
minimum at 208 nm is more intense due to a greater contribution from random coil 
conformations (Figure 3.2.6.2.2). Upon irradiation, the CD value at 190 nm clearly 
decreases whilst that at 222 nm increases and that at 208 remains roughly the same, 
suggesting that the α-helical contribution has diminished with more random coil 
present. The observed mean residue ellipticities at 222 nm of -50445 deg cm2 dmol-1 for 
dad- XL-PATF-1 and -40035 deg cm2 dmol-1 for irrad- XL-PATF-1 correspond to 
approximately 13.8% and 11.3% helicities respectively, which is a smaller percentage 
than found in previous work carried out on XL HDH-3 (40 % helicity for dad- and 
18.6% helicity for irrad), 154 suggesting that the linker and AD attached to the DBD 
contribute to a decrease in overall helicity and reduced structural changes upon 
irradiation of XL-PATF-1 with 360 nm UV light. Interestingly, the observed mean 
residue ellipticities at 222 nm of -38658 deg cm2 dmol-1 and -38642 deg cm2 dmol-1 for 
uncrosslinked PATF-1 and PATF-2 correspond to approximately 9.9% and 9.8% 
helicities respectively are similar to their irradiated state, suggesting less helical 
conformations. 
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Figure 3.2.6.2.1. CD spectra of dad-(blue), irrad-(red) and uncrosslinked-(green) A) PATF-1 and B) 
PATF-2 peptides carried out in 5 mM potassium phosphate (pH 8.0) at 25 oC.  
 
CD spectra of XL PATF-2 were similar to those of XL PATF-1, upon irradiation, the 
CD value at 190 nm decreases whilst that at 222 nm increases and that at 208 remains 
roughly unchanged  (Figure 3.2.6.2.1), suggesting that the use of different linker has 
little or no effect on the overall structure of the peptide. It is also important to mention 
that polyproline can adopt two structured conformations; polyproline type I (PPI) and 
polyproline type II (PP2) helices. PPII helices form predominantly short stretches of 
regular structure characterised by the repetitive pairs of Ramachandran φ and ψ angles. 
The PPII helix is an extended (3.1 Å per residue compared to 1.5 Å in the α-helix) left-
handed helix defined by the φ, ψ torsional angle cluster with the distribution maximum 
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at -75 ° and 145 °. 191 The right-handed polyproline I (PPI) on the other hand is less 
common since the prolines are in higher energy cis conformation than its trans PPII 
counterpart. PPI also has similar dihedral angles (-75 °, 160 °) to PPII. 192 Studies of 
polyproline helices by circular dichroism has shown that they result in similar spectra to 
those of unfolded proteins with minima at approximately 198 nm and maxima of 218 
nm. 191 The observed mean residue ellipticities for XL PATF-2 at 222 nm of -47961 deg 
cm2 dmol-1 for dark adapted XL-PATF-2 and -40272.5 deg cm2 dmol-1 for irrad- state 
correspond to approximately 13.1% and 11% helicities respectively, extending the 
similarity between XL PATF-1 and XL PATF-2 and reinforcing that the cross-linker 
has a relatively subtle effect on the overall structure of both peptides upon irradiation.  
 
 
Figure 3.2.6.2.2. CD spectra representation of uncross linked-(green), dad-(blue) and irrad-(red) 
crosslinked HDH-3 peptide. 175 
 
Structural changes of XL PATF-1 can also be induced by addition of 2,2,2-
trifluoroethanol (TFE), which is known to stabilise α-helical structures. The use of TFE 
can be considered as a way of weakening nonlocal interactions but favouring local 
interactions of protein structures. 193, 194 The change in structure of dad- XL PATF-1 
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with addition of 5-20% co-solvent TFE was investigated using CD spectroscopy 
(Figure 3.2.6.2.3). 
 
Figure 3.2.6.2.3. CD spectra of dad- XL PATF-1 in the presence of TFE. 
 
Upon gradual addition of TFE the minima around 210 and 222 nm increased and the 
maximum at 190 nm increased, which is expected as random coil contribution to the 
CD spectrum is gradually reduced and helicity is increased. This gradual change was 
also observed in previous work on Bak and HDH-3 peptides. Even though a change in 
CD absorption is observed, the changes seem rather smaller than expected for a large 
change in protein conformation. This may suggest that crosslinked PATF-1 is close to 
achieving its maximal helicity in its dark state. Studies have demonstrated that TFE has 
little or no effect to the stabilisation of polyproline helices. Ndao et al. have 
demonstrated that by introducing TFE (10%-70%) to a recombinant porcine amelogenin 
(rP172) protein, which contains a polyproline type II (PPII) region, did not respond to 
TFE addition with conformational changes. 195 Furthermore, it is believed that the PPII 
residues in rP172 act as conformational stabilisers and offer resistance to TFE-induced 
folding.  
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3.2.7 DNA Binding Specificity measured by Fluorescence Anisotropy 	  
Fluorescence anisotropy measurements were carried out to quantify the DNA binding 
affinities of the uncrosslinked PATF-1 and dark adapted and irradiated XL PATF 
peptides for DNA sequences containing QRE binding sites (Table 3.2.7.1). 169 QRE is 
known to contain the specific binding site for the Q50K engrailed homeodomain upon 
which the PATF peptides are based. 196, 197 Fluoresence anisotropy measures differences 
in the plane of excited and emitted light to determine differences in rates of rotation 
during the lifetime of excited dye molecules between free fluorescein-labelled 
oligonucleotides and oligonucleotide-peptide complexes. Pleasingly, in spite of the low 
molecular weight of the peptide compared to the dye-bearing oligonucleotide, which 
could make the assessment of change on anisotropy measurements difficult, the 
technique proved to be useful in allowing the determination of the dissociation 
constants (KD) of the DNA complexes of dark-adapted and irradiated PATF-XL 
peptides. 
Name                                            Sequences 
QRE                           5’-CGCAGTGTAATCCCCTCGAC-3’ 
	   3’-GCGTCACATTAGGGGAGCTG-3’ 
ERE                            5’-CGCAGTGTAATTACCTCGAC-3’ 
	   3’-GCGTCACATTAATGGAGCTG-3’ 
MCK-S                 5’-CAGGCAGCAGGTGTTGG-3’ 
	   3’-GTCCGTCGTCCACAACC-3’ 
 
Table 3.2.7.1. QRE, ERE and MCK-S DNA sequences. PATF peptides binding sequences are underlined. 
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The data was fitted to the Langmuir isotherm equation (Chapter 2, Section 2.7) with no 
restriction on the number of binding sites present. The best fit of the experimental data 
for dark-adapted XL PATF-1 was obtained for a binding mode where one peptide is 
bound to one DNA molecule. Dark-adapted XL PATF-1 bound tightly to its QRE target 
site with an equilibrium dissociation constant of 43.2 nM at 15 °C (Table 3.2.7.2). 
Compared to the uncrosslinked PATF-1-QRE complex KD of 702.2 nM at 15 °C (Table 
3.2.7.2), the dark adapted XL PATF-1-QRE complex was nearly 20 times more stable. 
Unlike the XL PATF-1-QRE complex, PATF-1-QRE complex could not be properly 
fitted to the Langmuir isotherm equation assuming one binding site, the best fit to 
experimental data was obtained assuming that four PATF-1 peptides are simultaneously 
bound to QRE DNA; a low-affinity binding mode clearly distinct from the high-affinity 
binding mode observed for dad-XL PATF-1. Similar binding behaviour had previously 
been observed for the non-crosslinked HDH3-QRE complex.154 The binding curve 
demonstrated a low binding degree up to approximately 400 nM followed by a 
relatively steep increase, suggestive of cooperative binding (Figure 3.2.7.1). 
 
Figure 3.2.7.1. Fractional occupancy curves obtained from fluorescence anisotropy measurements of the 
A) un-alkylated PATF-1 to QRE, B) dad- (blue) XL PATF-1 and irrad- (red) XL PATF-1 to QRE. 
 
XL PATF-1 does not bind as tightly as the reported affinity of the XL HDH-3 peptide-
QRE complex (7.5 nM for dad-XL HDH-3), nor indeed as tightly as un-alkylated HDH-
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3 (200 nM). The lower binding affinity of PATF-1 peptide to QRE DNA compared to 
XL HDH-3 must reflect the effect of the additional linker and AD on the overall 
structure of the DBD helix. Despite the lower binding affinity of XL PATF-1 when 
compared to XL HDH-3, XL PATF-1 forms a more stable complex with DNA than the 
isolated wild type helix-3 of Q50K engrailed-QRE complex (1.7 µM, approximately 30 
times weaker, albeit this binding was measured via EMSA) 103 but binds less strongly 
than full-length Q50K engrailed homeodomain (approximately 170 times tighter than 
dad XL PATF-1, measurements done via EMSA). 196,  79  
The complex between irrad-XL PATF-1 and QRE was more than 90 times weaker than 
dad-XL PATF-1 (KD = 3875 nM) (Table 3.2.7.2 and Figure 3.2.7.1). Comparing the 
CD spectra of irrad- XL PATF-1 with dad- XL PATF-1, where only slight changes in 
helicity between cis and trans conformations are evident, the large changes in binding 
affinity suggest that only small structural changes of the α-helix are required in order to 
reduce the ability of a peptide to bind tightly to target DNA. The anisotropy data 
obtained from the binding of irrad- XL PATF-1 to QRE DNA appeared not to reach 
saturation even at 6000 nM irrad- XL PATF-1. Individual titrations gave widely ranging 
anisotropy values for free DNA and at saturation, resulting in each run being separately 
fitted. For each fit KD, free DNA and saturation were varied, allowing each run to 
produce a separate value for KD. The individual values of KD were averaged to give the 
overall values for the dissociation constant. After these fits, data from separate 
experiments were combined by normalising the experimentally measured anisotropy to 
the fit parameters for graphical display.  
The DNA binding specificity of the HDH3-derived DBD was investigated by 
measuring the KD of XL-PATF 1 in complexes with DNA sequences containing the 
natural target wild-type engrailed (ERE) (Table 3.2.7.2), 79 and a completely unrelated 
  
 
 
  
127 
DNA sequence for which engrailed homeodomains have little affinity (MCK-S) (Table 
3.2.7.1). 46 No binding to MCK-S could be detected for concentrations up to 6 µM for 
both dad- and irrad- XL PATF-1 (Table 3.2.7.2), suggesting that the peptide 
discriminated fully between the typical DNA targets of homeodomain proteins and 
heterologous sequences. 
 
Figure 3.2.7.2. DNA binding curves obtained from fluorescence anisotropy measurements of dad- (blue) 
XL PATF-1 and irrad- (red) XL PATF-1 to ERE.  
 
 KD (nM) 
Peptide QRE ERE MCK-S 
dad-XL PATF-1 43.2 +/- 13.1  694.3 +/- 117.0  > 6000 
irrad-XL PATF-1 3875.2 +/- 2871.7  779.9 +/- 256.1  > 6000 
PATF-1 
dad-XL HDH-3 
irrad-XL HDH-3 
HDH-3 
 
702.1 +/- 131.2  
7.5 +/- 1.3 
140.0 +/- 25.0 
200.0 +/- 11.0 
ND 
140.0 +/- 11.0 
160.0 +/- 15.0 
175.0 +/- 16.0 
ND 
> 6000 
> 6000 
ND 
Table 3.2.7.2. KD values of dad-, irrad- and un-crosslinked PATF-1 and HDH-3 to DNA. 175 
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Binding of XL PATF-1 to ERE DNA showed no significant light-responsiveness, with 
dad- and irrad- dissociation constants of 694 nM and 779 nM repectively (Table 3.2.7.2 
and Figure 3.2.7.2). The binding of uncross-linked HDH-3 to ERE previously found to 
be similar to that with QRE, suggesting a non-specific binding mode for the 
unstructured peptide. 154 dad- XL PATF-1 displayed significant binding specificity and 
successfully discriminated between QRE and ERE in a similar fashion to XL HDH-3 
(Table 3.2.7.2). 175 
Despite similar CD spectra to XL PATF-1, both dad- and irrad- XL PATF-2 were found 
not to bind as tightly to QRE DNA with KD values of 765 nM and 16210 nM 
respectively. (Table 3.2.7.3 and Figure 3.2.7.3).   
 QRE KD (nM) 
Peptide dad irrad 
XL PATF-2 765.6 +/- 282.2  16210.4 +/- 326.0  
 
Table 3.2.7.3. KD values of dad- and irrad- XL PATF-2 to QRE DNA. Data fitted with single binding site. 
 
 
Figure 3.2.7.3. DNA binding curves obtained from fluorescence anisotropy measurements of the XL 
PATF-2 to QRE DNA. dad-state is represented in blue and irrad-state in red.  
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With identical DBD and AD regions, this must be due to the different linker region. 
Even though both linkers are approximately the same length, the flexible linker used in 
XL PATF-1 may allow the DBD to better fit the target DNA than the more rigid poly-
proline linker. The large alterations in binding affinities compared to small changes in 
helicity seen in CD experiment reiterate how sensitive DNA binding is to small 
structural changes. In contrast, while previous studies carried out by Arora et al. and 
Mapp et al. using flexible polyethers, dimerisation domain from yeast GCN4 and rigid 
polyproline linkers on their transcription factor model demonstrated that the use of 
different linker affected their binding affinity to target DNA, 167, 184, 198 their 
transcription factor showed the tightest binding to target DNA with the rigid polyproline 
linker (7.7 nM). Transcription factors constructed using GCN4 linker and polyether 
linkers demonstrated slightly lower binding affinity to target DNA (11 nM and 32 nM 
respectively, measurements made by EMSA). Larger differences were noted in in vitro 
transcriptional activation, with 90% activation observed for the transcription factor with 
GCN4 linker, 70% for the rigid polyproline linker and 40% activation with flexible 
polyether linker. 167, 184, 198 Tighter binding to target DNA therefore does not necessarily 
result in better transcriptional activation, with activation favoured by domains that can 
cause dimerisation through coiled-coil structures.  
 
3.2.8 In Vitro Transcription of PATF peptides 	  
In vitro transcription assays with HeLa nuclear extracts were used to investigate the 
efficacy of PATF peptides as transcription factors. Nuclear extracts contain all the 
additional factors, including RNA polymerase II, needed to initiate the process of 
transcription and have been successfully used by Mapp et al. and Kwon et al. to 
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demonstrate in vitro transcription using a small molecule transcription factor.167, 199 To 
create a transcriptional activation assay a technique described by Sawadogo et al. was 
adapted; the template plasmid pUCMLΔ53 was created based on the pMLΔ53 plasmid 
with a 75-bp × 5 repeat QRE binding sequences located 50-bp upstream of the TATA 
box (Figure 3.2.8.1). 200 An adenovirus major late promoter (AdML) sequence, an 
extensively studied promoter believed to be the strongest promoter available for most in 
vitro systems, lies 30-bp upstream of a 388-bp G-less cassette. 201 With this template, 
the specific transcripts initiated from the AdML promoter are templated upon a 
synthetic 388-bp DNA fragment that lacks cytidines, ensuring a large tract of the 
transcribed RNA strand will contain guanosine residues (Figure 3.2.8.2). In vitro 
transcription is then carried out in the presence of [α-32P]rUTP, a β-emitter with a half 
life of 14.3 days, and either in the absence of GTP or in the presence of RNase T1 and 
the chain terminator 3’-O-methyl-GTP. Under these conditions the only radioactively 
labelled RNA transcripts that can accumulate are the 388 nucleotide, RNase T1 resistant 
transcripts resulting from accurate initiation at the AdML promoter. These products can 
later be visualised via gel electrophoresis/autoradiography. 202 This assay system allows 
a rapid, direct and quantitative detection of promoter-dependent in vitro transcription by 
RNA polymerase II.  
For each reaction, 100 ng of pUCMLΔ53 plasmid was pre-incubated with a dad XL-
PATF (500 nM) peptide for 75 minutes at room temperature. irrad- XL PATFs were 
irradiated with 360 nm UV light for 6 minutes prior to addition to plasmid, which was 
then followed by continuous irradiation for the remaining 75 minutes. The plasmid-
peptide mixture was then added to HeLa nuclear extract (8 µL, Promega) in a 25 µL 
reaction volume and processed as described in Chapter 2. 203 RNA transcripts were 
resolved on 7.5% polyacrylamide gels containing 7 M urea. Gels were soaked for at 
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least 20 minutes in deionised water in order to remove urea, then dried and exposed to 
photo-stimulatable phosphorimaging plates (Kodak). The storage plates were visualised 
by using Typhoon 9400 (GE Healthcare Life) followed by quantitation using ImageJ 
(Figure 3.2.8.3).   
	  
Figure 3.2.8.1. Diagram of the	   pUCMLΔ53 plasmid DNA template used for in vitro transcription 
experiments. The promoter region is based on the Adenovirus major late promoter (AdML), and contains 
five cognate binding sites for PATF peptides upstream of G-less cassette reporter.   
 
 
 
 
 
 
 
 
 
 
!"#$ !"#$ !"#$ !"#$ !"#$ TATA 
G-less cassette AdML 50 bp 
5’-GTAATCCTTCTACTAATCCATCGATTAATCCTTCCATATAATCCATGCTTTAATCCC-3’ 
pUCMLD53 
3171 bp 
Ampicillin 
resistance  
EcoRI  
Restriction site 
HindIII  
Restriction site 
ScaI  
Restriction site 
RNase T1 
resistant transcript 
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Upstream 
1	  	  	  	  	  gaattcgcag	  tgTAATCCtt	  ctacTAATCC	  atcgatTAAT	  CCttccataT	  AATCCatgct	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
61	  	  	  	  tTAATCCcct	  cgaccgcggt	  accctatccc	  gcgccccggg	  tgttcctgaa	  ggggggcTAT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
121	  	  	  AAAAgggggt	  gggggcgcgt	  tcgtcctcAc	  tctcttccc	  
G-less cassette 
1	  	  	  	  	  ctccataccc	  ttcctccatc	  tataccaccc	  tactctcctt	  tcctcattat	  tcctcctatt	  	  
61	  	  	  	  atcttctcct	  cttctctcct	  tcttctatat	  ttcccaaatc	  tatcatcatt	  cactctcatc	  	  
121	  	  	  ccctcttcct	  tcactcccat	  tctattctac	  tcctttccct	  ttccatatcc	  cctccacccc	  	  
181	  	  	  ccttcctccc	  ctctttcaat	  cttatcccca	  atcataaaat	  tatctcaatt	  atattctcct	  
241	  	  	  tccatacccc	  ctatcatcct	  catccctatc	  accccctact	  cacccaatac	  tccctactca	  
301	  	  	  tctcatatat	  ccttatcctc	  tcctcacctc	  tccctcctct	  atctcccccc	  ctcacactca	  
361	  	  	  tttctcattc	  cactccc	  
Figure 3.2.8.2. DNA sequences of cognate binding sites for PATF peptides, AdML promoter and G-less 
cassette. Upstream, sequences present upstream of the G-less cassette. PATF binding sequences are in 
capitals and highlighted in yellow, TATA box is in capital letters and highlighted in cyan, and the start 
site of transcription is highlighted in green. G-less cassette, nucleotide sequences of the long G-less 
cassette (388 bp). 201 
 
 
 
Figure 3.2.8.3. Storage phosphor showing autoradiogram showing the results of in vitro transcription 
induced by XL PATF-1in dark adapted and irradiated  (dad and irrad) and XL PATF-2 (dad and irrad) 
at 500 nM concentration (+ve: positive control, -ve: negative control). Transcription reactions were 
performed for 60 minutes at 30 oC. The slant in the gel was due to uneven electric current running 
through the gel. 
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Figure 3.2.8.4. Photoswitching of in vitro transcriptional activation by XL PATF-1 (dad and irrad) and 
XL PATF-2 (dad and irrad). The amount of transcript obtained from each reaction was compared with 
cytomegalovirus immediate-early promoter (CMV, Promega) as positive control to give a fractional 
activation value.  
 
Transcription reactions using XL PATF-1 and XL PATF-2 show that they produce 
similar levels of transcription in their dark adapted forms, however irradiation decreases 
transcription by XL PATF-2 by over three fold, while XL PATF-1 only shows a 
twofold reduction in activation. Work on a similar polyproline linker and activating 
domain artificial transcription activators carried out by Ansari et al. have previously 
demonstrated equivalent activation potency using this linker/activating domain 
design.184  
However, a very dense band was noted at the top of the gel (Figure 3.2.8.5 A)). This 
was initially believed to be due to the RNA transcript not being cleaved properly by T1 
RNase treatment. After several attempts at optimising the reaction it was concluded that 
the T1 RNase was cleaving the RNA transcripts correctly, since the CMV positive 
control DNA creates two distinct bands (1.2 kb and 363 b). The prominent band in the 
positive control of 363 nucleotides, which is clearly visible on Figure 3.2.8.5, is similar 
in size as the G-less cassette nucleotides. One other possibility for the identity of the 
dark band derives from the circular nature of the pUCMLΔ53 plasmid. There could be 
many TATA binding sites scattered around the plasmid resulting in unspecified RNA 
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being transcribed. Furthermore, being a circular plasmid, transcription of these TATA 
sites might result in many very large RNA transcripts being produced. It was therefore 
decided to linearize the plasmid and monitor its effect on the appearance of the dense 
band. Three different designs of the linear pUCMLΔ53 were tested: pUCMLΔ53 doubly 
digested with ScaI and HindIII (approximately 1.5 kbp in size) and DNA singly 
digested with both HindIII and ScaI (Figure 3.2.8.5 B)). The plasmid was designed so 
that a HindIII restriction site is directly few base pairs downstream of the G-less 
cassette, so that transcription of the G-less cassette should stop immediately after the 
end of the cassette if the DNA is cleaved at this site. The other restriction site chosen 
was ScaI as it lies upstream of the AdML promoter in the ampicillin resistance gene.  
Transcription tests were then performed using dad- XL PATF-1 on new DNA 
transcription template, and as expected the dark band observed with the circular plasmid 
was greatly reduced (Figure 3.2.8.5 B)). Singly digested plasmid with ScaI and HindIII 
show some reduction in the large dense band, but are unable to eliminate it. The doubly 
digested plasmid shows no dense band with only the G-less cassette transcript evident. 
Circular pUCMLΔ53 with no PATF-1 peptide present used as a negative control 
confirms that transcription of the G-less cassette relies on the PATF peptide in order to 
‘activate’ transcription. In the absence of peptide transcription is minimal or even 
absent (* Figure 3.2.8.5 B)). To confirm that the remaining band represented the correct 
size for the G-less cassette, a denatured single strand 500 bp DNA ladder (Figure 
3.2.8.5 C)) was run along the transcription experiment and stained in ethidium bromide 
for UV visualisation. It was hypothesised that denatured single strand DNA should have 
similar gel migrating properties as RNA and that a 500 bp DNA ladder denatured into 
single strands would best estimate the speed at which the RNA transcript migrates. 
Once gel electrophoresis was performed, the Rf values of each DNA sizes and G-less 
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transcript were calculated and a graph plotted using Rf values obtained from the DNA 
ladder to estimate the mass of the G-less cassette transcript. The Rf value of the G-less 
cassette was calculated to be 0.47, which corresponded to approximately 291 
nucleotides on the DNA ladder graph. However, since SDS gels are known to have 10 
% error, this would put our G-less cassette transcript closer to the 388 nucleotides 
initially predicted, suggesting that this band does indeed represent the RNA transcript.  
 
Figure 3.2.8.5. A) Transcription of dad- and irrad- XL PATF-1 with CMV positive control. Two bands 
can be clearly seen for CMV representing 1.2 kb and 363 b nucleotide transcripts. Dark patches can also 
be seen for dad- and irrad- XL PATF-1 as well as the transcript from the G-less cassette (388 b), which 
runs at approximately the same speed as the CMV positive control. B) Transcription of dad-XL PATF-1 
using 1) doubly ScaI and HindIII digested pUCMLΔ53, 2) singly Hind III and 3) singly ScaI digested 
pUCMLΔ53. 4) circular pUCMLΔ53 without PATF-1 peptide as negative control. Note: a small amount 
of background transcription (*) can still be seen despite the absence of PATF-1 peptide and 5) CMV as a 
positive control. C) Urea gel of 6) ScaI and HindIII digested pUCMLΔ53 plasmid, 7) & 8) denatured 
single strand 500 bp DNA ladder (NEB) and 9) 500 bp DNA ladder (NEB). Gel was stained in ethidium 
bromide after electrophoresis and visualised under UV light.  
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3.2.9 Designing and cloning of i, i + 7 and i, i + 4 PATF peptides 	  
Since the i, i+11 spacing has successfully controlled the conformation and the DNA 
binding properties of PATF-1 and PATF-2 as well as their in vitro transcription 
activities, i, i+7 and i, i+4 cysteine spacings were also investigated to offer the 
possibility of positive photoregulation. Previously, the azobenzene cross-linker in the 
trans conformation has shown to be too long to allow the i, i+7 residues and intervening 
residues to adopt an α-helix conformation, whilst in the cis conformation its length 
better matches the spacing of i, i+7 or i, i+4 cysteines spacing. 142, 114Thus PATF-3  (i, 
i+7) and PATF-4 (i, i+4) are expected to increase transcription upon isomerisation with 
363 nm UV light. The AH activation domain used on PATF-1 and PATF-2 was retained 
for PATF-3 and PATF-4 along with the better performing rigid polyproline linker of 
PATF-2 (Figure 3.2.9.1) (Table 3.2.9.1). 
	  
Figure 3.2.9.1. Schematic of PATFs. A) Diagram of the helical wheel of cross-linked PATF-3 with i, i+7 
spacing and PP linker. B) Diagram of the helical wheel of cross-linked PATF-4 with i, i+4 spacing and 
PP linker. Residues that are in contact with DNA in the parent homeodomain structure are marked with 
asterisk, blue and red circles represent charged residues based on parent HDH-3 DNA binding domain. 
Residues that have been substituted in order to avoid steric clash with the cross-liner are marked in filled 
green circles. 154, 175    
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Name                                            Sequences 
PATF-3 i, i+7                      EAQCKIAAKNCRAKIKKA-PPPPPPPPPPPP-PEFPGIELQELQELQALLQQ 
PATF-4 i, i+4                    	  EAQIKICAKNCRAKIKKA-PPPPPPPPPPPP-PEFPGIELQELQELQALLQQ 
 
Table 3.2.9.1. Amino acid sequences of PATF-3 and PATF-4. 
 
3.2.10 Construction of PATF-3 and PATF-4 	  
Cloning of PATF-3 and PATF-4 peptides was carried out as for PATF-1 and PATF-2. 
The oligonucleotides encoding PATF were obtained from Eurofins (Chapter 2, Section 
2.1.4 and Section 2.2.8). The oligonucleotides (2 µl, 25 pmol, for1:for2 & rev1:rev2 in 
separate tubes) were phosphorylated at the 5’ end using T4 polynucleotide kinase (2.5 
µl, 10 000 U ml-1) in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 25 °C). The 
solutions were incubated at 37 oC for 60 min. The oligos were then annealed by mixing 
equimolar quantities of forward and reverse oligos in a heat block at 95 °C. After 5 min 
at 95 °C, the heat block was turned off and solution was left to cool to room 
temperature.  
The phosphorylated oligonucleotides (6 µl, 0.078 pmol) were ligated into a pET31b(+) 
vector (1:3 vector to insert ratio) via ligation of the desired gene with AlwNI digested 
dephosphorylated pET31b(+) (2 µl, 0.026 pmol) by mixing them together with T4 DNA 
ligase (0.5 µl) and 1 × ligase buffer (200 mM Tris-HCl, pH 7.6, 50 mM MgCl2, 100 
mM DTT, 10 mM ATP). The mixture was then incubated at 16 °C overnight and the 
resulting construct was used to transform E. coli XL1-Blue. The clones were checked 
by either re-digestion of plasmids with AlwNI to detect the removal of AlwNI restriction 
site upon successful insertion, by PCR analysis (using T7 prom and term as primers) 
(Figure 3.2.10) and by sequencing.  
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Figure 3.2.10. A) Map of the pET31b(+) expression vector and cloning charts of PATF-3 and PATF-4 
peptides.  B) Agarose gels stained with ethidium bromide. Lane 1: marker (fragment size is indicated in 
bp), lane 2: PATF-1 PCR product (+ve control), lane 3: empty pET31b(+) with no insert (-ve control), 
lane 4: PATF-3 PCR product, lane 5: PATF-4 PCR product.   
  
Sequencing results of chosen PATF-3 and PATF-4 clones demonstrated several 
deviations from the original sequences intended (Table 3.2.10). In this case PATF-3 has 
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four proline residues within the rigid oligo-proline linker missing, and PATF-4 has 
mutations within the rigid oligo-proline linker (Table 3.2.10) different from the original 
intended sequences (Section 3.2.9). As with the similar error observed for PATF-2 
clone, it is believed that the error could arise when there are high numbers of the same 
amino acids in a row previously discussed in section 3.2.2. Despite this deviation, both 
PATF-3 and PATF-4 still have the correct DBD and AD sequences for DNA 
recognition and transcription activation. It was predicted that PATF-3, having shorter 
rigid oligo-proline linker than PATF-2, may not be as effective at promoting 
transcription as PATF-2 according to previous studies. 184 As for PATF-4, having four 
mutations within the rigid oligo-proline linker could affect the binding affinity to target 
DNA and promoting the transcription process differently to PATF-2 and PATF-3 with 
rigid linkers. Despite the mutations observed, clones of PATF-3 and PATF-4 obtained 
were used for protein expression.    
Name Sequences 
PATF-3 i, i+7 gaagcgcagtgtaaaatcgcggctaagaactgccgtgcgaaaattaagaaagctccgccgccaccgcctccg 
  E   A  Q   C  K   I   A   A  K  N  C   R  A   K   I  K   K  A  P    P   P   P   P   P   
ccaccgccggaattcccgggtattgagctgcaagaactgcaagagctgcaggccctcctgcagcaa 
  P   P   P    E   F   P   G   I   E   L  Q  E   L  Q   E   L  Q   A   L  L  Q  Q 
PATF-4 i, i+4	   gaagcgcagatcaaaatctgtgctaagaactgccgtgcgaaaattaagaaagctccgccgccacgccccgcc 
 
  E   A  Q   I    K  I  C   A  K  N  C   R   A  K   I  K   K   A  P   P   P   R   P   A 
 
accgctccgccaccgccggaattcccgggtattgagctgcaagaactgcaagagctgcaggccctcctgcag 
 
  T   A  P   P   P   P    E  F  P    G   I   E   L  Q   E   L  Q   E   L  Q   A   L  L  Q    
   
caa  
 
 Q 
 
Table 3.2.10. Sequencing results of PATF-3 and PATF-3 clones. The obtained sequences are in 
minuscule letters (top) and the translated sequences are in capital letters (bottom). Residue mutations of 
PATF-4 are highlighted in blue. 
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3.2.11 Expression and purification of PATF-3 and PATF-4 
PATF-3 and PATF-4 peptides were expressed in BL21 Star cells using the same 
conditions as for PATF-1 and PATF-2. Expression of the peptides was assessed by 
SDS-PAGE (Figure 3.2.11.1). 
	  
Figure 3.2.11.1. SDS-PAGE analysis of PATF-3 and PATF-4 expression in Star cells. M: Protein marker 
(fragment size is indicated in kDa, Fermentas), lane 1: 3 hours induction of PATF-3, lane 2: 3 hours 
induction of PATF-4.  
 
KSI-PATF-3-His6 and KSI-PATF-4-His6 fusion protein inclusion bodies were 
solubilized in lysis buffer, re-precipitated and the KSI and His-tag were removed by 
cyanogen bromide cleavage. Purification was carried out by reverse phase HPLC 
(Phenomenex Gemini C18 column). PATF-3 and 4 both eluted at approximately 21 
minutes using a 10-100% acetonitrile:water (containing 0.1 % TFA) linear gradient over 
the course of 60 minutes at a flow rate of 5 ml min-1 (Figure 3.2.11.2). PATF-3 and 
PATF-4 have similar retention times to PATF-2 due to their shared linker. The masses 
of PATF-3 and PATF-4 were confirmed by MALDI-TOF MS (Table 3.2.11.1). 
Deviation in masses by approximately 281.72 and 47.96 from the calculated 
monoisotopic mass of PATF-3 and PATF-4 respectively were also observed. Similar 
causes for the deviation were previously discussed in Section 3.2.3. Despite this 
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deviation, we can also assume that the correct peptides were obtained due to the 
confirmation from the sequencing results.      
 
Figure 3.2.11.2. Chromatogram from the analytical HPLC analysis and MALDI-TOF mass spectrum of 
A) PATF-3 and B) PATF-4.   
  
 
Peptide Calculated monoisotopic mass Observed mass 
PATF-3 5137.77 5419.49  
 PATF-4 5481.99 5529.95  
  
Table 3.2.11.1. Calculated monoisotopic masses and observed masses of PATF-3 and PATF-4 peptides. 
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3.2.12 Cross-linking of PATF-3 and PATF-4 with 3,3’–bis-(sulfo)-4,4’-bis 
(chloroacetamino)azobenzene 
 
PATF-3 and PATF-4 were alkylated with BSBCA and purified as previously. The HPL 
chromatogram shows absorption at 360 nm at around 19 minutes for XL-PATF-3 XL 
PATF-4 (Figure 3.2.12.1). The masses were measured by MALDI-TOF MS (Table 
4.2.12.1). Deviation in masses by approximately 281.71 and 47.96 from the calculated 
monoisotopic mass of XL-PATF-3 and XL-PATF-4 respectively were also observed. 
Similar causes for the deviation were previously discussed in Section 3.2.3. Despite this 
deviation, we can also assume that the correct peptides were obtained due to the 
confirmation from the sequencing results.      
 
Figure 3.2.12.1. Chromatogram from the HPLC analysis and MALDI-TOF mass spectrum of A) XL 
PATF-3 and B) XL PATF-4. 
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Peptide Calculated monoisotopic mass Observed mass 
XL PATF-3 5589.78 5871.49  
XL PATF-4 5933.99 5981.95  
 
Table 3.2.12.1. Calculated monoisotopic masses and observed masses of XL PATF-3 and XL PATF-4 
peptides. 
 
3.2.13 Spectroscopic characterisation of XL-PATF-3 and XL-PATF-4 
3.2.13.1 UV-Visible absorption 	  
The change in crosslinker conformation of XL-PATF-3 and XL-PATF-4 upon 
irradiation was observed by UV spectroscopy and at different temperatures as 
previously. Both peptides were irradiated for 6 minutes under UV light (363 nm) and 
the absorption spectra of dark-adapted XL PATF-3 and XL PATF-4 were recorded at 
different timepoints (Figure 3.2.13.1.1). 
 
Figure 3.2.13.1.1. UV/Vis spectra of A) XL PATF-3 and B) XL PATF-4 at 25 oC. Spectra were acquired 
on the dark-adapted state (trans), the irradiated state (cis) and 2 minute intervals after irradiation. 
 
Irradiated XL PATF-3 and XL PATF-4 peptides reverted to the dark-adapted state with 
similar half-lives of 45 and 40 mins respectively at 15 °C despite the fact that XL 
PATF-4 has mutations withing the polyproline linker (Figure 3.2.13.1.2). XL PATF-3 
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and XL PATF-4 also possess significantly shorter half-lives than the XL HDH-3 
peptide, consistent with this reduction being a by-product of the attached linker and 
activating domain. Additional support for this hypothesis is lent by the similarity of the 
relaxation rates of XL PATF-3 to XL PATF-2, which shares similar rigid linkers. 
Interestingly, despite the mutations withing the rigid polyproline linker, XL PATF-4 
demonstrated similar relaxation rates to XL PATF-3, suggesting that the position of the 
cysteine residues maybe have greater effect on the relaxation of the peptide than the 
linker used to link DBD and AD domains.  
 
Figure 3.2.13.1.2. Relaxation of different PATF peptides as a function of time in the dark as monitored 
by UV (363 nm). A) XL PATF-3 and B) XL PATF-4; Blue: 15 oC, red: 25 oC and green: 37 oC.  
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Three different temperatures were selected and the temperature dependence of the rates 
compared in Arrhenius plots, which show XL PATF-3 and XL PATF-4 peptides to have 
similar Ea values, but both are higher than found for the i, i + 11 peptides (Figure 
3.2.13.1.3) (Table 3.2.13.1.1).  
 
 
Figure 3.2.13.1.3. Arrhenius plot of the UV relaxation rates of XL PATF-3 (green) and XL PATF-4 
(orange).  
 
Peptide Ea (kJ mol-1) A (s-1) 
XL PATF-3 69.8 +/- 1.8 4.97 × 1010 +/- 1.26 × 109 
XL PATF-4 64.2 +/- 1.5 2.12 × 1010 +/- 1.07 × 109 
 
Table 3.2.13.1.1. Arrhenius parameters for the relaxation of XL PATF-3 and XL PATF-4 peptides. 
Similar observations have been made with crosslinked Bak peptides where Bak72-87i,i+7	  
has significantly higher activation energy (Ea) than Bak72-87i,i+11. 147 The rates of thermal 
relaxation of the irradiated XL PATF-3 and XL PATF-4 were calculated from triplicate 
UV spectroscopy experiments. Both peptides have similar and shorter relaxation rates 
compared to XL PATF-2 (Table 3.2.6.1.3).  
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Peptide t½ at 15 °C (min) t½ at 25 °C (min) t½ at 37 °C (min) 
XL PATF-3 45 +/- 2 16 +/- 0.2 5  +/- 0.8 
XL PATF-4 40 +/- 4 16 +/- 2 2 +/- 1.5 
 
Table 3.2.6.1.2. Half-life of the cis-isomer for XL PATF-3 and XL PATF-4 peptides. 
 
3.2.13.2 Circular Dichroism (CD) spectroscopy of XL PATF-3 and XL PATF-4 
  
CD spectra were measured to analyse the helicity of XL PATF-3 and XL PATF-4 
peptides and investigating changes in structure induced by photoswitching. The CD 
spectra of XL PATF-3 and XL PATF-4 showed almost no difference between the dark 
adapted and irradiated states eventhough XL PATF-4 having mutations within the 
polyproline linker (Figure 3.2.13.2.1). Both XL PATF-3 and XL PATF-4 display high 
intensity minima peaks at approximately 205 nm, but only XL PATF-4 posessed a 
minima at 222 nm. The lack of clear minima at 208 and 222 nm (corresponding to 
peaks observed in α-helical structures), suggest that XL PATF-3 is mostly comprised of 
random coil structures. Circular Dichroism software (Dichroweb) was used to analyse 
the structure, which also confirms a predominantly random coil structure for XL PATF-
3 (Fitted to SELCON3, model: Set 6 [optimised for 185-240 nm], 0% helix, 1.9% sheet, 
21% coil) 204 The observed mean residue ellipticities of XL PATF-4 at 222 nm of -
2160.3 deg cm2 dmol-1 (dark adapted state) and -2570.6 deg cm2 dmol-1 (irradiated state) 
which correspond to 5.9% and 7% helicities. As with XL PATF-3, CD spectra also 
suggest that the structure is mostly random coil. Circular Dichroism software suggested 
that XL PATF-4 the structure is also mostly random coil (Fitted to SELCON3, model: 
Set 6 [optimised for 185-240 nm], 0% helix, 1.9% sheet, 22% coil). Different cysteine 
spacings employed to disfavour a helical conformation in the trans azobenzene 
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conformation (i, i+7 spacing on XL PATF-3 and i, i+4 spacing on XL PATF-4) seem to 
have successfully distorted the structure, but have limited use in reinstating helicity in 
the peptides upon irradiating with UV light.  
 
 
Figure 3.2.13.2.1. CD spectra of dad-(blue) and irrad-(red) A) XL PATF-3 and B) XL PATF-4 peptides 
carried out in 5 mM potassium phosphate (pH 8.0) at 25 oC. The introduction of the BSBCA crosslinker 
seems to have little to no effect to the structure of both peptides upon isomerisation. 
 
3.2.14 DNA Binding Specificity measured by Fluorescence Anisotropy 	  
Fluorescence anisotropy measurements were carried out to quantify the DNA binding 
affinities of dark adapted and irradiated XL PATF-3 and XL PATF-4 peptides for 
sequences containing QRE binding sites. XL PATF-3-QRE and XL PATF-4-QRE 
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complexes were both successfully fitted to the Langmuir isotherm equation assuming 
one binding site as previously done for dad- XL PATF-1-QRE and dad- XL PATF-2-
QRE complexes. XL PATF-3 and XL PATF-4 demonstrated similar complex stabilities 
in their dad- and irrad-forms (Figure 3.2.14.1).  
 
Figure 3.2.14.1. DNA binding curves obtained from fluorescence anisotropy normalised to fit parameters 
measurements of the A) XL PATF-3, and B) XL PATF-4 to QRE DNA. dad-state is represented in blue 
and irrad-state in red.  
 
 QRE KD (µM) 
 dad irrad 
XL PATF-3 2.4 +/- 0.3  1.7 +/- 1.1  
XL PATF-4 4.8 +/- 2.9  1.3 +/- 0.7 
 
Table 3.2.14.1. KD values of dad- and irrad- XL PATF-3 and XL PATF-4 peptides to QRE DNA. Data 
fitted with single binding site model. 
 
The presence of a trans azobenzene cross-linker prevented XL PATF-3 (KD = 2.4 μM) 
and XL PATF-4 (KD = 4.8 μM) from forming high affinity complexes (Table 3.2.14.1). 
After irradiation, the stability of complexes formed between QRE DNA and the irrad- 
forms of XL PATF-3 and XL PATF-4 were increased by almost 2 fold (KD = 1.7 μM) 
and 4 fold (KD = 1.3 μM) respectively. This was anticipated since i, i+4 spacing on 
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PATF-4 is shorter than i, i+7 of PATF-3, allowing more effective distortion the DBD 
helix, as previously observed with alkylated BH3 peptides. 189 Slightly lower KD value 
observed for XL PATF-4 could be due to the presence of mutations within the 
polyproline linker, possibly making the linker a little more flexible than the polyproline 
linker in XL PATF-3, thus allowing the DBD of XL PATF-4 to better fit the target 
DNA as previously observed with XL PATF-1. The relatively small KD differences 
between trans- and cis- configurations were commensurate with the small changes in 
the CD spectra of the peptides that indicated few signs of structural changes upon 
irradiation and with the low degree of helicity. Previous work on crosslinked BH3 
peptides with i, i+7 and i, i+4 spacings yielded approximately 20 fold changes between 
dad- and irrad- forms in in vitro binding studies 205 and despite only small changes 
being evident in CD spectra these peptides proved capable of inducing light-dependant 
biochemical responses in permeabilised cells.	  206 
3.2.15 In vitro transcription of XL PATF-3 and XL PATF-4 peptides 	  
In vitro transcription assays by HeLa nuclear extracts were used to investigate the 
efficiency of XL PATF-3 and XL PATF-4 peptides as transcription factors using doubly 
digested ScaI and HindIII pUCMLΔ53 plasmid as a template. It was hypothesised that i, 
i+7 and i, i+4 cysteine spacings would disfavour DBD binding to target DNA and 
would reduce the transcription activation of the peptide in vitro in the dark, whereas the 
irradiated state should show higher levels of transcription. Having mutations within the 
polyproline line linker could also affect the transcription activity of XL PATF-4 since 
the linker may not be fully rigid as with XL PATF-3. Experimental results showed dad- 
XL PATF-3 and dad- XL PATF-4 displayed similar transcription levels with small 
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increases in activation for both irrad- XL PATF-3 and irrad- XL PATF-4 peptides 
(Figure 3.2.15.1). 
In this case the pMLΔ53 plasmid, generously donated by Prof. Robert Roeder, was used 
as the positive control instead of CMV. pMLΔ53 also contains a G-less cassette and can 
be transcribed by RNA polymerase II without the use of other artificial transcription 
factors. 200 The efficiency of pMLΔ53 is very similar to CMV (14557 +/- 1610 for 
CMV, 14239 +/-5479 for pMLΔ53, obtained via densitometry using ImageJ software) 
(Figure 3.2.15.2). Irradiated XL PATF-4 showed the higher activation level of the two 
peptides, possibly due to the linker used in XL PATF-4 being longer than the rigid 
linker in XL PATF-3 since it was suggested that longer linkers (12-15 residues) were 
more effective at promoting transcription. 184 Also not being fully rigid could also mean 
that this had allowed better fit of XL PATF-4’s DBD to target DNA. However, neither 
seems to be able to match the dynamic range of XL PATF-1 and XL PATF-2, with 
changes in activity below 50% (Figure 3.2.15.3 A) and B)). 
The reduced transcriptional activity of dad- XL PATF-3 and dad- XL PATF-4 is 
concordant with their CD spectra and fluorescence anisotropy results. Despite little or 
no changes in structural conformation for both peptides observed by CD these 
techniques the KD values the irrad- states of both peptides suggest a measure of optical 
control over the binding to target DNA. Furthermore, the CD spectrum of XL PATF-4 
suggested more helical structure than XL PATF-3 (a more obvious minima at 222 nm, 
possibly due to the presence of alanine and arginine residues within the linker), 
corresponding to higher binding affinity to QRE in the irrad-state, might explain the 
larger increase in activation upon irradiation than XL PATF-3. This could also suggest 
that rigidity may not be the only factor contributing to increasing the transcription 
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activity but also the length of the linker. Since the half-life of XL PATF-3 and XL 
PATF-4 are relatively short, photoswitching of transcriptional activation could be 
augmented by using lower temperatures during in vitro transcription, although this 
would be offset by the decreased rate of RNA polymerase II reaction. 
 
Figure 3.2.15.1. Storage phosphor autoradiogram showing an in vitro transcription of A) XL PATF-3 
(dad and irrad) and B) XL PATF-4 (dad and dad) at 500 nM concentration. Transcription reactions were 
performed for 60 minutes at 30 oC.  
 
Figure 3.2.15.2. In vitro transcriptional activation of XL PATF-3 (dad and irrad) and XL PATF-4 (dad 
and irrad) normalised to the transcription product of pMLΔ53.  
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Figure 3.2.15.3. A) Storage phosphor autoradiogram showing in vitro transcription pMLΔ53 and CMV. 
B) In vitro transcriptional activation of CMV and pMLΔ53.   
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3.3 Summary 	  
In summary, four light-responsive artificial transcriptional activators based on an 18 
amino acid DNA binding domain of an engrailed homeodomain with azobenzene-
derived photo-activatable cross-linkers were fused with an amphipathic activating 
domain (AH) connected by different linkers to regulate the conformation of peptides. 
The azobenzene proved able to not only control the binding specificity of these peptides 
to target DNA, but also demonstrated their potency at activating and deactivating the 
transcription process in an in vitro environment.  
XL PATF-1 and XL PATF-2 were more potent transcription activators/deactivators 
when compared to XL PATF-3. XL PATF-4, with presence of mutations and therefore 
possibly affecting the rigidity of the linker, has demonstrated similar character to XL 
PATF-3 in terms of photoswitching, KD and transcription activation. It would be 
interesting to investigate how full-length polyproline XL PATF-4 perform.   
Despite smaller changes in KD values between dad- and irrad states, XL PATF-2 seem 
to be the best design for a miniature artificial transcriptional factor due to its higher 
dynamic range in in vitro transcription assays. Previous work carried out by Woolley et 
al. on an artificial transcription activator has shown that the in vivo activity of their 
peptide was decreased by approximately 40% upon irradiation. 157 However, our XL 
PATF-2 has shown over 60% decrease in in vitro activation upon irradiation, which 
could be very promising for in vivo studies and a very good model for the design of 
future photo-switchable artificial activators. 
Further in vivo studies of these peptides would enable us to investigate how potent these 
peptides are in live cell environment and potentially pave a way for the designs of more 
potent miniature artificial transcription activators.  
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4. Conclusion 	  
Incorporation of a photoswitchable azobenzene crosslinker to an PATF artificial 
transcription factor demonstrated that it is possible to reduce the size of the protein 
DBD motif by providing alternative means of stabilising the secondary structure. It also 
was possible to control the binding affinity of this miniature artificial transcription 
factor to its cognate DNA and to control the transcription process in vitro. Studies have 
also demonstrated that types of linkers connecting the DBD and AD domains can be 
crucial at promoting the transcription process and the binding affinities do not directly 
drive dynamic range in in vitro transcription assays.   
However, there are also drawbacks to this system; UV light is required to isomerise the 
photoswitch, which could limit its use in in vivo environments as UV light can trigger 
unwanted responses such as apoptosis. One way around this would be the use of non-
UV switchable azobenzene crosslinker developed by Beharry et al. However these non-
UV switchable azobenzene crosslinkers have short half-life due to sensitivity to 
reducing conditions, which can be a drawback for in vivo environment. 125 More recent 
developments of a new family of azobenzene crosslinker could offer a way to 
effectively using these switches in vivo. For example, Bleger et al. have synthesised a 
new class of azobenzene with fluorine atoms ortho to the azo moiety, allowing the 
ability to reversibly isomerise the two isomers in the visible region of the spectrum. 207 
Isomerisation from trans-to-cis of the tetrafluoro-substituted azobenzene was done by 
exposure to green light (λ > 450 nm), and the reverse from cis-to-trans was done by 
exposure to blue light (410 nm). The isomerisation with green light also produced 91% 
cis conformation, which is greater than previously observed for any azobenzene designs 
(70-80% cis). Moreover, this photoswitch has an exceptionally long half-life (700 days 
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at 25 oC) for an azobenzene derivative, which could make it an attractive system to use 
to photocontrol in vivo. Samanta et al. have also developed an azobenzene in which all 
four ortho positions to the azo group have been chloro-substituted. 208 This azobenzene 
moiety demonstrated effective trans-to-cis switching with red light (630-660 nm), a 
wavelength range that is orders of magnitude more penetrating through tissue than other 
parts of the visible spectrum as well as stability to reduction by glutathione under 
reduced condition. The azobenzene switch was also tested in vivo by microinjecting into 
zebrafish embryos, where it was possible to photoswitch the azobenzene with red-light 
without causing any morphological changes or apparent toxicity to the embryos. These 
results showcase the delivery of a specific biomolecule modified with a photoswitch to 
an organism using microinjection. Cell-penetrating peptide sequences could also be 
used to allow non-specific peptide delivery, followed by directed photoactivation. 157, 161  
The results obtained might be extended by additional studies exploring the use of more 
potent activating domains such as the natural viral protein VP16 or the yeast activator 
Gal4 to potentially achieve higher transcriptional activation. Since different linker 
domains seem to strongly affect the level of transcription activation, this might also be a 
fruitful route to improve these artificial transcription factors. Combinations of 
improvements in visible light photoswitching, activation activity and linker optimisation 
could ultimately lead to the creation of more potent and easily controllable artificial 
transcription factor of broad utility in live cells.   
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